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Abstract
Human mitochondrial DNA (mtDNA) is a double-stranded circular molecule of ~16 kb.
In the major coding strand of human mtDNA there are two transcription units, one of
which is dedicated to the synthesis of ribosomal RNAs and two transfer RNAs (the
‘rRNA transcription unit’) and the other one to the synthesis of all messenger RNAs and
the remaining transfer RNAs (the ‘mRNA transcription unit’). The initiation sites for
these two transcription units are located near each other and the transcription units
partially overlap. They are independently controlled and differentially expressed. The
central aim of the present project was to study the functional roles of human
mitochondrial transcription termination factor (MTERF), the protein that is believed to
control the relative activities of the two transcription units in the major coding strand of
mtDNA.
MTERF is a DNA-binding protein that interacts with mtDNA as a monomer. It binds
to a 28 bp region within the leucine (UUR) transfer RNA (tRNALeu(UUR)) gene at the
position immediately adjacent and downstream of the 16S ribosomal gene. In vitro
MTERF has been shown to promote transcription termination but so far no evidence has
been reported supporting the idea that it performs such a role in vivo. The A3243G
MELAS (mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes)
mutation is located within the MTERF binding sequence in mtDNA. It has been
suggested that elucidating the physiological function(s) of MTERF could help to
understand the pathogenesis of MELAS syndrome. It has been shown that the A3243G
mutation reduces the binding affinity of MTERF to its target sequence, which should
mean that the efficiency of rRNA transcription termination decreases.
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MTERF belongs to a family of related proteins whose physiological functions are
unclear. This study addressed the issue of the functional role of MTERF and that of two
novel MTERF protein family members MTERFD1 and MTERFD3 in vivo at the cellular
level. The effect of MTERF over-expression and knock down in HEK293T-derived cells
was studied on steady-state mitochondrial transcript levels and after mtDNA and RNA
depletion with EtBr. Modulating MTERF levels in vivo had a modest effect on
mitochondrial transcription. It may be inferred that MTERF levels do not determine the
relative levels of transcripts representing the two different transcription units of the heavy
strand in a simple manner but that compensatory mechanisms are involved. Whereas
altering MTERF levels had only minor effects on mitochondrial transcript levels, over-
expression of TFAM had a clear effect by slowing down the recovery of the tRNA levels
after EtBr-induced depletion of mitochondrial DNA and RNA.
Using two-dimensional neutral agarose gel electrophoresis (2DNAGE), MTERF over-
expression or knockdown was found to affect mtDNA replication pausing, although no
effect on mtDNA copynumber was detected. MTERF was inferred to promote pausing
both at the canonical MTERF-binding site as well as at novel, weaker binding sites
identified by electrophoretic mobility shift assay (EMSA) and by using systematic
evolution of ligands by exponential enrichment (SELEX). In contrast to MTERF over-
expression enhanced replication pause sites, the pause sites enhanced by TFAM over-
expression were found comparatively diffuse.
Immunocytochemistry showed that epitope-tagged MTERFD1 and MTERFD3 are
mitochondrially targeted, but EMSA and SELEX did not identify plausible sites of
sequence-specific DNA binding for either of these proteins. Over-expression of epitope-
tagged MTERFD3 or, to a lesser extent, MTERFD1 in HEK293T-derived cells was
found to decrease mtDNA copynumber and to impair the completion of mtDNA
replication, based on the accumulation of specific classes of replication intermediates, as
revealed by 2DNAGE.
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In conclusion, the results presented in this thesis further elucidate the role of MTERF
in mitochondrial transcription and moreover establish that MTERF has a role also in
mtDNA replication. These findings are further analyzed in light of TFAM results. A solid
ground for further studies on MTERFD1 and MTERFD3 is laid here as results reported in
this thesis indicate that MTERFD1 and MTERFD3 have a role in mtDNA replication too.
16
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Lyhennelmä
Ihmisen mitokondrion DNA (mtDNA) on ~16 kb pitkä kaksijuosteinen rengasmainen
molekyyli. Ihmisen mtDNA:n raskaassa koodaavassa juosteessa on kaksi
transkriptioyksikköä, joista toinen on dedikoitu ribosomaalisten RNA:iden ja kahden
siirtäjä-RNA:n synteesiä varten (’rRNA transkriptioyksikkö’) ja toinen kaikkien lähetti-
RNA:iden ja loppujen siirtäjä-RNA:iden synteesille (’mRNA transkriptioyksikkö’).
Transkriptioyksiköt menevät osittain päälletysten ja niiden aloituskohdat sijaitsevat
lähellä toisiaan. Niitä myös säädellään itsenäisesti ja ilmennetään erillisesti. Ihmisen
mitokondriaalisen transkription terminaatiofaktorin (MTERF) oletetaan kontrolloivan
mtDNA:n raskaan koodaavan juosteen kahden transkriptioyksikön suhteellisia
aktiivisuuksia. Tämän projektin keskeinen tavoite oli tutkia MTERF:n tehtäviä mtDNA:n
transkriptiossa ja replikaatiossa.
MTERF on DNA:han sitoutuva proteiini, joka sitoutuu mtDNA:han monomeerinä. Se
sitoutuu 28 emäsparin mittaiselle alueelle leusiini (UUR) siirtäjä-RNA:ta (tRNALeu(UUR))
koodaavaan geeniin, 16S koodaavan geenin välittömään läheisyyteen siitä alavirtaan.
MTERF:n on in vitro osoitettu edistävän transkription terminaatiota, mutta toistaiseksi ei
ole näytetty, että sillä olisi vastaava rooli in vivo. MELAS-syndrooman
(mitokondriaalinen enkefalopatia, laktaattiasidoosi ja kohtausmaiset episodit) aiheuttava
A3243G-mutaatio sijaitsee MTERF:n kohdesekvenssissä mtDNA:ssa. On esitetty, että
MTERF:n fysiologisten tehtävien selvittäminen voisi auttaa ymmärtämään MELAS-
syndrooman syntyä. A3243G-mutaation on osoitettu vähentävän MTERF:n
sitoutumisaffiniteettia sen kohdesekvenssiin, jonka pitäisi merkitä sitä, että transkription
lopetus rRNA-transkriptioyksikön jälkeen vähenee.
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MTERF kuuluu proteiiniperheeseen, jonka muiden jäsenten fysiologiset tehtävät ovat
toistaiseksi vielä epäselvät. Tässä projektissa tutkittiin MTERF:n ja kahden uuden
MTERF-proteiiniperheen jäsenen, MTERFD1:n ja MTERFD3:n, tehtäviä in vivo
käyttäen viljeltyjä ihmissoluja. MTERF:n ylituotannon ja vaiennuksen vaikutusta
mitokondriaalisiin transkriptitasoihin tutkittiin normaalisti kasvavissa HEK293T-soluissa
ja lisäksi EtBr-käsittelyllä aiheutetun mtDNA- ja RNA-depleetion jälkeen. MTERF-
proteiinitasojen muuntelu in vivo vaikutti vain lievästi mitokondriaaliseen transkriptioon.
Tämä implikoi, että MTERF-proteiinin määrä ei määrittele raskaan juosteen eri
transkriptioyksiköitä edustavien transkriptien suhteellisia tasoja millään yksinkertaisella
tavalla vaan että siihen liittyy kompensaatiomekanismeja. Siinä missä MTERF-proteiinin
määrän muutoksella oli vain vähäinen vaikutus mitokondrion transkriptitasoihin,
TFAM:n ylituotannolla oli selkeä vaikutus, sillä se hidasti tRNA-tasojen palautumista
normaalille tasolle EtBr-käsittelyllä aiheutetun mitokondriaalisen DNA- ja RNA-
depleetion jälkeen.
2DNAGE:n (kaksiulotteinen neutraali agaroosigeelielektroforeesi) perusteella
MTERF:n ylituotannon sekä vaiennuksen havaittiin vaikuttavan mtDNA:n replikaation
taukoamiseen, vaikkei vaikutusta mtDNA:n kopiolukumäärään havaittu. Siksi katsottiin,
että MTERF edistää replikaation taukoamista kanoonisessa sitoutumiskohdassaan ja
myös uusissa, heikommissa sitoutumiskohdissaan, jotka löydettiin käyttäen EMSA:a
(elektroforeettinen liikkuvuudenmuutoskoe) ja SELEX:ä (DNA-ligandien systemaattinen
evoluutio eksponentiaalisella rikastuksella). TFAM:n voimistamat replikaation
pysäytyskohdat olivat varsin diffuuseja toisin kuin MTERF:n vastaavat.
Immunosytokemia osoitti, että epitooppi-merkityt MTERFD1 ja MTERFD3 ovat
mitokondriaalisesti kohdennettuja proteiineja, mutta EMSA:n ja SELEX:n keinoin ei
löydetty sekvenssispesifejä sitoutumiskohtia kummallekaan näistä proteiineista.
Epitooppi-merkityn MTERFD3:n ja hieman vähemmissä määrin MTERFD1:n
ylituotannon havaittiin vähentävän mtDNA:n kopiolukumäärää ja estävän mtDNA:n
replikaation loppuunsaattamista HEK293T-johdetuissa soluissa perustuen 2DNAGE:lla
havaittuun tiettyjen replikaatiovälituotteiden lisääntyneeseen määrään.
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Yhteenvetona tässä väitöskirjassa esitetyt tulokset valottavat MTERF:n roolia
mitokondriaalisessa transkriptiossa ja osoittavat, että MTERF vaikuttaa myös mtDNA:n
replikaatiossa. Näitä löydöksiä analysoidaan myös TFAM-tutkimuksen tulosten valossa.
Tämä tutkimus luo hyvän pohjan MTERFD1:n ja MTERFD3:n jatkotutkimukselle, sillä
nyt raportoidut tulokset osoittavat, että niillä mahdollisesti on rooli mtDNA:n
replikaatiossa.
20
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1. Introduction
Mitochondria have evolved from a symbiotic relationship between an ancestral eukaryote
cell lacking mitochondria and an aerobic eubacterium (proteobacterium) capable of
oxidative phosphorylation, as described by Margulis (1981). Nowadays this commonly
accepted endosymbiosis theory considers that the protoeukaryote has internalized the
simpler proteobacterium, which then evolved into mitochondria (Gray et al. 1999,
Andersson et al. 2002). From those early days mitochondria have evolved to be
membrane-bound cell organelles with a genome and genetic code of their own.
The most important function of mitochondria is to release energy from carbohydrates,
fatty acids and amino acids to be used by the cells, and thus mitochondria are sometimes
called the power plants of cells. The respiratory chain is located in the inner
mitochondrial membrane where the final steps of energy conservation take place
(Scheffler 1999). It has been established that mitochondria have other functions, in
addition to energy production. Mitochondria are generally needed for proper cell function
since they have various tasks in building, breaking down and recycling molecules within
the cell. Mitochondria function in heat production as reviewed by Watanabe et al. (2008),
they serve as a storage for calcium and play a role in calcium signalling as well as have a
role in regulating membrane potential (Graier et al. 2007). Mitochondria have a role in
cell metabolism and are required for biosynthesis of heme (Schultz et al. 2010) and
steroids (Sewer and Li 2008) and then again in liver in metabolic detoxification of
ammonia in urea cycle (Campbell 1997). Mitochondria also have a role in cell
proliferation (Merkwirth and Langer 2009). They have been reported to be involved in
apoptosis (Desagher and Martinou 2000, Sastre et al. 2000, Kar et al. 2010) and
mutations occurring in the mitochondrial genome have been suggested to have a role in
the pathogenesis of many diseases (Jacobs 1997, Taylor and Turnbull 2005, Copeland
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2010). Mitochondrial diseases are a broad range of diseases that are due to various point
mutations and genome rearrangements occurring in the mitochondrial genome
(Suomalainen 1997, Zeviani 2004) or in nuclear genes coding for mitochondrial proteins.
Mitochondrial dysfunction is suggested to have a role in type 2 diabetes (Wang et al.
2010) and in many neurogenerative diseases as well as in cancer (de Moura et al. 2010).
Recently mitochondria were established to have a role in metastasis, as ROS scavengers
were found to be therapeutically effective in suppressing metastasis (Ishikawa and
Hayashi 2010). Also more and more data is published supporting mitochondria having a
role in aging (Jacobs 2003, Trifunovic et al. 2004, Sanz et al. 2010b). However, such a
role is not necessarily a direct one, as in Drosophila mitochondrial ROS production was
found to correlate with lifespan but not to regulate it (Sanz et al. 2010a).
Mitochondria have their own genome and even use a variant of the genetic code,
making them different from other mammalian cell organelles (Barrell et al. 1979,
Anderson et al. 1981). This is due to the evolution of the mitochondria following the
symbiosis of the protoeukaryote and the proteobacterium. This evolutionary background
makes mitochondrial transcription and replication processes interesting fields of research.
Different models have been presented to describe mitochondrial DNA replication,
discussing whether it resembles more its nuclear or bacterial equivalent.
In the following literature review the mechanisms of mitochondrial DNA replication
and transcription, the proteins of the mitochondrial transcription termination factor
(MTERF) family and their possible roles in human mtDNA maintenance are discussed.
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2. Literature review
2.1 Mitochondria
2.1.1 Structure of mitochondria
Mitochondria are membrane bound cell organelles dedicated to energy production.
Historically from the 1950s up until the 1990s it was considered that mitochondria are
formed from two highly specialized membranes, the inner (IM) and outer membrane
(OM) and that the inner membrane forms cristae by infolding. This is also referred to as
the ‘baffle model’ of mitochondrial structure (Palade 1952).
Nowadays, the prevailing opinion is that mitochondria consist of at least 6
compartments, namely the outer membrane, the inner boundary membrane, the space
between the two membranes called the intermembrane space, the cristal membranes, the
intracristal space and the space inside the inner membrane which is called the
mitochondrial matrix (Perkins et al. 1997, Frey and Mannella 2000, Logan 2006). The
cristal membranes form lamellar structures. These are connected to the inner boundary
membrane by small tubular structures called crista junctions (Perkins et al. 1997). Sites,
where the inner boundary membrane comes into close contact with the outer membrane,
are known as contact sites. At these numerous contact sites there are protein translocation
pores through which the transportation of proteins from the cytosol to the matrix is
effected (Schatz and Dobberstein 1996).
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2.1.2  The mitochondrial network
Mitochondria are present in all human cells with few exceptions (essentially only mature
red blood cells). Different cells have a different degree of energy demand and this
determines the number and the shape of the mitochondria in each cell type. Mitochondria
form a dynamic network inside the cell, which can be considered as a reticulum
characterized by constant fusion and fission of the mitochondria (Bereiter-Hahn and Voth
1994, Nunnari et al. 1997), affected by many proteins (Thomson 2002). Mitochondria are
also attached to the cytoskeleton and it is established that cytoskeleton has an important
role in mitochondrial and cell morphology (Anesti and Scorrano 2006). In mammalian
cells the precise distribution of the mitochondria appears to be organized by the
microtubular network, and is modulated by many connector and motor proteins (for
review see Vale 2003, Hollenbeck and Saxton 2005). Intracellular transportation of
mitochondria is necessary if more mitochondria are required in certain part of the cell due
to increased energy demand or if a mitochondrion is to be degraded as reviewed by
Hollenbeck and Saxton (2005). Also, mitochondrial dynamics and organization within a
cell is highly cell-type specific, indicating the importance of interactions between
mitochondria and other intracellular compartments. Mitochondria are comparatively
immobile for example in adult rat cardiomyocytes where they present low amplitude
fluctuation or vibration (Beraud et al. 2009); conversely they are very mobile inside
neurons or pancreatic cells, showing complex dynamics including fission, fusion,
oscillating movement and even rapid long-distance migration as reviewed by Boldogh
and Pon (2007). It remains to be studied which proteins mediate the attachment between
mitochondria and microtubules. Also the role of these proteins, if any, in organizing
mtDNA remains to be elucidated.
2.1.3 The human mitochondrial genome
Mitochondrial DNA – or the rho factor as it was then called - was first reported in the
1940’s. Nass and Nass (1963) were the first who were able to detect chicken mtDNA
using microscopy. In the course of metazoan evolution the mitochondrial genome has
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gradually shortened to vary between 15-20 kb. Spacer sequences have almost completely
disappeared and most of the ‘original’ mitochondrial genes have been transferred to the
nuclear genome, which may facilitate mtDNA replication and make it less error-prone.
Human mtDNA, as illustrated in Figure 2.1, is a 16 568 bp long circular, double-stranded
DNA molecule (Anderson et al.  1981, Andrews et al.  1999).
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Figure 2.1. Human mitochondrial DNA (Anderson et al. 1981). Transfer RNAs are denoted in
the one letter amino-acid code and in addition L(UUA/G) = tRNALeu(UUR), L(CUN) = tRNALeu(CUN),
S(UCN) = tRNASer(UCN) and S(AGY) = tRNASer(AGY). 12S = 12S ribosomal RNA, 16S = 16S
ribosomal RNA, ND1-6 = NADH dehydrogenase 1-6, COXI-III = Cytochrome c oxidase I - III,
ATPase 8 = ATP synthase subunit 8, ATPase 6 = ATP synthase subunit 6, Cytb =
apocytochrome b.
2.1.4 Organization of the human mitochondrial genome
13 out of the 37 human mitochondrial genes encode protein subunits needed in oxidative
phosphorylation. ND1-6 and ND4L encode subunits of NADH dehydrogenase (complex
I) of the respiratory chain. Apocytochrome b encodes a protein subunit of the bc1
complex (complex III), COXI-III encode subunits of the cytochrome c oxidase (complex
IV) and ATP synthase subunits 6 and 8 are part of the ATP synthase complex (complex
V) (Anderson et al. 1981, Chomyn et al. 1985). Two genes encode ribosomal RNA
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(rRNA) molecules needed for mitochondrial translation. mtDNA also contains the tRNA-
encoding genes needed for mitochondrial translation, although nuclearly encoded tRNA
has been also shown to be imported to mitochondria under some conditions. Suyama
(1967) first reported nucleus-encoded tRNA present in Tetrahymena pyroformis
mitochondria. According to Tarassov et al. (2007) mitochondria import tRNAs to
compensate for any lack of mitochondrial tRNAs. For example the marsupial
mitochondrial tRNALys gene is actually a pseudogene, the functional tRNALys being
imported from the cytosol (Dörner et al. 2001). Cytosolic tRNAGln(CUG) and tRNAGln(UUG)
are also imported in yeast and human mitochondria (Rinehart et al. 2005, Rubio et al.
2008) even if the mitochondrial tRNAGln(UUR) is expressed and able to read the CAA and
CAG codons (Maréchal-Drouard et al. 1993). This kind of redundancy found in yeast and
human mitochondria cannot yet be explained.
2.1.5 Mitochondrial nucleoids and inheritance of mtDNA
According to present knowledge mitochondrial DNA is organized in nucleoids as
reviewed by Spelbrink (2010). One nucleoid has been reported to contain typically 2-10
mtDNA molecules (Iborra et al. 2004, Legros et al. 2004). mtDNA has been shown to be
packed with proteins as dynamic nucleoids (Garrido et al. 2003, Alam et al. 2003) in
which it is wrapped with TFAM proteins. Spelbrink et al. (2001) reported that the human
Twinkle helicase colocalizes with mtDNA and Garrido et al. (2003) showed that mtDNA
polymerase POLG also copurifies with mtDNA nucleoids.  The list of confirmed
nucleoid proteins currently includes the human DEAH helicase DHX30 (Wang and
Bogenhagen 2006), the protein designated M19 (Sumitami et al. 2009), the DNA binding
protein ATAD3 (He et al. 2007), Dna2 (Duxin et al. 2009) and recently MTERFD3
(Pellegrini et al. 2009). mtSSB, mitochondrial single stranded DNA binding protein, is
required for maintenance of mtDNA but not for mitochondrial nucleoid organization
(Ruhanen et al. 2010). mtDNA is often erroneously referred to as ‘naked’ which is
clearly not the case.
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To explain the organization and maintenance of mtDNA in mammalian somatic cells
Jacobs et al. (2000) proposed that a group of mtDNA molecules known as a
mitochondrial nucleoid form the unit of genetic function. The mtDNA molecules
comprising one nucleoid can also be diverse genetically. Jacobs et al. (2000) suggested
that a nucleoid replicates as a unit and that the genetically identical daughter nucleoids
segregate in a manner resembling mitosis when the nucleoid finally divides. The slow
rate of mitotic segregation in cultured heteroplasmic cell-lines could be explained by this
model, although there is no direct experimental evidence to support it.
Nuclear genes are inherited in Mendelian fashion, one allele from each parent. The
mitochondrial genome on the other hand is inherited only from the mother (maternal
inheritance). Shitara et al. (2000) reported that mitochondria of spermatozoa enter the egg
but are soon after destroyed or inactivated during embryonic development (i.e. they do
not affect the zygote genetically). Schwartz and Vissing (2002) reported the first
observed case of paternal inheritance (i.e. paternal leakage of mtDNA). The case reported
was a patient suffering from a mitochondrial myopathy resulting from a 2 bp deletion in
the ND2 gene of mtDNA. The authors found out that this mutation was of paternal origin
and was present in 90% of the patient’s muscle mtDNA (Schwartz and Vissing 2002).
Later on Kraytsberg et al. (2004) reported recombination of maternal and paternal human
mitochondrial DNA in this same patient. However, to date this remains the sole such
case.
When all mtDNA molecules in a mitochondrion or in a cell are identical, the situation
is referred to as homoplasmy, whereas the opposite situation is referred to as
heteroplasmy. When mtDNA is heteroplasmic random mitotic segregation has been
proposed to cause variation in mitochondrial genotype between tissues (Macmillan et al.
1993, Shoubridge 2000). It was long ago suggested that during oogenesis and early
embryogenesis there is little or no selection against pathogenic mtDNA mutations, and a
genetic bottleneck was proposed to explain the rapid selection of mtDNA genotype.
Jenuth et al. (1996) showed that, in murine cells, mtDNA genotype varied less in
primordial germ cells than in primary or mature oocytes and therefore the genetic
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bottleneck was suggested to cause selection early in the developing oocyte. Individuals
could therefore finally carry different amounts of mutant and normal mtDNAs in
different tissues and family members suffering from the same mitochondrial disease may
thus present very different phenotypes (mitochondrial diseases are discussed in more
detail in section 2.1.6 below). Wai et al. (2008) finally showed that, during
folliculogenesis, some nucleoids are actively replicated whereas some are not and this
correlates with an increase in the mtDNA genotype variance in the primary or mature
oocytes.
2.1.6 Diseases caused by mutations in mitochondrial DNA
Human disorders rising from mutations in the mitochondrial genome were first reported
in the late 1980s (Holt et al. 1988, Wallace et al. 1988a, Wallace et al. 1988b). They may
be grouped by their target gene or the type of the mutation.
2.1.6.1 Point mutations in mitochondrial protein coding genes
The first group consists of inherited and often heteroplasmic point mutations in
mitochondrial protein coding genes. Leber’s hereditary optic neuropathy (LHON) is
caused by mutations in genes encoding complexes I or III (Wallace et al. 1988a, Brown
et al. 1992). The disease is characterized by the destruction of the optic nerve, leading to
rapid bilateral loss of central vision during adolescence.
2.1.6.2 mtDNA rearrangements
Partial mtDNA deletions or duplications (mtDNA rearrangements) cause changes in the
relative content of mitochondrial genes and create abnormal gene junctions. Such
mutations are sporadic i.e. they occur with no inheritance. Holt et al. (1988) found
deletions in the muscle cell mtDNA of patients suffering from different types of
mitochondrial myopathy. mtDNA depletion is characterized by a reduced amount of
mtDNA molecules, as reviewed by Suomalainen and Isohanni (2010). The associated
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disease mechanism is greatly affected by mtDNA replication and nucleotide pool
regulation (Suomalainen and Isohanni 2010). Depleted mtDNA and multiple mtDNA
deletions have been found to be autosomally inherited but they occur also as sporadic
cases. The major phenotype, PEO (progressive external ophthalmoplegia) manifests as
ragged-red fibers in the muscle together with ptosis and external ophtalmoplegia (Laforet
et al. 1995). PEO is often caused by multiple deletions of mtDNA (Zeviani et al. 1989).
Some patients carrying mtDNA deletions show only progressive external
ophthalmoplegia (PEO) (Schon et al. 1997) whereas others may have Kearns-Sayre
syndrome (KSS). KSS is a severe disease affecting many tissues and organs, the features
often including PEO, ragged-red fibres, ataxia, heart symptoms, mental retardation and
dwarfism. The patient is often affected before the age of 20 years (Schon et al.  1997),
and clinical features differ greatly between patients, which makes the diagnosis of such
diseases rather demanding for a physician.
2.1.6.3 Point mutations in mitochondrial tRNA and rRNA genes
Third group of mitochondrial mutations are point mutations in tRNA and rRNA coding
genes. More than 70 mutations have been found in tRNA genes (Brandon et al. 2005). In
addition, a well documented mutation in an rRNA coding gene has been reported, namely
the A1555G mutation in 12S rRNA, which is associated with maternally inherited non-
syndromic deafness and aminoglycoside-induced deafness (Prezant et al. 1993).
Regarding non-syndromic deafness, the nuclear genetic background affects the
phenotypic expression of the A1555G mutation (Guan et al. 2001).
Different mutations in the same tRNA gene and also mutations in different tRNA
genes may cause different diseases. In addition, individuals within one family carrying
the same mutation may present phenotypes differing dramatically from each other.
Mutations in mitochondrial tRNA coding genes cause a wide range of diseases. Goto et
al. (1990), Kobayashi et al. (1990) and Goto et al. (1991) first reported that certain
mutations in the tRNALeu(UUR) encoding gene cause MELAS syndrome (mitochondrial
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encephalomyopathy with lactic acidosis and strokelike episodes). The same mutation also
causes maternally inherited diabetes mellitus +/- deafness, mitochondrial myopathy,
CPEO (chronic progressive external ophtalmoplegia) and PE (progressive
encephalopathy) in different patients (Brandon et al. 2005). tRNALys mutations cause
MERRF syndrome (myoclonus epilepsy and ragged red fibers) (Wallace et al. 1988b,
Shoffner et al.  1990) whereas tRNASer mutations cause maternally inherited
sensorineural deafness and ataxia (Tiranti et al. 1995). In addition, many other point
mutations found in tRNA coding genes are pathogenic with a variety of clinical
phenotypes.
2.1.6.4 MELAS mutations
The A>G transition at np 3243 within the tRNALeu gene responsible for decoding UUR
(R = A or G) leucine codons (tRNALeu(UUR)) is the most common mutation causing the
MELAS syndrome. Up to 80% of MELAS patients carry the A3243G mutation (Goto et
al. 1990, Kobayashi et al. 1990). Approximately 10% of MELAS patients have a T>C
transition mutation at np 3271 (Goto et al. 1991). The remaining 10% of MELAS patients
carry other mutations in the tRNALeu(UUR) gene or in some other gene. In the tRNALeu(UUR)
coding gene the A3243G mutation site is located in the dihydrouridine (DHU) loop and
the T3271C mutation in the anticodon stem. Interestingly, the clinical phenotypes are the
same even if the two mutations are located in different areas of the tRNA.
Pavlakis et al. (1984) first described the MELAS syndrome. If mutated mtDNA is
present at a relatively low percentage, the patient manifests only type II diabetes, which
in some cases can occur with deafness (van den Ouweland et al. 1992). However, some
patients can carry high levels of mutant mtDNA yet only show mild or tissue-restricted
phenotypes, such as diabetes/deafness or PEO. This variability remains unexplained. It is
generally considered that the different patient phenotypes are affected also by nuclear
genes, in addition to the heteroplasmy level and the distribution of the mutant mtDNA in
different tissues.
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One mutation can cause clinical phenotypes that differ greatly from each other in
different families, indicating that the relative amount of mutant mtDNA does not fully
explain all of the variation (van den Ouweland et al. 1992, Lightowlers et al. 1997).
When studying the distribution of the A3243G mutation Chinnery et al. (1999) tested
whether the mutation percentage of different tissues arises from a totally random process.
They found out instead that it segregates in a non-random fashion. This finding suggests
a nuclear impact on mtDNA segregation. Battersby et al. (2003) reported evidence for the
nuclear control of mtDNA segregation in the mouse.
2.2 mtDNA transcription
The two strands of the mitochondrial DNA are named as heavy (H-strand) and light (L-
strand) strands as shown below in Figure 2.2. The nomenclature is due to the strands
showing different buoyant densities under cesium chloride density gradient
centrifugation, since the heavy strand is purine rich and the light strand purine poor. Each
strand has one promoter, designated thus as the H-strand promoter (HSP) and the L-
strand promoter (LSP). The light and heavy strands are transcribed in opposite directions.
Most of the genes are transcribed from the heavy strand. 10 mRNAs, 2 rRNAs and 14
tRNAs of the heavy strand are part of two polycistronic transcripts and only 1 mRNA and
8 tRNAs are encoded by the light strand, as illustrated in Figure 2.1. Genes encoding
ATPase 8 + ATPase 6 and ND4L + ND4 are translated from bicistronic mRNAs. Only
part of the light strand is coding, but nevertheless it is transcribed almost completely.
Chang and Clayton (1984) first identified the independent promoter sequences for both
heavy and light strand transcription using in vitro assays.
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Figure 2.2. The two strands of the mitochondrial genome are called the heavy and light
strand. HSP = heavy strand promoter, LSP = light strand promoter, 12S = 12S ribosomal RNA,
16S = 16S ribosomal RNA, TERM = transcription termination sequence. See Figure 2.1. for more
detailed description of the human mtDNA functional loci.
Human mitochondrial DNA is packed very tightly and economically as there are virtually
no non-coding sequences between genes i.e. human mtDNA lacks introns and spacers.
Genes are packed so tightly that some of the genes partially overlap. The polycistronic
preliminary transcript therefore has to be post-transcriptionally processed to obtain the
final transcription products. According to Reichert et al. (1998) one tRNA containing the
common base is cleaved out first when processing two adjacent tRNAs sharing a
common base. Subsequently the remaining tRNA, now lacking one base, is edited to
form the final transcript. Quoting Börner et al. (1997), tRNA editing is common in many
organisms. In addition to the 37 genes in the human mtDNA there is a ~1 kb long non-
coding (D-loop) region (D-loop = displacement loop) that is needed for initiation of
mtDNA replication and transcription (Anderson et al. 1981, Shadel and Clayton 1997).
2.2.1 Proteins needed for transcription initiation
The mitochondrial transcription machinery is a rather simple system, consisting of
mitochondrial RNA polymerase, the core protein, mitochondrial transcription factor A
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(TFAM) which acts as an activator, and TFB1M or TFB2M which are needed for
initiation. TFB2M has been shown to be primarily the transcription factor (Cotney et al.
2007). In 1985 it was reported that a transcription factor (or factors) is needed for specific
initiation of transcription at HSP and LSP (Fisher and Clayton 1985) and the same year
Hixson and Clayton (1985) established that specific residues at the transcription initiation
sites are needed for transcription initiation from either HSP or LSP. Subsequently Fisher
et al. (1987) established that binding of a transcription factor to a regulatory element,
independent of orientation, is required for successful promoter selection. The relevant
factor, human TFAM protein of 24.4 kDa, was finally purified and characterized in 1988
(Fisher and Clayton 1988). Recently, Shutt et al. (2010) reported that specific
transcription initiation can take place in vitro independent of TFAM from both LSP and
HSP1.
2.2.1.1 Mitochondrial RNA polymerase
Mitochondrial RNA polymerase activity was first characterized by Shuey and Attardi
(1985). Masters et al. (1987) first established the homology between the yeast
mitochondrial RNA polymerase and those of bacteriophages T3 and T7 whereas no
homology was detected between the yeast mitochondrial enzyme and E. coli RNA
polymerase. Tiranti et al. (1997) identified the nuclear gene on chromosome 19p13.3.
coding for the human mitochondrial RNA polymerase (h-mtRPOL, here called
POLRMT) which is a protein of 1230 amino acids. Prieto-Martin et al. (2001) suggested
that additional factors are needed for transcription initiation, since POLRMT, either alone
or together with TFAM or the termination factor MTERF (see below, section 2.2.2), was
not able to initiate transcription in vitro. Note also the recent finding of Shutt et al.
(2010), showing that TFAM is not necessary to initiate transcription in vitro from LSP or
HSP1.
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2.2.1.2 Mitochondrial transcription factor A
TFAM belongs to the high mobility group (HMG)–box family of DNA-binding proteins
(Parisi and Clayton 1991), and is able to alter mtDNA structure, condensing, unwinding
and bending it (Fisher et al. 1992) which in turn might facilitate transcription initiation.
TFAM protein has two HMG-box domains with a 27 amino acid (aa) linker region
between them and a 25 aa C-terminal tail that has been established to be important for
accurate DNA recognition, and is limiting for transcriptional activation (Dairaghi et al.
1995). Knocking out murine Tfam leads to a decrease in mtDNA copynumber in
heterozygous mice and in homozygous mice the knockout is embryonic lethal with
massive depletion of mitochondrial DNA (Larsson et al. 1998). These findings clearly
show that TFAM has an important role in mtDNA maintenance and is also an essential
protein for embryonic development (Larsson et al. 1998).
TFAM is important in the initiation of mitochondrial transcription, since human
mitochondrial RNA polymerase needs TFAM to recognize the promoters of human
mitochondrial DNA. TFAM is a rather typical HMG protein in many respects e.g. it
prefers binding oxidatively damaged mitochondrial DNA (Yoshida et al. 2002), is able to
recognize cisplatin damaged DNA where it induces bends (Chow et al. 1994, Chow et al.
1995). TFAM binds mtDNA showing no sequence specificity (Fisher et al. 1989, Fisher
et al. 1992). The TFAM monomer also binds four-way DNA junctions for which it needs
both of the HMG-box domains (Ohno et al. 2000). TFAM, like many other HMG-box
proteins, can be acetylated: Dinardo et al. (2003) reported that TFAM is acetylated at one
lysine residue. Ohgaki et al. (2007) reported that the C-terminal tail of TFAM strengthens
its binding to mtDNA. The evidence presented by Shutt et al. (2010) that transcription
can be initiated in vitro from LSP and HSP1 independently of TFAM, raises questions
concerning the primary role of TFAM in mitochondrial transcription.
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2.2.1.3 Mitochondrial transcription factor B
A human counterpart of Saccharomyces cerevisiae mitochondrial transcription factor B
was first reported by McCulloch et al. (2002). Human “mtTFB” was shown to bind
mtDNA in a non-sequence-specific manner. McCulloch et al. (2002) showed that, in
vitro, mtTFB (now designated TFB1M) and TFAM together are able to activate
transcription from the human mitochondrial light-strand promoter. TFB1M can bind S-
adenosylmethionine and shows homology to N6 adenine RNA methyltransferases
methylating the N6 position of adenine in specific nucleotides in rRNA (McCulloch et al.
2002). This was the first report of a transcription factor related to an RNA-modifying
enzyme (McCulloch et al. 2002).
Falkenberg et al. (2002) named two novel ubiquitously expressed transcription factors
needed to initiate mammalian mitochondrial transcription as TFB1M and TFB2M:
TFB1M is identical to the mtTFB identified by McCullogh et al. (2002). Falkenberg et
al. (2002) used purified recombinant versions of the mitochondrial proteins and
suggested that the minimum requirement for transcription from both heavy and light
strand human mtDNA promoters consists of a protein complex of TFB1M or TFB2M,
TFAM and the mitochondrial RNA polymerase. TFB2M is more active in transcription
activation than TFB1M but is also related to bacterial rRNA methyltransferase
(Falkenberg et al. 2002). Seidel-Rogol et al. (2003) reported that TFB1M has two
functions: a role in transcription and also as an rRNA methyltransferase, which can
methylate a conserved stem-loop both in bacterial 16S rRNA and in the homologous
human 12S rRNA molecule. Cotney et al. (2007) established, using cultured cells, that
TFB2M is primarily the transcription factor, as over-expression of TFB2M induces an
approximately 2-fold increase in overall mitochondrial transcript levels whereas TFB1M
has no such effect. Using cultured cells over-expressing TFB1M Cotney et al. (2007) also
first presented in vivo evidence that TFB1M is the primary human mitochondrial 12S
rRNA methyltransferase. Furthermore, Cotney et al. (2009) showed that TFB1M and
TFB2M collaborate in mitochondrial biogenesis.
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Tfb1m and Tfb2m, the murine TFB1M and TFB2M homologues, are ubiquitously
expressed (Rantanen et al. 2003). Most metazoans seem to have two TFBM genes
(Rantanen et al. 2003, Cotney and Shadel 2006). Cotney and Shadel (2006) reported that
the two TFBM genes found in metazoans arise from a gene duplication event that took
place before the divergence of fungi and metazoans in evolution, and in some organisms
the selective pressure finally led to loss one of the genes.
Human TFB1M and TFB2M are both capable of binding the C-terminal tail of TFAM,
the region that is needed for the activation of transcription (McCulloch et al. 2003).
Human TFB1M co-immunoprecipitates with human POLRMT (McCulloch et al. 2003)
indicating that it forms a link between the human TFAM and POLRMT which would
further explain the initiation of transcription in human mtDNA (McCulloch et al. 2003).
As TFB1M co-immunoprecipitates with POLRMT and in vitro has been shown to
activate transcription, it is still possible that TFB1M has a role also in transcription which
remains to be elucidated.
TFAM is essential in transcription initiation and it is required for POLRMT /TFB2M
to be able to recognize the promoter (Gaspari et al. 2004). Gaspari et al. (2004) proposed
that TFAM binds mtDNA inducing a structural change, enabling the POLRMT /TFB2M
complex to recognize the promoter sequence. Sologub et al. (2009) showed that TFB2M
facilitates promoter melting but is not a limiting factor for protein recognition. They also
proposed that TFB2M has a role as a transient component of the catalytic site of the
transcription initiation complex since it interacts with the priming substrate (Sologub et
al. 2009). Lodeiro et al. (2010) showed using transcription factors A and B2, which were
isolated from Escherichia coli, that both of them are needed for open complex formation
which is the rate-limiting step for production of the first phosphodiester bond whereas the
subsequent steps require only TFB2M. Litonin et al. (2010) established that only TFAM
and TFB2M are needed for successful transcription in vitro whereas, as mentioned above,
Shutt et al. (2010) have presented data indicating that in vitro transcription initiation can
occur independently of TFAM.
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2.2.2 Models for heavy strand transcription
Several models have been proposed to explain the transcription pattern of the heavy
strand. Montoya et al. (1983) suggested the now generally accepted idea that there are
two heavy strand transcription units, one principally for the rRNAs and one for the
mRNAs, shown in Figure 2.3. This model was based on the identification of two 5’-
triphosphate termini in heavy strand transcripts (Montoya et al. 1981, 1982).
Transcription starts from two sites, PH1 (16 bp upstream of the tRNAPhe encoding gene)
and PH2 (located close to the 5´ end of the 12S rRNA encoding gene) (Montoya et al.
1982). Transcription from these sites yields two distinct polycistronic transcripts which
are processed to mature transcripts (Clayton 1984). This model also explains why rRNAs
are synthesised more frequently than mRNA molecules, as reported by Ojala et al.
(1981). mRNA and rRNA molecules also have different decay rates which may also
affect the relative steady-state levels of these molecules.
According to Montoya’s model, transcription unit starting from PH1 is dedicated to
transcription of the rRNA genes whereas transcription starting from PH2 produces a
primary transcript of almost the whole heavy strand. The protein and rRNA coding genes
are flanked by tRNA genes and cutting and processing of tRNAs is a prerequisite to
producing mature mRNA and rRNA transcripts. Interestingly, the tRNAPhe gene is read
only as a part of the rRNA transcription unit (Montoya et al. 1983). On the other hand,
tRNALeu(UUR) is only included in the mRNA transcription unit, since rRNA transcription
unit is terminated within the tRNALeu(UUR) coding sequence.
A competing theory states, based purely on in vitro experiments, that there is only one
initiation site for heavy strand transcription. According to Ojala et al. (1981) there is a
premature transcription termination site after the rRNA genes. The two models described
above are not completely exclusive and in addition there are several other models which
fall somewhere in between them.
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Figure 2.3. Proposed transcription units of the heavy and light strand in mammalian
mtDNA and the proteins needed for transcription. The mRNA transcription unit produces a full
length transcript of the mtDNA heavy strand. The rRNA transcription unit is dedicated to the
transcription of mitochondrial rRNAs and two tRNAs. TFAM is shown here as a part of the
transcription machinery although Shutt et al. (2010) have recently shown that in vitro transcription
can occur independently of TFAM from LSP and HSP1. Adapted from Scarpulla (2008).
The finding of two promoter sites in vivo strongly indicates that there are two initiation
sites for transcription. Both of the models presented above are credible but only one of
the promoters has been clearly shown to be functional in vitro. These transcription units
partially overlap and their initiation sites are located close to each other (Montoya et al.
1983). A protein promoting premature termination of transcription immediately after
rRNA genes in vitro was later characterized, initially supporting the idea of a single
initiation site (Kruse et al. 1989). This protein, mitochondrial transcription termination
factor (MTERF), operates in vitro at the gene boundary between 16S rRNA and
tRNALeu(UUR) (Kruse et al. 1989). However, Fernandez-Silva et al. (1997) showed that, in
vitro, MTERF alone cannot terminate transcription although in vivo studies of this issue
have not yet been carried out. Many questions remain to be answered concerning the
functions of MTERF. Importantly, even if MTERF turns out to function as a
mitochondrial transcription termination factor in vivo, this does not exclude Montoya’s
model.
2.2.3 Mitochondrial light strand transcription
The light strand promoter (LSP) is located near to the origin of the heavy strand
replication (see figure 2.3) and therefore it was suggested that LSP also provides heavy-
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strand replication with RNA primers. Light-strand transcripts starting from the non-
coding region were first found by Wallberg and Clayton (1983) and Chang and Clayton
(1985) proved evidence that transcription from LSP, indeed provides RNA primers for
replication. Chang and Clayton (1987) furthermore identified and partially purified an
mtRNA-processing endoribonuclease (RNase MRP) that is able to cut RNA in a site-
specific manner creating the 3’-hydroxyl groups needed for the DNA polymerase to
initiate replication. Later, however, mitochondrial heavy strand replication and light
strand transcription were showed to be coupled, as the RNA primer for the initiation of
mtDNA replication was established to be synthesized in conjunction with transcription
and subsequently to remain annealed to the mtDNA template (Lee and Clayton 1998).
Recently it has been suggested that very little RNase MRP is found in mitochondria and
its role in mtDNA replication is questionable.
2.3 The MTERF protein family
The human MTERF protein was identified and purified some 20 years ago and is the
founder member of the MTERF protein family (Linder et al.  2005, Chen et al. 2005).
Human MTERF is the first characterized mitochondrial transcription termination factor
based on its in vitro activity. The nomenclature of the MTERF proteins, however, is
confusing. In this study and thesis the official (HUGO approved) names of the MTERF
genes and proteins are used. The nomenclature of the MTERF proteins is shown in Table
2.1. below.
Table 2.1. Nomenclature of the MTERF protein family
Official name Other names in literature NCBI accession number
(human protein)
MTERF mTERF, mTERF1 NP_008911
MTERFD1 mTERF3 NP_057026
MTERFD2 mTERF4 NP_872307
MTERFD3 mTERF2 NP_001028222
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Vertebrates, other metazoans and plants all have homologues of the human MTERF
proteins as reported by Linder et al. (2005). The MTERF family proteins share sequence
similarity and a conserved 30 aa long MTERF motif. Linder et al. (2005) established that
there are 4 subfamilies in the MTERF protein family. Vertebrates have all four different
MTERF genes and MTERF and MTERFD3 are unique to vertebrates. MTERFD1 and
MTERFD2 are found also in worms and insects, and represent the ancestral MTERF
genes in metazoans (Linder et al. 2005).  Interestingly fungi do not contain any MTERF-
like proteins which might indicate that fungi lost the MTERF genes early in evolution or
else that there has been some kind of lateral gene transfer between ancestral metazoans
and plants. In plants, MTERF genes were also observed to have been duplicated many
times (Linder et al. 2005). All the metazoan MTERF proteins are predicted to be
mitochondrial. Most of the plant MTERF proteins are also predicted to be targeted to
mitochondria or chloroplasts. Very recently, the MTERF crystal structure was published,
shedding more light on the functional role of MTERF and also the other members of the
MTERF protein family (Jiménez-Menéndez et al. 2010, Yakubovskaya et al. 2010).
2.3.1 The mitochondrial transcription termination factor
The human MTERF encoding gene is located on chromosome 7, at locus 7q21-q22
(Fernandez-Silva et al. 1997). The mature protein consists of 342 amino acids
(Fernandez-Silva et al. 1997), having a mitochondrial targeting sequence of 57 amino
acids and an alternative start codon located at nucleotide position 138. Daga et al. (1993)
reported that in vivo MTERF exists in 2 or 3 isoforms. The sizes of these isoforms were
reported to range from 31 to 34 kDa (Daga et al. 1993). A protein corresponding to the
34 kDa sized isoform was shown to terminate transcription in vitro (Daga et al. 1993).
MTERF brings about transcription termination in a biased ‘bipolar’ manner and it is not
dependent on POLRMT (Shang and Clayton 1994) (i.e. it works in the presence of other
RNA polymerases). The latter authors also were first to report that MTERF is capable of
bending mtDNA (Shang and Clayton 1994).
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Termination of the rRNA transcription unit occurs at the boundary of the 16S rRNA
and tRNALeu(UUR) genes. MTERF has been proposed to have a limiting role in regulating
rRNA synthesis in relation to that other of RNA molecules. Human MTERF specifically
is proposed to affect the transcript starting from the rRNA specific initiation site of the
heavy strand in the mtDNA (Kruse et al. 1989, Daga et al. 1993).
Kruse et al. (1989) established that MTERF binds a 28 bp sequence in the
tRNALeu(UUR) gene which is downstream and adjacent to the 16S rRNA gene, now also
referred to as the canonical binding site. A 13 bp sequence in the middle of this fragment
is needed to carry out accurate termination of the rRNA transcription unit i.e. is needed to
form the 3’ end of 16S rRNA (Christianson and Clayton 1988). The DNA sequence is
capable of functioning in a bidirectional manner to bring about accurate termination of
transcription (Christianson and Clayton 1986). The A3243G MELAS mutation is situated
in the middle of the MTERF DNA binding sequence which makes the functional role of
MTERF an interesting topic to study relating to disease. The A3243G MELAS mutation
has been shown to decrease the binding affinity of MTERF to its target sequence in vitro
(Chomyn et al. 1992), as well as to downregulate transcription termination in vitro (Hess
et al. 1991). Yakubovskaya et al. (2010) furthermore reported that the G3242A mutation
prevents MTERF from terminating transcription in vitro and that the G3249A mutation
prevents MTERF from binding specifically, and therefore decreases MTERF termination
activity.
Martin et al. (2005) reported a second binding site for MTERF, suggesting that it
creates a DNA ‘loop’ bringing together the transcription initiation and termination sites.
They further proposed that this could explain the many fold higher transcription activity
of the rRNA genes. Yakubovskaya et al. (2010) recently reported that MTERF binds
DNA initially in a sequence independent manner which is then followed by sequence
recognition. This then leads to an altered DNA structure, unwinding of the DNA double-
helix and base flipping. Yakubovskaya et al. (2010) also found that MTERF has more
interaction sites with the DNA light strand than with the heavy strand which supports the
findings of Nam and Kang (2005), who reported that MTERF shows preference for light-
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strand binding. These findings might also explain the orientation-influenced termination
activity, reported by Asin-Cayuela et al. (2005).
The crystal structure of MTERF (Arg56 – Ala399) in complex with the canonical
binding site DNA fragment (Jiménez-Menéndez et al. 2010, Yakubovskaya et al. 2010)
shows that the protein comprises nine left-handed helical MTERF repeats, each
consisting of three helices. These helices together create a left-handed superhelix called
the Zurdo domain, that binds continuous dsDNA altering its structure by inducing a bend
in it (Jiménez-Menéndez et al. 2010). They also discovered that a shorter variant of
MTERF, MTERF DN (Arg99 – Ala399), arising due to spontaneous proteolysis, is
capable of binding DNA although in a purely nonspecific manner (Jiménez-Menéndez et
al. 2010). The structural findings refute the suggestion that MTERF contains three
leucine zipper motifs forming an intramolecular structure to bring together the two basic
domains of MTERF in close proximity to the DNA target sequence (Fernandez-Silva et
al. 1997).
Prieto-Martin et al. (2004a) reported that rat MTERF needs to be in the
phosphorylated form in order to carry out efficient transcription termination in vitro. Rat
MTERF was shown to be phosphorylated at four sites (threonine, tyrosine and serine),
but this is not required for binding dsDNA.  Asin-Cayuela et al. (2005) reported a
completely opposite finding, namely that MTERF is functional in transcription
termination in vitro in the non-phosphorylated form and found no evidence of MTERF
being posttranslationally modified. Using recombinant human MTERF, Asin-Cayuela et
al. (2005) showed that MTERF transcription termination shows clear polarity in vitro;
when MTERF binds HSP in the forward orientation, transcription is arrested completely,
but in the opposite orientation it leads only to a partial arrest of transcription. According
to Asin-Cayuela et al. (2005) MTERF alone is capable of terminating transcription in
vitro.
Asin-Cayuela et al. (2004) suggested that MTERF is present in mitochondria in two
forms, either as an active monomer or as an inactive homotrimer and that MTERF binds
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mtDNA and it is active in transcription termination in vitro only when it is present as a
monomer. Asin-Cayuela et al. (2004) also proposed that the quantity of active MTERF in
transcription termination is regulated by the transition between the monomer and
homotrimer.
2.3.2 MTERF homologues in other organisms
As MTERF is a well conserved protein, its functional role maybe inferred from the
properties of its homologues in other organisms. Several MTERF homologues have been
cloned and characterized. These include the MTERF homologue in sea urchin, mtDBP
(Loguercio Polosa et al. 1999), and that from Drosophila called DmTTF (Roberti et al.
2003). mtDBP and DmTTF are, in terms of evolution, closer to MTERF and to
MTERFD3 than to MTERFD1 and MTERFD2 (Roberti et al. 2009). The murine
homolog of MTERF has also been cloned and characterized (Li et al. 2005).
mtDBP is a 348 aa mitochondrially targeted protein binding mtDNA at two distinct
sites, in the NCR at the 3´ end of the D-loop and in the gene boundary between the ND5
and ND6 genes (Roberti et al. 1991). mtDBP is thought to terminate rather than pause
mitochondrial transcription in sea urchins (Fernandez-Silva et al. 2001). Loguercio
Polosa et al. (1999) and Fernandez-Silva et al. (2001) showed that mtDBP arrests the
mitochondrial RNA polymerase of Paracentrotus lividus and that mitochondrial
transcription is regulated at the level of transcription termination. mtDBP has been
established to be the limiting factor in transcription termination, when the RNA
polymerase approaches the mtDBP binding site from the L-strand transcription direction.
Interestingly, when RNA polymerase approached from the opposite direction,
transcription termination was not affected by mtDBP (Loguercio Polosa et al. 2007).
Loguercio Polosa et al. (2007) therefore suggested that mtDBP is a polar transcription
termination factor. mtDBP acts also as a contrahelicase, indicating that it may have a role
in DNA replication, possibly as a negative regulator thereof (Loguercio Polosa et al.
2005).
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DmTTF binds two short non-coding sequences of the Drosophila mtDNA that earlier
had been predicted to be transcription termination sites (Berthier et al. 1986). The
binding sites are located in the gene junctions between tRNAGlu and tRNAPhe and
between tRNASer(UCN) and ND1 respectively (Roberti et al. 2003). Roberti et al. (2005)
established that DmTTF acts as a transcription termination factor in vitro, but does not
have a role in the formation of the 3´ end of mitochondrial transcripts (Roberti et al.
2006b). When DmTTF was knocked down, the transcript levels downstream of the
DmTTF binding sites were, however, increased, indicating that knocking down DmTTF
removes a transcriptional block (Roberti et al. 2006b). Rather surprisingly knocking
down DmTTF decreased some transcript levels upstream of its binding sites.
2.3.3  MTERFD1 and MTERFD3
Spåhr et al. (2010) have presented the structure of human MTERFD1, which consists of
alfa helical tandem repeats displaying a similar triangular three-helix motif as reported
for MTERF (Spåhr et al. 2010, Jiménez-Menéndez et al. 2010, Yakubovskaya et al.
2010). Park et al. (2007) established that MTERFD1 down-regulates mammalian
mitochondrial transcription initiation in vivo and that it can bind DNA, preferentially the
mtDNA promoter region. In the mouse, homozygous knockout of Mterfd1 is lethal and
the mouse embryos die at midgestation (Park et al. 2007) indicating that it is an essential
gene.
The Drosophila homologue of MTERFD1, Mterf3, has been reported to play a role in
mitochondrial protein synthesis (Roberti et al. 2006a). When Mterf3 was knocked down
it did not affect mitochondrial DNA replication, nor did it affect mitochondrial
transcription, but altered labelling of mitochondrially translated polypeptides indicates
that it plays a role in translation.
MTERFD3 has been reported to be a mitochondrial nucleoid protein (Pellegrini et al.
2009). It is expressed at high levels in heart, liver and skeletal muscle (Chen et al. 2005)
and also, according to Pellegrini et al. (2009), it is a rather abundant protein. Pellegrini et
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al. (2009) estimated that there is one MTERFD3 molecule per 265 bp of mtDNA.
MTERFD3 also binds mtDNA in a non-sequence specific manner according to Pellegrini
et al. (2009). Wenz et al. (2009) reported that loss of MTERFD3 leads to decreased
levels of mitochondrial mRNA and modulates OXPHOS function in mammals. However,
they localized MTERFD3 to the mitochondrial matrix (Wenz et al. 2009), and found
MTERFD3 to be immunoprecipitated with MTERF and MTERFD1, indicating that these
proteins can interact.
2.4 Mitochondrial translation
Barrell et al. (1979) first reported that the mammalian mtDNA genetic code differs from
the so called universal code. Four out of the 64 codons have a different meaning in the
mammalian mitochondrial genome when compared to other genomes. The unique
features of the mammalian mitochondrial genetic code are listed in Table 2.2. In human
mitochondria the ARG triplets as listed in Table 2.2. appear to serve as termination
signals, which is seen rarely in other mammals. Temperley et al. (2010) showed that in
human mitochondria these ARG triplets, likely together with other cis elements, promote
frameshifting in the mitoribosomes.
Table 2.2. Differences between the universal code and the mammalian
mitochondrial genetic code.
Codon Universal genetic code Mitochondrial genetic code (mammals)
UGA STOP Trp
AUA Ile Met
AGA Arg STOP
AGG Arg STOP
Nuclear-encoded factors are needed for mammalian mitochondrial translation, as
reviewed by Rorbach et al. (2007). Protein synthesis in the cytosol (or in chloroplasts in
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plants) requires 30 or more different tRNAs, whereas only 22 different tRNAs are needed
for human mitochondrial protein synthesis (Anderson et al. 1981). In mitochondria many
tRNA molecules can recognize any of the four nucleotides in the third ”wobble” position
in the triplet because of the relaxed codon-anticodon pairing rule (Barrell et al. 1980).
Mitochondrial amino acids generally need only one tRNA to read their codons but there
are two exceptions; leucine and serine require two tRNAs each. tRNALeu(UUR) and
tRNALeu(CUN), and tRNASer(AGY) and tRNASer(UCN) are dedicated to separate codon groups.
2.5 The principles of DNA replication
Conventionally, DNA is copied semi-conservatively i.e. replicated so that each of the
parental strands is used as a template (see Figure 2.4) to produce the complementary
strands as reviewed in Alberts et al. (2002). Only as the replication event is over and the
nascent DNA strands -consisting of one parental strand and its complementary strand- are
ready, they are separated.
3´
5´
3´
5´
3´
5´
5´
3´
5´
3´
Leading strand
Lagging strand
Okazaki fragments
Figure 2.4. DNA replication fork. DNA polymerase synthesizes DNA in the 5´ to 3´ direction and
therefore the lagging strand has to be replicated in Okazaki fragments.
The protein machinery required for DNA replication consists of several proteins having
different roles in the replication process as illustrated in Figure 2.5. DNA polymerase
catalyzes DNA synthesis, for which it requires a primer (a short RNA or DNA fragment).
DNA polymerase synthesizes DNA in the 5´ to 3´ direction. Before DNA polymerase can
advance, the DNA double helix needs to be opened. This is done by a protein called DNA
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helicase. It opens up the hydrogen bonds between the parental DNA strands, the
unwinding leading to supercoiling of the double stranded DNA template and creating
torsional stress. A protein called topoisomerase is thus needed to remove torsional stress
and supercoiling. Therefore, both helicase and topoisomerase are crucial for the DNA
polymerase to be able to copy the template DNA.
There are a few additional proteins needed for successful DNA replication. As the
lagging-strand is synthesized discontinuously, as Okazaki fragments, the parental strand
is temporarily left exposed. Single-strand binding protein SSB is needed to protect the
exposed single strand before the synthesis of the lagging strand takes place. Synthesis of
the lagging strand also needs a primer, and the priming is carried out separately for each
advancing Okazaki fragment to be elongated by the DNA polymerase. Once the Okazaki
fragment reaches the primer sequence of the previously completed Okazaki fragment, the
primer is removed by a ribonuclease, and DNA synthesis is continued up to the first
nucleotide of the preceding fragment. Finally a DNA ligase is needed to join together the
Okazaki fragments to create a continuous DNA strand.
RNA
primers
DNA polymerase on leading strand
Topoisomerase
Helicase
SSB
3´
3´
3´
3´
5´
5´
5´
5´
DNA polymerase on lagging strand
(replicated in Okazaki fragments)
Figure 2.5. The protein machinery required for DNA replication.
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2.6 Replication of human mtDNA
2.6.1 Different models of replication
As the mitochondria originate from the symbiotic relationship of an early eukaryotic cell
with a prokaryotic cell, the interesting question is whether the replication of the modern-
day mitochondrial DNA resembles more that of its prokaryotic ancestor cell or that of
eukaryotic cells. There are two competing models to describe mtDNA replication, the
strand-displacement model and the conventional, coupled leading- and lagging-strand
DNA synthesis model.
2.6.1.1 Strand-asynchronous replication of mtDNA
In 1972, studies by electron microscopy indicated that mammalian mtDNA is replicated
in an unconventional way, the replicating mtDNA having a single-stranded branch
(Robberson et al. 1972). This gave rise to the model presented by Clayton (1982),
referred to as the strand-displacement model involving strand-asynchronous and
asymmetric DNA replication. Until quite recently, mtDNA replication was thought to
occur uniquely as described in this model.
In the strand-displacement model the mtDNA strands are replicated at different times
as shown in Figures 2.6 and 2.8a. According to this model there are two replication
initiation sites for the two strands, heavy (leading) and light (lagging) strands, and these
initiation sites are located far apart from each other in the circular genome (Clayton
1982). Replication starts from the heavy strand replication (illustrated as green dotted line
in Figure 2.6) initiation site, OH, and two thirds of the leading strand is replicated before
replication of the lagging strand from OL (illustrated as red dotted line in Figure 2.6), the
light strand replication initiation site, in the opposite direction is initiated. As the heavy
strand is replicated the parental strands are separated from each other. Once the initiation
site for light strand replication has been uncovered, lagging strand replication may begin.
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All this involves continuous ssDNA synthesis taking places in both directions (Clayton
1982).
OH
OL
OH
OL
OH
OL
OL
OH
OL
OH
Figure 2.6. The strand-asynchronous replication model of the human mitochondrial DNA.
Adapted from Clayton (2000).
2.6.1.2 Strand-synchronous replication of mtDNA
Holt et al. (2000) first presented evidence for a more conventional mode of mtDNA
replication based on coupled leading- and lagging-strand DNA synthesis (see Figure
2.8b). This mechanism is similar to the one used to replicate mammalian nuclear DNA
(Lodish et al. 1999). This model suggests that the two strands are replicated
symmetrically and it occurs simultaneously. Only one replication initiation site is
therefore needed and replication proceeds on both strands in the same direction at the
same time. Bowmaker et al. (2003) reported that bidirectional replication starts
downstream of OH that is the heavy strand replication origin. Yasukawa et al. (2005)
mapped two sites in the NCR for bidirectional replication initiation in cultured cells
recovering from drug-induced mtDNA depletion. At OH one of the replication forks is
stalled whereas the other one continues replicating through the whole genome as shown
below in Figure 2.7. The replication machinery replicates mtDNA only in the
conventional 5’ - 3’ direction meaning that one of the strands is replicated in Okazaki
fragments (see Figure 2.8b). Black arrows in Figure 2.7 denote the replication fork
movement direction.
Holt et al. (2000) suggested that these two replication mechanisms might function in
mammalian mtDNA under different conditions. Namely, the two replication mechanisms
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introduced above are not mutually exclusive. In support of this idea, it was found that
strand-coupled replication occurs after EtBr-induced mtDNA depletion when cells
replicate mtDNA more actively. When the mtDNA is only maintained in cells that grow
‘normally’ replication seems to occur according to a mechanism more akin to the model
presented by Clayton (1982). Twenty-four hours after mtDNA depletion, cells were
found to contain replication intermediates from both replication modes indicating that the
cells were shifting back to normal mtDNA maintenance from active amplification mode.
Therefore, it is also possible to hypothesize that Clayton’s model with its single light
strand replication initiation site is an extreme case of Holt’s model (Holt et al. 2000).
OH OH
ab
OH
a
b
Figure 2.7. Bidirectional strand-coupled replication of mtDNA. Adapted from Bowmaker et al.
(2003) and Yasukawa et al. (2005).
2.6.1.3 RITOLS replication
There are many recent publications where authors using 2DNAGE have failed to detect
the single stranded replication intermediates predicted by the Clayton model (Holt et al.
2000, Kajander et al. 2001, Yang et al. 2002, Bowmaker et al. 2003, Reyes et al. 2005,
Yasukawa et al. 2005, Yasukawa et al. 2006). Instead of such partially single-stranded
replication intermediates, two groups of double stranded replication intermediates were
reported in these publications. The first are intermediates originating from coupled
leading- and lagging-strand DNA synthesis (Holt et al. 2000, Kajander et al. 2001, Reyes
et al. 2005, Yasukawa et al. 2006). Secondly, Yang et al. (2002) established that the
mammalian mtDNA contains extended regions of RNA:DNA hybrid as ribonucleotides,
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incorporated on the light strand, which are finally converted to DNA (see Figure 2.8c).
Yasukawa et al. (2006) subsequently found replication intermediates containing long
RNA segments extending over the whole lagging-strand before lagging-strand DNA
synthesis had taken place, introducing the concept of RITOLS replication i.e. RNA
incorporation throughout the lagging strand.
These two groups of replication intermediates not only have different ribonucleotide
content but also their initiation sites differ. Coupled leading- and lagging-strand DNA
synthesis initiates from a broad zone of many kilobases (Bowmaker et al. 2003, Reyes et
al. 2005), whereas RITOLS replication initiates only within the NCR (Yasukawa et al.
2006). This finding indicates that replication might occur in several different ways in
vertebrate mtDNA. On the other hand, the RITOLS type of replication resembles the
strand-asynchronous model presented by Clayton (1982), since there is considerable
delay between leading and lagging-strand DNA synthesis in both models. The single
stranded replication intermediates visualized by means of electron microscopy in 1970´s
and later by means of atomic force microscopy (Robberson et al. 1972, Kasamatsu and
Vinograd 1973, Brown et al. 2005) may be explained on the basis of loss of
ribonucleotide segments from RITOLS RIs.
Leading strand Leading strand
Okazaki
fragments
5´ ends of
RNA
Leading strand
Lagging strand
Template DNA
Nascent DNA
Nascent RNA
a) Strand-displacement
model
b) Coupled leading- and
lagging strand synthesis
c) RITOLS
replication
Figure 2.8. Different modes of mtDNA replication. a) Strand-displacement model. b)
Conventional coupled leading- and lagging-strand DNA synthesis. c) RITOLS replication.
(Adapted from Holt 2009).
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2.6.2  mtDNA replication machinery
2.6.2.1 mtDNA Polymerase gamma
The genes encoding components of the mtDNA replication machinery have been cloned
and the proteins characterized only rather recently, compared to other systems. So far the
only DNA polymerase implicated in mtDNA replication is the mtDNA polymerase
gamma (POLg) (Gray and Wong 1992, Ropp and Copeland 1996, Lecrenier et al. 1997).
Walker et al. (1997) mapped the human POLg coding gene to chromosome 15 at locus
15q25. It resembles both the E. coli DNA polymerase I and T7 DNA polymerase,
belonging to the family A group of DNA polymerases (Fridlender and Weissbach 1971,
Fridlender et al. 1972, Beese et al. 1993). The POLgA (catalytic) subunit polymerizes
DNA in the 5´?3´ direction and also has proofreading exonuclease activity acting in the
3´?5´ direction (Gray and Wong 1992). POLgA synthesizes DNA at 180 bp/min rate
according to Korhonen et al. (2004).
POLgA interacts with the mtDNA polymerase g subunit, POLgB (Gray and Wong
1992), the structure of which highly resembles class IIa aminoacyl tRNA synthetases
(Fan et al. 2006). POLgB binds double stranded DNA of at least 45 bp, and also forms a
functional homodimer (Carrodeguas et al. 2001). Carrodeguas et al. (2002) established
that both DNA binding sites are needed for binding DNA since b subunit heterodimers,
in which one of the two DNA binding sites is mutated, could not bind dsDNA. Together
with POLgA, POLgB forms a heterotrimer, POLgAB2 (Yakubovskaya et al. 2006).
POLgB prevents DNA polymerase gamma from falling off when it finds a local difficulty
in the template DNA strand, notably enhances the processivity and the catalytic
effectiveness of the enzyme, and is needed to maintain the structure of the holoenzyme
(Carrodeguas et al. 1999, Lim et al. 1999). Fan et al. (1999) suggested that POLgB
recognizes the primer that is needed for replication initiation.
When considering the Drosophila replication machinery, Wernette and Kaguni (1986)
purified the mitochondrial DNA polymerase from Drosophila embryos and found two
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proteins, one of 125 kDa and other of 35 kDa, in 1:1 ratio, and concluded that the
Drosophila DNA polymerase gamma is a heterodimer. Kaguni and Olson (1989) detected
3´ ? 5´ exonuclease activity associated with the mitochondrial DNA polymerase g in
Drosophila embryos. Lewis et al. (1996) cloned a cDNA encoding the catalytic subunit.
The implied molecular mass of the protein was 129.9 kDa. The catalytic subunit shows a
high degree of amino acid sequence conservation to Escherichia coli DNA polymerase I
(Klenow fragment) (Lewis et al. 1996). Wang et al. (1997) cloned and sequenced a
cDNA encoding the accessory subunit in from Drosophila embryos. The predicted size of
the protein was 41 kDa. Iyengar et al. (2002) provided evidence that the accessory
subunit is required for replication and for development. Luo and Kaguni (2005) studied
the functional role of the spacer region between the exonuclease and DNA polymerase
domains of the catalytic subunit and showed that mutating conserved sequence elements
therein led to changes in enzyme activity, processivity and/or DNA binding affinity in
three cases out of four. Mutations were also found to affect interaction with the mtSSB
(Luo and Kaguni 2005). The conserved sequence elements in the spacer region were
suggested to serve to place the substrate in the correct orientation with respect to the
polymerase catalytic domains (Luo and Kaguni 2005).
2.6.2.2 Mitochondrial transcription factor A in mtDNA replication
TFAM has been characterized as an essential protein in bringing about transcription
initiation in vitro at the HSP and LSP promoter sequences, together with the
mitochondrial RNA polymerase and TFB1M or TFB2M (Fisher and Clayton 1988,
Falkenberg et al. 2002), although Shutt et al. (2010) have questioned the role of TFAM in
this process. Light strand transcription potentially provides the primer for leading-strand
synthesis, which is why TFAM has been suggested to have an important role in mtDNA
replication. TFAM is also a mitochondrial nucleoid protein (Alam et al. 2003, Garrido et
al. 2003), see also above in section 2.1.6.
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2.6.2.3 Mitochondrial single-strand DNA-binding protein
Pavco and van Tuyle (1985) reported the characterization of a rat mitochondrial protein
needed to stabilize single-stranded DNA fragments during replication or repair,
mitochondrial single-strand DNA binding protein (mtSSB). Tiranti et al. (1993) cloned
the human and rat mtSSB encoding cDNAs. Thömmes et al. (1995) isolated the
Drosophila mtSSB of 18 kDa from Drosophila embryos. Drosophila mtSSB is capable
of binding a ~17 nt fragment of mtDNA, and it upregulates replication initiation
(Thömmes et al. 1995). Farr et al. (1999) published that Drosophila mtSSB enhances
both the 5´ ? 3´ DNA polymerase and 3´ ? 5´ exonuclease activities of Drosophila
DNA polymerase g by 15-20 fold and stimulates the initiation of DNA strands 30-fold.
Maier et al. (2001) showed that the Drosophila mtSSB mutation lopo1 leads to mtDNA
depletion and loss of respiration. The lopo1 mutants die before metamorphosis is
complete. Maier et al. (2001) showed that Drosophila mtSSB is essential both for
mtDNA replication and development. Farr et al. (2004) established that mtSSB mutants
defective for DNA binding cannot stimulate DNA replication by pol g.
The human mtSSB is a protein of about 16 kDa and its sequence resembles that of E.
coli SSB (Curth et al. 1994). It forms a tetramer in solution and binds 50-70 nt per
tetramer (Curth et al. 1994). It has been shown to function also in the resolution of
mtDNA junctions by enhancing RecG, which is a junction-specific helicase from E. coli
(Takamatsu et al. 2002). mtSSB and TFAM have been suggested to stabilize the D-loop
region together (Takamatsu et al. 2002). mtSSB has been also reported specifically to
stimulate Twinkle protein activity (Korhonen et al. 2003).
2.6.2.4 Mitochondrial primase
In both replication mechanisms there also must exist a primase that makes at least a short
RNA-primer. This primer is supplied by transcription, hence replication and transcription
are coupled processes in mitochondria. Until quite recently the mechanism of lagging
strand replication initiation has remained unclear: although Wong and Clayton (1985)
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reported primase activity in human mitochondria but never identified the protein.
Twinkle helicase has been a candidate for human mitochondrial primase as it has primase
activity in some nonmetazoan cells (Shutt and Gray 2006). However, it has became clear
that the human mitochondrial Twinkle protein has lost this activity (Farge et al. 2008).
Wanrooij et al. (2008) reported that mitochondrial RNA polymerase (POLRMT) shows a
primase activity in vitro. Fuste et al. (2010) finally established that the POLRMT has a
primase activity which could potentially serve for the initiation of lagging-strand
synthesis on longer, double stranded DNA templates. Fuste et al. (2010) showed that
depleting POLRMT causes decreased replication initiation at the lagging strand
replication initiation site in vivo. On the basis of in vitro studies they suggest that leading-
DNA synthesis starts from the OH, continues till OL and when OL is exposed, adopts a
stem-loop structure. POLRMT then initiates primer synthesis from a poly-dT sequence in
the single-stranded loop, after which it then synthesises about 25 nt until it is replaced by
POLg. However, proof that this is the mechanism whereby the lagging strand initiates in
vivo is still lacking.
2.6.2.5 Mitochondrial DNA helicase, Twinkle
The Twinkle sequence highly resembles that of phage T7 gene 4 primase/helicase
(Spelbrink et al. 2001), and belongs to the RecA/DnaB superfamily. Ziebarth et al.
(2007) showed that the human mtDNA helicase belongs to the DnaB-like family of
helicases. Characteristically for protein functioning in mtDNA metabolism Twinkle co-
localises with mtDNA and is also a nucleoid protein. In vitro functional Twinkle protein
forms hexamers in solution just like other ring helicases (Spelbrink et al. 2001). Ziebarth
et al. (2007) established, using velocity-sedimentation and gel-filtration analyses, that the
human mtDNA helicase indeed forms hexamers. They established that the human
mtDNA helicase and bacteriophage T7 primase-helicase show similar modular
architecture and that both proteins form hexamers.
Korhonen et al. (2003) established that Twinkle indeed has 5’?3’ helicase activity. It
opens the DNA double strand for the proceeding DNA polymerase and therefore creates
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torsional stress and supercoiling in the DNA duplex. Both groups failed to find primase
activity for Twinkle. Matsushima and Kaguni (2007) cloned the Drosophila counterpart
of the human mtDNA helicase, Twinkle. They showed that silencing d-mtDNA helicase
leads to a decrease in mtDNA copynumber whereas over-expression leads to an increase.
Furthermore Matsushima and Kaguni (2009) failed to detect any primase activity of the
Drosophila mtDNA helicase. Certain N-terminal amino acid residues, mapping in the
vicinity of the central linker region, have been suggested to be important for the C-
terminal helicase activity (Matsushima and Kaguni 2009).
The human Twinkle needs mitochondrial ssDNA binding protein to be efficient in
unwinding DNA (Korhonen et al. 2003). Twinkle has been reported to be mutated in
some patients affected with progressive external ophtalmoplegia (PEO) (Spelbrink et al.
2001). Dominant Twinkle mutations cause accumulation of mtDNA replication
intermediates in cultured cells and also mtDNA depletion (Goffart et al. 2009). Goffart et
al. (2009) suggested that Twinkle PEO mutations lead to mtDNA replication stalling and
that this finally leads to multiple deletions characteristic of PEO patient mtDNA.
2.6.2.6 Other proteins needed in mitochondrial replication
Other proteins are also needed for mitochondrial replication. A topoisomerase is needed
to remove the torsional stress and supercoiling created by the replicative helicase. Zhang
et al. (2001) cloned the mitochondrial topoisomerase, Top1mt, which has a mitochondrial
targeting sequence and shows homology to the nuclear topoisomerase, Top1. They also
showed that when Top1mt was inhibited by camptothecin 7S DNA levels were reduced,
indicating that Top1mt might have other, as yet unrecognized roles in mtDNA
maintenance (Zhang and Pommier 2008).
Lakshmipathy and Campbell (1999) identified a mitochondrial DNA ligase that is
potentially the one needed in both replication models to seal new strands to form circles
and also in the strand-synchronous model to join together the Okazaki fragments. Finally,
mitochondrially localized RNaseH1, which should be needed for removing short RNA
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primers that arise during lagging-strand priming, has been reported to be able to process
also long RNA/DNA hybrids (Gaidamakov et al. 2005).
2.6.3 mtDNA replication pausing
Controlled replication and/or transcription termination and pausing are of outmost
importance. For example, in bacteria and yeast unregulated head-on collision of two
protein machineries can inhibit DNA replication, therefore creating genomic instability
(Bierne and Michel 1994, Weitao et al. 2003, Mirkin and Mirkin 2005, Prado and
Aguilera 2005).
In mammalian cell nuclei such head-on collision of two protein machineries can cause
dramatic gene amplification events (Hashizume and Shimizu 2007). Having an important
role in maintaining genomic stability, the pause binding proteins constitute an interesting
object for study.
Tus protein in E. coli regulates chromosomal DNA replication termination, providing
a good example of a protein with contrahelicase activity (Mulcair et al. 2006). Ter
sequences, which are Tus binding sites, are scattered around in the terminator region. Tus
binds Ter and therefore stops the advancing replication fork in a directional manner at
this terminator region (Hill et al. 1989, Neylon et al. 2005). Mitochondrial replication
pauses have been reported for mtDNA as well, but no Tus homologue has yet been found
(Mayhook et al. 1992, Holt et al. 2000, Reyes et al. 2005). Tus protein, however, is not
only able to stall an advancing replication fork but is also able to block transcription
(Mohanty et al. 1996). In fact, Tus prefers to block transcription in the same polar
fashion, permitting DNA synthesis to proceed (Mohanty et al. 1996, Guajardo and Sousa
1999). The sea urchin MTERF homologue mtDBP also has contrahelicase activity
(Loguercio Polosa et al. 2005). So far mtDBP is the only mitochondrial protein with
characterized contrahelicase activity in vitro (Loguercio Polosa et al. 2005). It remains to
be established which, if any, of the previously characterised human mitochondrial
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proteins has contrahelicase activity or whether there remains a novel mitochondrial
protein awaiting discovery.
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3. Aims of the research
The main purpose of this work is to further characterize the functional role of the human
MTERF family of proteins in mitochondrial transcription and replication. Also the role of
TFAM in human mitochondrial DNA metabolism is further elucidated.
More specifically the aims of the work were as follows:
1) To further elucidate the role of MTERF in mtDNA transcription termination in
vivo: MTERF has been previously shown to promote premature heavy strand
transcription termination in vitro at the canonical binding site following the rRNA
encoding genes in human mitochondrial DNA.
2) To determine if MTERF has any novel yet unknown binding site(s) in mtDNA in
addition to its canonical binding site within the tRNALeu(UUR) coding gene. This might
shed further light on its possible role(s) in mtDNA metabolism.
3) To test whether MTERF has a role in human mtDNA replication, as well as its
putative role in transcription.
4) To determine whether the novel MTERF protein family members, MTERFD1 and
MTERFD3 show sequence-specific DNA binding activity.
5) To investigate whether MTERFD1 and/or MTERFD3 have a role in human mtDNA
replication.
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6) To test whether modulating TFAM levels in cultured human cells affects
mitochondrial tRNA transcript production; as a by-product of this work, conducted in
collaboration with J. Pohjoismäki, it was additionally of interest to compare the effects of
TFAM and MTERF modulation on mtDNA replication.
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4. Materials and methods
4.1 Plasmid DNA constructs and molecular cloning
4.1.1  MTERF constructs
The MTERF coding region containing the mitochondrial targeting signal and the protein
coding sequence, a total of 1197 bp starting from the first start codon, was amplified from
HeLa cDNA. cDNA had been prepared by reverse transcription of 0.8 mg of HeLa
mRNA (cDNA was a gift from Professor Johannes Spelbrink). The MTERF coding
region was amplified using cloned Pfu polymerase (Stratagene) and chimeric primers.
MTERF was amplified with and without its natural STOP codon. A C-terminal fusion
with the MycHis epitope tag was created using the following primers, BamHI-MTERF
F1 5´ - CGCGGATCCCTGTTCTCCAGCCTTTCTGG - 3´ together with HindIII-
MTERF R1 5´ - CCCAAGCTTGGCAAATCTGCTTAACTTTTTC - 3´ and an MTERF
expression construct with the natural stop codon was created using the following primers,
BamHI-MTERF F1 plus HindIII-MTERF R STOP 5´ -
CCCAAGCTTTCAGGCAAATCTGCTTAACTTTTTC - 3´. Here restriction sites are
underlined and the stop codon is shown in italics. Constructs were sequence verified,
digested with BamHI and HindIII (Fermentas) and ligated using T4 DNA ligase
(Fermentas) with pcDNA3.1(-)/Myc-His A (Invitrogen) or pcDNA3/hygro(-) vector
(Invitrogen) vector that was similarly digested. Inducible Flp-In™  T-Rex™ -293 cell lines
expressing MTERF and MTERF-MycHis were created subsequently by digesting the
previously created plasmid constructs with PmeI (New England Biolabs) and ligating to
similarly digested pcDNA5/FRT/TO vector (Invitrogen).
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4.1.2 MTERFD1 and MTERFD3 constructs
The MTERFD1 (CGI12) coding region, in total 1254 bp, was amplified from HeLa cell
cDNA using the following chimeric primer pair: KpnI/Terfin1F1 5´ -
AAAGGTACCACGGGAAGCAGGCCTCGCCACAGACTAAG – 3´ plus
XhoI/Terfin1flagR1 5´ - TTTCTCGAGCTTATCGTCGTCATCCTTGTAATCAAGCG
TTTTTAAGAA – 3´ creating an in-frame C-terminal fusion to the FLAG epitope tag. In
order to create an MTERFD1 expression construct with natural stop codon cDNA was
amplified with KpnI/Terfin1F2  5´ - CGCGGTACCAGGCCTCGCCACAGACTAAG –
3´ and XhoI/Terfin1stopR2 5´ - GCCCCTCGAGTCAAAGCGTTTTTAAGAA
TTTTTCAAA – 3´. Restriction sites are underlined and the stop codon is shown in
italics.
Similarly the MTERFD3 (LOC80298) coding sequence of 1158 bp was cloned to
create an in-frame C-terminal fusion to the HA epitope tag using chimeric primer pair
KpnI/Terfin2F1 5´ - GGGGGTACCCCCAGGACGGTGGAAACTAGCTAGTAGATT
GC – 3´   plus XhoI/Terfin2HAR1 5´ - TTCTCGAGAGCGTAATCCGGAACATCGTA
TGGGTATTCTTCAACATTTAA – 3´. To create an MTERFD3 expression construct
with natural stop codon, the following chimeric primers were used: KpnI/Terfin2F2 5´ –
CCCGGTACCGTGGAAACTAGCTAGTAGATTGC – 3´ and XhoI/Terfin2stopR2 5´ -
CCCCTCGAGTCATTCTTCAACATTTAATGG –3´. In addition, MTERFD3 was
cloned using the following chimeric primers to produce an in-frame C-terminal fusion to
the FLAG epitope tag, KpnI/Terfin2F2 5´ –
CCCGGTACCGTGGAAACTAGCTAGTAGATTGC - 3´ plus XhoI/Terfin2flagR2: 5´ –
TTTCTCGAGTCACTTATCGTCGTCATCCTTGTAATCTTCTTCAACATTTA – 3´.
Restriction sites are underlined and the stop codon is shown in italics.
After the sequences were verified, PCR products were digested with XhoI and KpnI
(New England Biolabs), ligated to similarly digested pcDNA3/hygro(+) vector
(Invitrogen) or  pcDNA5/FRT/TO (Invitrogen) and stably transfected into Flp-In™  T-
REx™  293 recipient cells (Invitrogen) as described by Wanrooij et al. (2007). FLAG
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epitope-tagged MTERFD3 expression construct was cloned only into the
pcDNA3/hygro(+) vector.
4.1.3 TFAM constructs
The TFAM gene was amplified from a cDNA clone (Maniura-Weber et al. 2004) as
described in detail in paper IV.
4.2 Bacterial and mammalian cell culture
4.2.1 Bacteria
Bacteria used in this study were chemically competent E. coli cells of XL1-blue strain
(Stratagene) which were cultured in LB-medium (1% tryptone (Pronadisa), 0.5% Yeast
extract (Pronadisa), 0.5% NaCl) containing 0.1 mg/ml of ampicillin (Sigma) or 0.05
mg/ml kanamycin (Sigma) for selection.
4.2.2 Cell culture
Human embryonic kidney cells line, HEK293T, 143B osteosarcoma cells (and cybrids
containing wild type mtDNA), HeLa, Jurkat and Flp-In™  T-Rex™ -293 cells (Invitrogen)
were cultured at 37 °C in an incubator with 5% CO2 in air in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma) with the following additives: 4.5 g/l of D-glucose, 10%
foetal calf serum (FCS) (GibcoBRL), 50 mg/ml uridine (Sigma) and 2 mM L-Glutamine
(Bio-Whittaker/Cambrex). Flp-In™  T-Rex™ -293-derived cell lines were blasticidin and
hygromycin selected in culture according to the manufacturer’s protocol, induced to
express the protein of interest with 10 ng/ml doxycyclin (Sigma-Aldrich) which was
renewed every 48 h. Stably transfected HEK293T cells were cultured under 2 mg/ml
G418 Sulfate (Calbiochem) or hygromycin (Calbiochem, 200 ?g/ml) selection. Cells
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were routinely passaged every 3-4 days at 1:10-1:20 dilution. HeLa cells were detached
with Trypsin-EDTA (Bio-Whittaker/Cambrex) and other adherent cells by pipetting only.
Jurkat cells growing in suspension were passaged by centrifugation and resuspension in
fresh medium.
4.3 DNA transfections
Plasmid DNA constructs were introduced into HEK293T cells by transfection of 3 ?g of
plasmid DNA and using 30 ?l of LipofectAMINE transfection reagent (Invitrogen,
protocol supplied by the manufacturer) or 10 ?g of DNA and 40 ?l of TransFectin™
Lipid Reagent (Bio-Rad, protocol supplied by the manufacturer). Transiently transfected
cells were either harvested for different assays typically 24 h or 48 h after transfection, or
placed under selection using 2 mg/ml G418 Sulfate (Calbiochem) or hygromycin
(Calbiochem, 200 ?g/ml) in order to select stably transfected clones.
4.4 Establishing Flp-In™  T-Rex™ -293 cell lines
Flp-In™  T-REx™  293 cell lines were created as described by Wanrooij et al. (2007).
4.5 Doubly expressing cell lines
In order to create cell clones expressing two proteins of interest simultaneously,
uninduced Flp-In™  T-Rex™ -293 cells previously transfected with either MTERFD1-
FLAG or MTERFD3-HA were transfected a second time with an MTERF-MycHis
expression construct with G418 resistance coding gene. Doubly expressing clones were
screened by means of Western blotting.
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4.6 DNA sequencing
Expression vector constructs and DNA probes were sequence-verified using the ABI
PRISM® BigDye™  Terminator Ready Reaction kit (AppliedBiosystems). Primers that
were used for sequencing were either vector specific M13F, M13R, T7, BGH or
transgene specific. Sequencing reactions were ethanol precipitated and resuspended in
HiDi Formamide (AppliedBiosystems). Resuspended DNA products were denaturated at
92°C for 2 min and subsequently cooled on ice. An ABI310 or ABI3100 Genetic
Analyzer (AppliedBiosystems) was used for separation and analysis of the sequencing
PCR products under denaturing conditions, according to manufacturer’s protocol.
4.7 RNA interference
4.7.1 RNAi constructs
4.7.1.1 siRNA constructs
A prediction programme (http://www.ambion.com/techlib/misc/siRNA_finder.html) was
used to design the MTERF specific siRNAs, which were synthesized by means of in vitro
transcription using the Silencer™  siRNA construction kit (Ambion). Five siRNAs were
tested and one was found by Western blotting to be efficient in MTERF silencing and
that one was chosen for further experiments. The target site in MTERF mRNA was nt
585–605 (5? - AAG CGG GUG AAA GCU AAC AUU - 3?).
4.7.1.2 Lentiviral shRNA vector constructs
shRNAmir inserts (Open Biosystems Expression ArrestTM pSM2 Retroviral shRNAmir
Library (Thermo Fisher Scientific, Huntsville, AL, USA)) were delivered in pSM2c
retroviral vector (Open Biosystems) with one exception. Insert containing constructs
were digested with XhoI (NEB) and MluI (NEB) and religated in similarly digested
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pGIPZ vector (Open Biosystems). The constructs found to be efficient in silencing based
on Western blotting were the following: for MTERF (5´ to 3´):
GCUGUAACUUGAGUACUUU, Oligo ID V2HS_95064; for MTERFD1 (5´ to 3´):
CCUCAGAUAUCCUCUGACA, Oligo ID V2HS_235060; for MTERFD3 (5´ to 3´):
CAGGCUGUGUUCUUUCAGA, Oligo ID V2HS_137356 when compared to cells
transfected with Empty pGIPZ vector (Open Biosystems). In addition, the following
specific shRNA constructs, all in 5´ to 3´ orientation, were also tested for MTERFD1,
GCUGUUUAAGGUCAAAGAA, Oligo ID V2HS_236922 (denoted shRNA 4 in
Supplementary Figure S3 of III); for MTERFD3, CGCUGUUAACACCCAGAGAA,
Oligo ID V2LHS_236692 (supplied in vector pGIPZ) (denoted shRNA 8 in Supplementary
Figure S3 of III) and for MTERF, CUGUAACUUGAGUACUUUA, Oligo ID
V2HS_231874 (denoted shRNA 5 in Supplementary Figure S3E of II).
4.7.2 RNAi transfections
MTERF was knocked down in HEK293T cells (either with or without prior stable
transfection with the MTERF-MycHis expression construct) by transfecting the cells with
10 nM (final concentration) MTERF-specific siRNA molecules using Lipofectamine™
2000 transfection reagent (Invitrogen, protocol supplied by the manufacturer). An siRNA
reagent targeted on 5?- GGA GAA GGU ACG AGG GGC AUU -3? (siRNA Control) was
used as a negative control. Cells were harvested 48 h after transfection with the siRNA
or, in the case of the depletion assay with EtBr, at different time points following the
EtBr treatment.
When transfecting cells with shRNAmir constructs, 10 ?g of plasmid construct DNA
was introduced to cells using Lipofectamine™  2000 (Invitrogen) transfection reagent.
Cells were harvested 48 h after transfection.
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4.8 SDS-PAGE and Western blotting
Proteins were extracted as previously described by Spelbrink et al. (2000). Protein
concentrations were determined according to Bradford (1976). SDS-PAGE using 12%
polyacrylamide gels was run under standard conditions (Laemmli 1970).
Wetblotting to Hybond™ -C extra (Amersham Life Science) nitrocellulose membrane
was carried out according to Towbin et al. (1979). After transfer, the blots were blocked
in 5% w/v non-fat dried milk. Primary antibodies mouse anti-Myc monoclonal 9E10
(Roche Molecular Biochemicals) 1:15000 dilution, custom made anti-peptide antibody
rabbit anti-human MTERF, (KLH-conjugated CSNDYARRSYANIKE), (Invitrogen),
1:5000 dilution, mouse Anti-FLAG® M2_antibody (Stratagene) 1:5000 dilution and
mouse monoclonal antibody HA.11 (Covance, Princeton, NJ, USA) in 1:5000 dilution
were used. Secondary antibodies used were peroxidase-labelled horse anti-mouse IgG
(H+L, Vector Technologies Inc., affinity purified) and peroxidase-labelled goat anti-
rabbit IgG (H+L, Vector Technologies Inc., affinity purified). Homemade
chemiluminescence detection was carried out as described by Spelbrink et al. (2000) and
the film (Kodak BiomaxTM ML) was exposed from 15 s to 5 min.
4.9 Immunocytochemistry
Cells cultured on coverslips were first stained for mitochondria using 100 mM
MitoTracker® Red CMXRos (Molecular Probes) followed by fixation in 4%
formaldehyde/5% sucrose in PBS. Cells were permeabilized for immunostaining using
0.5% Triton X-100 in PBS and blocked in 5% w/v nonfat milk. Immunodetection was
carried out using primary antibodies, mouse anti-Myc monoclonal 9E10 (Roche
Molecular Biochemicals) 1:1000 dilution and mouse Anti-FLAG® M2 antibody
(Stratagene), 1:200 dilution. Secondary antibody was horse anti-mouse Fluorescein
vector (Vector Technologies Inc, stock 1.5 mg/ml) 1:200 dilution. Coverslips were
mounted on slides using Vectashield with DAPI (Vector Technologies Inc). Cells were
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visualized and pictures were taken with an Olympus BX50 microscope using 100x
magnification or with an Olympus IX70 inverted confocal microscope using 100x
magnification.
4.10 Subcellular fractionation
Subcellular fractionation was carried out according to the protocol of Fernandez-Silva et
al. (1996) with some modifications. Cells were harvested from 80% confluent plates.
After washing with resuspension buffer (0.133 M NaCl, 5 mM KCl, 0.7 mM Na2HPO4,
25 mM Tris-HCl pH 7.5) they were swollen in 10 mM NaCl, 1.5 mM CaCl2, 10 mM
Tris-HCl pH 7.5, followed by dounce-homogenization (20-25 strokes, tight-fitting pestle)
on ice and breakage of the cells was verified by microscopy. An equal volume of sterile
filtered sucrose/EDTA buffer (0.68 M sucrose, 2 mM EDTA, 20 mM Tris-HCl pH 7.5)
was added immediately after cell lysis. Nuclei and debri were pelleted by two rounds of
centrifugation at 1200 gmax for 10 min at 4 °C, the supernatant was re-centrifuged at 16
000 gmax for 30 min at 4 °C to pellet the mitochondria. The mitochondrial pellet was
washed once with PBS and stored at –80 °C or lysed immediately.
4.11 Lysis of mitochondria
Mitochondria were resuspended in one volume of lysis buffer (25 mM HEPES-KOH, pH
7.6, 5 mM MgCl2, 0.5 mM EDTA, 10% glycerol and freshly added 0.5 M KCl, 1 mM
DTT, 0.5% Tween 20, 1 mM PMSF), lysed by pipetting up and down repeatedly until the
suspension had clarified, and then by vortexing vigorously for 30 s. The lysate was
incubated on ice for 5 min, and the vortexing step was repeated. The lysate was
centrifuged for 45 min at 13 000 gmax at 4 °C. The clear supernatant was collected,
carefully avoiding the fluffy layer. Protein concentration was measured using the
Bradford test (Bradford 1976), using 2 ml of the supernatant.
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4.12 Electrophoretic mobility shift assay (EMSA)
EMSA probes were PCR amplified using various primer pairs (See Supplementary Table
1 in I) covering several sites of interest in the human mtDNA. mtDNA was used as
template for PCR and the resulting products were verified by means of sequencing.
Double stranded DNA oligonucleotide probes were used for EMSA (See Supplementary
Table 1 in I). Equal amounts of complementary oligonucleotide pairs were annealed to
create the dsDNA oligonucleotide probes. PCR fragments and dsDNA oligonucleotide
probes were labelled using T4 polynucleotide kinase (Fermentas) and [?-32P] ATP
(Amersham Pharmacia Biotech, 3000 Ci/mmol). EMSA binding reactions with minor
modifications were carried out as described by Fernandez-Silva et al. (1996). Binding
reactions contained at least 10 ?l of the binding buffer (25 mM HEPES–KOH, pH 7.5,
12.5 mM MgCl2, 20% glycerol, 0.1% Tween-20, 1 mM DTT), 0.2 pmol of labelled
dsDNA oligonucleotide or 3 ng of labelled PCR product as probe, 5 ?g of mitochondrial
lysate, 100 mM KCl, 5 ?g BSA and 5 ?g of non-specific competitor DNA poly(dI-
dC)·(dI-dC) (Amersham Pharmacia Biotech). Binding reactions were carried out at room
temperature for 20 min and the tubes were placed on ice and 0.25 volume of 30%
glycerol was added to terminate the binding reactions. For competition EMSA a 100-fold
excess of the non-labelled competing probe was added into the reaction. Supershift
EMSA reactions contained, in addition, 0.5 ?g of anti-Myc monoclonal 9E10 (Roche
Molecular Biochemicals), 1 ?g of anti-FLAG® M2 antibody (Stratagene) or 1 ?g of
monoclonal antibody HA.11 (Covance, Princeton, NJ, USA). Antibody was added 30
min prior to the labelled probe. Complexes were separated and analyzed on 5–10% non-
denaturing polyacrylamide TBE gels which were dried and autoradiographed using
KODAK BioMax™  MS film.
4.13 RNA extraction and reverse transcriptase PCR
Total RNA for various experiments was extracted from cells using TRIzol™  Reagent
(Life Technologies) according to the manufacturer’s instructions and remaining traces of
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DNA were removed by RNase free DNase I (Pharmacia Biotech) treatment. Ten mg of
isopropanol precipitated RNA was used for cDNA synthesis using random hexamers
(Pharmacia) and M-MLV reverse transcriptase (GibcoBRL), and when M-MuLV
Reverse Transcriptase (Fermentas) was used five mg of isopropanol precipitated total
RNA was required. Alternatively specific primers were used to synthesize specific sense
and antisense transcripts of 12S, 16S, ND1 and 18S (See Supplementary Table 1 in II)
using M-MuLV Reverse Transcriptase (Fermentas). cDNA for MTERF quantification
was prepared using random hexamers with High Capacity cDNA Reverse Transcription
Kit (AppliedBiosystems).
4.14 Quantitative RT-PCR
4.14.1 Quantitative RT-PCR using thermal cycler
Quantitative PCR was carried out using three different methods as appropriate to
different experiments. cDNA was synthesized using 10 mg RNA, 0.00125 u/ml random
hexamers (Pharmacia) and 200 U of M-MLV reverse transcriptase (GibcoBRL). The
reaction mix was incubated for 1 h at 37 °C, boiled again for 2 min and cooled on ice for
2 min. For quantitative PCR step using MJ Research Thermo Cycler PTC-200 (GMI) 2 ml
of this mixture was used in a 25 ml reaction containing the manufacturer’s buffer
(Finnzymes) plus 0.4 mM dNTPs (Fermentas), 0.4 mM of both primers and 2 u of
Dynazyme DNA polymerase (Finnzymes). One of the primers used was specific for the
expression vector (BGH: 5¢ TAGAAGGCACAGTCGAGGC 3¢) and the other for
MTERF (MTERF465F: 5¢ CGAGCAATAACACGTACTCC 3¢). As quantification
control, 18S was amplified in parallel using primers 18S-F (5¢
TACCTGGTTGATCCTGCCAG 3¢) and 18S-R (5¢ TCGGGAGTGGGTAATTTGC 3¢).
DNaseI treated RNA was used as template for 18S PCR to study if there were any
remaining traces of DNA.
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4.14.2 SYBR green quantitative RT-PCR
Relative amounts of 16S rRNA, ND1 mRNA and cytosolic 18S rRNA were measured by
means of SYBR Green quantitative PCR using a LightCycler™  instrument and
LightCycler FastStart DNA Master SYBR Green I kit (Roche) according to the
manufacturer’s instructions. cDNA was synthesized using 5 mg of RNA, 40 u M-MuLV
reverse transcriptase (Fermentas, protocol supplied by the manufacturer) and 0.2 mg
random hexamers (Pharmacia). Three dilutions of each cDNA sample (1:10, 1:20 and
1:50) were analysed, and each reaction was performed in three technical replicates. The
following primer pairs (all 5´ to 3´) and annealing temperatures were used: for 18S
rRNA, 18SFOR1 – GACCATCAGATACCGTCGTA and 18SREV1 –
TGAGGTTTCCCGTGTTGAGT, 52 °C; for 16S rRNA, 16Sfor1 –
GGTAGAGGCGACAAACCTACCG and 16Srev1 – TTTAGGCCTACTATGGGTGT,
50 °C; for ND1, ND1for1 – GGCCAACCTCCTACTCC and ND1rev1 –
GATGGTAGATGTGGCGGGTT, 50 °C. cDNA synthesized from 5 ?g of RNA pooled
from different cell-lines was used to prepare the standard curve, based on a five-fold
dilution series. The homogeneity of all products was checked after each run by melting
curve analysis.
4.14.3 Quantitative PCR using hybridization probes
To measure the relative levels of 12S, 16S, ND1, MTERF and 18S sense + antisense
strand transcripts the LightCycler™  instrument was employed, together with
LightCycler® FastStart DNA Master HybProbe kit (Roche). To prepare a standard curve,
5 ?g of total RNA pooled from different cell lines was reverse transcribed with M-MuLV
Reverse Transcriptase (Fermentas) using specific primers (TIB MOLBIOL) (see
Supplementary Table 1 in II for list of primers and probes used). Three dilutions (1:10,
1:20 and 1:50) were analysed from each cDNA. After 10 min of initial denaturation at 95
°C, the cycling conditions (45 cycles) were the following: denaturation at 95 °C for 10 s,
annealing at TM-5 °C depending on the primer for 10 s, and elongation at 72 °C for
(length of the amplified fragment bp/25 bp) s. Samples were also electrophoresed in
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agarose gel to ensure that the single amplified product was of the correct size. In addition,
melting curve analysis was used to ensure the purity of the amplified PCR product. For
normalization of expression levels, the expression of 18S rRNA was measured. The
relative expression of each gene was calculated by dividing the value by the 18S value of
each sample.
4.15 EtBr-induced depletion of mitochondrial RNA + DNA
To deplete mtDNA from cells EtBr was added in 60 x 15 mm plates at ~50% confluence.
250 ng/ml of EtBr was added and the cells were cultured for a further 48 h then passaged
at different densities so that plates were always ~70-80% confluent when harvested.
Samples were collected before adding EtBr (day -2), on the day when drug was washed
away (day 0) and 24, 48, 72, 96 and 120 h after removing EtBr. EtBr was washed away
by changing the medium 3 and 6 h after passaging the cells on day 0 and then every day.
RNA was extracted using TRIzol™  Reagent (Life Technologies). When the effect of
silencing of MTERF was being studied on the transcript levels during the recovery period
following EtBr treatment, the cells were transfected with siRNA on day -2 before adding
EtBr and transfected again on day 2.
Alternatively, when suppressing mtDNA copynumber and mitochondrial transcription
in TFAM over-expressing cells, the cells were treated with 50 ng/ml EtBr for 72 h and
then washed and replated in fresh medium followed by further 48 h in culture.
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4.16 Northern blot quantification of RNA
4.16.1 Northern blotting using neutral acrylamide/urea gel
electrophoresis
Total RNA samples were electrophoresed at 4 °C overnight at 100 V in neutral 12%
acrylamide/7 M urea gels in TBE buffer and electroblotted onto Zeta-Probe GT
membrane (BIO-RAD) at 4 °C first at 15 V for 30 min and then at 30 V for 60 min in
1xTBE buffer. RNA was u.v.-crosslinked to the membrane using Kodak UltraLinker.
Oligonucleotide probes were labelled using T4 polynucleotide kinase (PNK, MBI
Fermentas, protocol supplied by the manufacturer) and [g-32P] ATP (Amersham
Pharmacia Biotech, 3000 Ci/mmol). The probes were as follows: 5S (5´-
GGGTGGTATGGCCGTAGAC -3´), tRNALeu(UUR) (5´- GTTTTATGCGATTACCGGGC
-3´) and tRNAPhe (5´- CTAAACATTTTCAGTGTATTGC -3´). The effect of modified
TFAM level on mitochondrial transcripts was studied also using ND3 (5´-
GTCACTCATAGGCCAGACTT -3´) and tRNATyr (5´-
ATTTACAGTCCAATGCTTCACTC    -3´) probes as previously described by Toompuu
et al. (2002). Labelled probes were purified using mini Quick Spin Columns (Roche)
according to the manufacturer’s protocol.
Blots were prehybridised in buffer containing 50 mM PIPES, 100 mM NaCl, 50 mM
NaH2PO4×H2O, 1 mM EDTA, 5% SDS pH 6.8 and 0.1 mg/ml of herring sperm DNA
(hsDNA) for two hours at 42 °C. Hybridization was continued overnight after adding the
labelled probe into the prehybridization solution. After hybridization the membranes
were washed at 42 °C with 2 x SSC - 0.1% SDS (20 x SSC = 3 M NaCl, 0.3 M sodium
citrate) twice for 5 min and then once for 10 min with 1 x SSC - 0.1% SDS. Membranes
were exposed to X-ray film (Kodak BioMax MS film) at -80°C and autoradiographic
signal was quantified by phosphorimaging (Phosphorimager SI, Molecular Dynamics).
Probe was washed away from the membranes by stripping them in boiling 0.5% SDS
solution for 3 min.
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4.16.2  Northern blotting using formaldehyde/agarose gel
electrophoresis
Formaldehyde agarose gel electrophoresis and subsequent hybridization were carried out
as described previously by El Meziane et al. (1998). 16S rRNA or ND1 probes used for
Northern blotting were labelled by random-priming as described earlier by Toompuu et
al. (1999). The ND1 and 16S probes were synthesized according to Toompuu et al.
(1999) by ApaI digesting the amplified fragment to produce the two probes.
4.17 Systematic evolution of ligands by exponential
enrichment (SELEX)
Randomized DNA ligand library was created according to Blackwell (1995) with minor
modifications. The 46 nt long oligonucleotide template contained 14 randomized
nucleotides in the middle and fixed ends of 16 nt matching with the primers coding
recognition site either for BamHI or EcoRI. Klenow fragment (Fermentas) was used to
synthesize the second strand and dsDNA ligand library was gel-purified from an EtBr-
stained 14% native polyacrylamide gel using the QIAEX kit (QIAGEN, protocol supplied
by the manufacturer). Ligand selection was carried out as described for EMSA binding
reactions with the exception that 10 ?g of mitochondrial protein lysate from epitope-
tagged protein of interest expressing Flp-In™  T-REx™ -293 cells, 0.8 ?g of the ligand
DNA and 6.25 ?g of non-specific competitor DNA poly(dI-dC)·(dI-dC) were used. Pre-
swollen antibody linked Sepharose beads (Amersham Biosciences) were washed twice
with EMSA binding buffer lacking poly(dI-dC)·(dI-dC) and resuspended in 1.5 volumes
of the same buffer containing now also poly(dI-dC)·(dI-dC). Antibody-linked beads were
added to binding reactions and after this selection step, beads were washed in poly(dI-
dC)·(dI-dC) containing EMSA buffer, followed by seven washes in the buffer lacking
poly(dI-dC)·(dI-dC). Proteins were digested by proteinase K (Fermentas) overnight and
DNA was recovered by phenol extraction. After ethanol precipitation DNA ligands were
resuspended in H2O and used as template for PCR using SELEX primers (5´ -
GGTGAATTCGCTCACG - 3´and 5´- GAACGGATCCCTTTCG – 3´, restriction sites
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for cloning underlined) and Pfu DNA polymerase (Promega). The enriched ligand DNA
was gel-purified as above. After seven cycles of selection and enrichment, the enriched
ligand DNA was cloned into pCR®4Blunt-TOPO® vector (Invitrogen). Clones were
sequence verified using standard primers on an ABI 3100 sequencer using the BigDye®
Terminator v3.1 cycle sequencing kit (AppliedBiosystems).
4.18 Chromatin immunoprecipitation
Mitochondrial DNA immunoprecipitation (mIP) was carried out according to Lu et al.
(2007) with some modifications. Protease inhibitor used in lysis buffer was Complete,
Mini protease inhibitor cocktail (Roche). The mtDNA was sheared to fragments using
Sonics Vibra-Cell sonicator, 3 mm tip at 25% power for 3 × 20 s (1 s on, 1 s off) and
incubated on ice for 30 s between to produce DNA fragments of approximately 500–600
bp. Pre-swollen Protein A Sepharose (Amersham Biosciences) beads were added to
lysates to pre-clear them. For immunoprecipitation 5 µg of mouse anti-Myc monoclonal
9E10 (Roche Molecular Biochemicals) or anti-FLAG® M2 antibody (Sigma) was used
per reaction. Immunoprecipitation was carried out overnight at 4°C. See Supplementary
Table I in paper I for the primers used for the mIP PCR.
4.19 mtDNA copynumber assay
Total DNA was extracted from cultured human cells as described by Sambrook et al.
(1989) for mtDNA copynumber analysis. Copynumber was determined by means of
quantitative PCR using ABI Prism 7000 (AppliedBiosystems) with amyloid precursor
protein (APP) as a single-copy nuclear DNA standard. Following primers and probes
were used (all shown in 5´-3´ orientation):  APP Forward:
TTTTTGTGTGCTCTCCCAGGTCT, APP Reverse: TGGTCACTGGTTGGTTGGC,
APP Probe (FAM+BHQ): CCCTGAACTGCAGATCACCAATGTGGTAG, Cyt-b
Forward: GCCTGCCTGATCCTCCAAAT, Cyt-b Reverse:
AAGGTAGCGGATGATTCAGCC, Cyt-b Probe (TET+BHQ):
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CACCAGACGCCTCAACCGCCTT. Analysis of the data was carried out using the
software supplied by the manufacturer (AppliedBiosystems).
4.20 Isolation of mtDNA
For mtDNA isolation mitochondria were isolated according to Spelbrink et al. (2000).
mtDNA (mitochondrial nucleic acids) was extracted for 2DNAGE from cultured cells as
described in IV.
4.21  Two dimensional neutral agarose gel electrophoresis
4.21.1 Enzymatic treatments of mtDNA
For 2DNAGE analysis one µg aliquots of total mitochondrial nucleic acids were digested
with a restriction enzyme to produce the fragment of interest. NheI, BclI, HincII and
PvuII (Fermentas) and AccI and BamHI (New England Biolabs (Finnzymes)) were used
for digesting mtDNA. Restriction enzymes were used according to protocols supplied by
the manufacturers with one exception; digestion with BclI was allowed to continue for
double the recommended time. In certain experiments the restriction enzyme digestion
was followed by ethanol precipitation and digestion with 50 U of S1 Nuclease (Promega).
S1 nuclease digestion was terminated by phenol extraction.
4.21.2 Two dimensional neutral agarose gel electrophoresis and
Southern blotting
2DNAGE was generally carried out as described by Friedman and Brewer (1995). To
study restriction intermediates of different sizes, different gel conditions were applied for
2DNAGE (Table 4.1). Electrophoresis in the first dimension (1D) was carried out in TBE
buffer without EtBr and the gel was stained with EtBr (300 ng/ml) only after
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electrophoresis. The first dimension separates DNA molecules in proportion only to their
mass. The mtDNA lanes were cut out exposing the mtDNA to u.v.-light as briefly as
possible. The cut lanes were positioned at a 90° angle in the gel tray and the second
dimension (2D) agarose gel, cooled to 55°C, was cast around them. The second
dimension agarose gel contains 300 ng/ml EtBr and the migration of replication
intermediates is thus strongly affected by their shape. Electrophoresis of shorter
fragments was carried out at 4 °C and the electrophoresis of full genome-length mtDNA
fragments, when a restriction enzyme cutting mtDNA only once had been used, was
performed at room temperature. After second dimension electrophoresis Southern
blotting was carried out, transferring DNA by capillary action to Hybond N nylon
membrane (Amersham) overnight. Before blotting, the gels were soaked in 0.25 M HCl
for 20 min, rinsed with water, denatured in 0.5 NaOH, 1.5 M NaCl for 2 x 20 min and
neutralized in 1.0 M Tris-HCl pH 7.2, 2.0 M NaCl.
Table 4.1 Different gel conditions for 2DNAGE.
Fragment
length
Dimension Gel (agarose %) Voltage
(V/cm)
Temp (°C) Time (h)
< 2 kb First 0.6 1.2 4 20
Second 1.4 9 4 6
2 – 5 kb First 0.4 1.8 4 20
Second 1.0 10 4 6
16.6 kb First 0.28 1.7 Room Temp 24
Second 0.58 1.8 Room Temp 67
4.21.3 Interpretation of 2D gels
2DNAGE gels were generally interpreted according to Friedman and Brewer (1995). For
a typical 2D gel mtDNA is first digested with a restriction enzyme and DNA fragments
are separated on the basis of their mass in the first dimension electrophoresis and on the
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basis of their shape in the second dimension electrophoresis as described above. When
transferred to membrane the fragment of interest is detected with a suitable probe. Figure
4.1 shows how non-replicating molecules form a shallow arc of linears (linear arc). The
1n spot consists of nonreplicating molecules on the arc of linears that are the size of the
fragment. Replicating molecules migrate above the shallow arc of linears and form the
simple Y, bubble or double-Y arcs. Also an X-spike (X-arc) can be seen which is formed
by X-shaped replication or recombination intermediates. On the simple Y arc a
replication fork stall can be seen as a replication pause site visualized as a discrete spot.
1n
simple Y arc
X-arc
linear arc
bubble arc
Figure 4.1. Interpretation of a 2 dimensional neutral agarose gel.
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5. Results
5.1 Functional studies on mitochondrial transcription
termination factor MTERF (I, II)
5.1.1  Over-expressed MTERF is mitochondrially targeted in
cultured human cells (I)
HEK293-derived cells were established to express both epitope-tagged MTERF as well
as natural MTERF in order to study the functional role of MTERF in mitochondrial DNA
maintenance. MTERF was observed to be efficiently over-expressed in cultured human
cells (Figure 5.1). As MTERF has been reported to be a mitochondrial protein the
mitochondrial targeting of the epitope-tagged MTERF was checked by means of
immunocytochemistry. HEK293T cells were either stably or transiently transfected with
MTERF-MycHis. A filamentous staining pattern typical for mitochondria with no nuclear
staining was seen by means of immunocytochemistry therefore demonstrating MTERF to
be mitochondrially localized (Figure 5.2).
Figure 5.1. Over-expression of MTERF and MTERF-MycHis in cultured human cells. MTERF
or MTERF-MycHis transfected Flp-InTM T-RExTM-293 cells were induced for expression as
described (0, 24, 48 h) and HEK293T cells were transiently transfected (t). Western blots were
probed with anti-Myc or anti-MTERF antibodies. The endogenous MTERF protein detected by the
anti-MTERF antibody is marked with one arrow and the MTERF-MycHis fusion protein detected
by anti-Myc antibody is indicated with double arrows. Reprinted from original article (I), copyright
(2007), by permission of Oxford University Press.
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Figure 5.2. Subcellular localization of MTERF-MycHis in HEK293T cells. HEK293T cells were
either transiently or stably transfected with MTERF-MycHis and detection was carried out by anti-
Myc monoclonal antibody and counterstained with Mitotracker Red. Reprinted from original article
(I), copyright (2007), by permission of Oxford University Press.
5.1.2 MTERF efficiently binds mtDNA (I, II)
Previously MTERF has been shown to be a DNA-binding protein having binding affinity
to a 28 bp sequence in the tRNALeu(UUR) gene which is in downstream and adjacent to the
16S rRNA gene (Kruse et al. 1989). Therefore we tested whether over-expressed MTERF
as well as epitope-tagged MTERF are also able to bind DNA (Figure 5.3). Studying the
effect of over-expressed MTERF on its binding to DNA by means of EMSA, using
probes covering the reported canonical MTERF binding site together with mitochondrial
protein lysate is also relevant to later studies of the effects of modulating MTERF levels
on human mtDNA replication in vivo. Because crude mitochondrial protein extracts were
used, other proteins present may have an effect on MTERF binding in these experiments.
Over-expression of MTERF in any manner tested, transient and stable transfection or
under doxycyclin induction, resulted in a clear increase in the binding of MTERF to its
target site (Figures 5.3, 2C in I, Supplementary Figure S1B in II).
Cell clones stably transfected with MTERF were tested for MTERF over-expression
by means of EMSA, and the cell clones showing the highest expression were chosen for
further study (Supplementary Figure S1B in II).
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The binding of MTERF to its canonical binding site was shown to be specific by
EMSA supershift. The Myc epitope-tagged MTERF protein was supershifted by anti-
Myc antibody but not with anti-FLAG antibody. Also the signal was competed out when
excess unlabelled probe was added to the reaction mix (Figure 5.3).
Figure 5.3. MTERF binding to human mtDNA. MTERF or MTERF-MycHis transfected Flp-InTM
T-RExTM-293 cells were induced for protein expression and EMSA was carried out using Leu-
short dsDNA oligonucleotide probe and mitochondrial protein lysates from the cells. Supershift
EMSA was carried out using anti-Myc antibody and competition EMSA using 1-, 10-, 100- and
1000-fold mass excess of Leu-short dsDNA oligonucleotide competitor (‘cold’) or without
competition. F denotes free probe, BN denotes for natural MTERF complexes and BF the MTERF-
MycHis fusion protein complexes. S denotes anti-Myc antibody supershifted complex. Reprinted
from original article (I), copyright (2007), by permission of Oxford University Press.
5.1.3 Silencing MTERF by means of RNAi (I)
To study the effect of knocking down MTERF, using the RNA interference (RNAi)
method, I tested several siRNAs targeting MTERF for silencing efficiency, using stably
transfected MTERF-MycHis over-expressing cells in order to be able to determine the
knockdown efficiency at protein level using Western blotting. siRNA molecule
MTERF.1 was observed to lead to efficient silencing of MTERF when studied by means
of Western blotting (Figure 5.4A) or immunocytochemistry (Figure 5B in I). When the
effect of silencing MTERF on DNA-binding activity was studied by means of EMSA 48
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h after the transfection of cells with the siRNAs, it was estimated that knock-down lead to
loss of ~90% of the protein based on densitometry of the autograph signals (Figure 5.4B).
A B
Figure 5.4. Silencing MTERF by means of RNAi. A) MTERF was knocked down using siRNA
mTERF.1 and the silencing efficiency versus siRNA control (Control) was checked by means of
Western blotting. Cells that were used were either untransfected (-), transiently transfected (t) or
stably transfected with MTERF-MycHis expression construct. Cells were harvested 24, 48 and 72
h after transfection with the siRNA. MTERF-MycHis fusion protein is denoted with arrows.
MTERF-MycHis fusion protein migrates between two background bands which are present in all
western blots and thus these bands serve as internal loading control. The penultimate lane in the
upper panel showing the untransfected, non-siRNA-treated cells is approximately 3-fold
overloaded. B) EMSA was carried out using mitochondrial protein extract from HEK293T cells +/-
stable transfection with MTERF-MycHis. Cells were harvested 48 h after being transiently
transfected with or without MTERF.1 siRNA. Leu-short dsDNA oligonucleotide probe was used in
EMSA. The experimental conditions in this figure are the same as in Figure 5.3, but here the
amount of the background signal and the exposure time are different. Reprinted from original
article (I), copyright (2007), by permission of Oxford University Press.
5.1.4 Effects of over-expressing MTERF on mtRNA synthesis (II)
5.1.4.1 Steady state RNA levels are not affected by MTERF over-expression
The relative activities of the two transcription units of the mtDNA heavy strand, namely
PH1 and PH2 transcription units, were studied in MTERF stably over-expressing
HEK293T cell clones during normal growth. The relative activities of these two
transcription units can be determined by means of Northern blot analysis measuring the
steady-state level of transcripts within different transcription units, here tRNALeu(UUR) and
ND1 mRNA for the PH2 transcription unit, and tRNAPhe plus 16S rRNA for the PH1
transcription unit.
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I studied the tRNAPhe/tRNALeu(UUR) ratio in MTERF over-expressing cell clones
compared to cells transfected with empty expression vector, normalized using 5S rRNA
as a loading control. I established that there is no significant difference in the ratio of
tRNAPhe/tRNALeu(UUR) in different cell clones over-expressing the natural variant of
MTERF compared to the control cells, cells transiently transfected with the MTERF
over-expression construct or mock transfected cells (Figure 5.5A). The ratio of tRNAPhe
to cytosolic 5S rRNA, which represents the global amount of mitochondrial transcription,
was more variable, but there was no systematic relationship with MTERF over-
expression (Figure 5.5A).
I used Q-RT-PCR to determine the mature ND1 mRNA and 16S rRNA levels in
inducible Flp-In™  T-Rex™ -293 cells stably transfected with the MTERF-MycHis
construct compared to non-induced cells. There was no significant difference in the
relative amounts of mature 16S rRNA and ND1 mRNA observed (Figure 5.5B). There
was no difference between MTERF over-expressing clones and control cells on the basis
of Northern blots: see Figure 5.6C and compare lanes 1 of panels i and ii (control cells)
with lanes 1 of panels iii and iv (over-expressor cells).
5.1.4.2 Over-expression of MTERF does not affect mitochondrial tRNA levels during
the recovery period after EtBr depletion
MTERF stably over-expressing and control cells were depleted of mitochondrial RNA
and DNA with EtBr for 48 h. Our reasoning was that the possible effect of MTERF
protein level modification on mitochondrial tRNA synthesis would be clearer during the
recovery period when new mtDNA is synthesized and transcribed in large amounts. Cells
were allowed to recover over 5 days during which tRNA levels were measured at regular
intervals. The tRNAPhe/ tRNALeu(UUR) ratio was determined by means of Northern blot
analysis. MTERF over-expression was not observed to alter the mitochondrial RNA
levels during recovery from mtDNA depletion (Figure 5.5C).
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Figure 5.5. The effect of over-expressing MTERF on mitochondrial RNA levels. A) Northern
blot signal ratios of tRNAPhe to tRNALeu(UUR) (F/L) and tRNAPhe to 5S rRNA (F/5S) for MTERF-over-
expressing clones, normalized to the corresponding ratio in cells stably transfected with empty-
vector. Shown here alongside are the HEK293T cells transiently transfected with the same
MTERF construct or mock-transfected, both single reference experiments. B) Mitochondrial
transcript and cytosolic 18S rRNA levels measured by means of Q-RT-PCR 3 days after induction
in Flp-In™  T-Rex™ -293 cells stably transfected with MTERF-MycHis versus non-induced cells.
Data normalized, in each case, to the relevant ratio for non-induced cells. C) Northern blot
analysis of cells stably transfected with empty vector or an MTERF over-expressor clone (OE),
probed with mitochondrial tRNAPhe and tRNALeu(UUR) and normalized to the ratio at timepoint -2 d.
EtBr was added on day -2, washed away on day 0, and the cells allowed to recover over 5 days.
Reprinted from original article (II), copyright (2010), by permission of BioMed Central.
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5.1.5 Effects of silencing MTERF on mtRNA synthesis (II)
5.1.5.1 Effects of MTERF knockdown on steady-state mature mitochondrial RNA
levels
Over-expression of MTERF is not necessarily enough to cause any effects on
mitochondrial RNA synthesis because according to Micol et al. (1997) the MTERF target
binding sites are up to 80% occupied in vivo. Therefore an opposite approach was used
and MTERF expression was down-regulated by RNA interference (RNAi) using short
interfering RNAs (siRNA) (Elbashir et al. 2001a, Elbashir et al. 2002b) in HEK293T
cells and also in MTERF-MycHis over-expressing cells.
The effect of MTERF knockdown on the tRNAPhe/tRNALeu(UUR) ratio was studied 7
days after the first siRNA transfection by means of Northern blot. siRNA transfection
was repeated on day 4. When MTERF-MycHis over-expressing cells were studied, there
was no significant difference between the siRNA-treated and the control cells. HEK293T
cells showed a slight decrease on the tRNAPhe/tRNALeu(UUR) ratio due to MTERF
knockdown, with a modest increase on the levels of both mitochondrial tRNAs compared
with 5S rRNA relative to untreated cells (Figure 5.6A). Mature 16S rRNA and ND1
mRNA levels were determined as well and they were found to be unaffected in both
cases (Figure 5.6C, compare lanes 1 and 2 of panels i and ii and lanes 1 and 2 of panels iii
and iv). As tRNA and rRNA steady-state levels are rather stable they do not necessarily
correlate well with the rates of their transcription. mRNA transcripts are generally less
stable i.e. ND1 mRNA levels might correlate better with its transcription rate.
5.1.5.2 Knocking down MTERF does not affect relative mitochondrial tRNA levels
during the recovery period after EtBr induced depletion
We next studied whether the re-accumulation of mitochondrial transcripts is affected by
MTERF knockdown after depletion of mitochondrial RNA and DNA with EtBr. Cells
were silenced for MTERF prior to treatment with EtBr on day -2 and then again on day 2.
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EtBr treatment was carried out from day 0 for 48 h, after which it was washed away and
cells were subsequently washed daily. MTERF silenced cells did not differ from mock-
transfected cells when the relative mitochondrial RNA levels were studied after the EtBr-
induced depletion of mitochondrial RNA species (Figure 5.6B).
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Figure 5.6. The effect of silencing MTERF on mitochondrial RNA levels. A) MTERF was
knocked down and the relative activities of the transcription units were calculated from Northern
blot data and normalized to the corresponding ratio of the mock-transfected cells. Statistically
significant difference (*) from the corresponding mock-transfected cells (t-test, p<0.05) and
significant difference (#) between cell lines (t-test, p<0.01). Original blots shown in Figure S1C in
II. B) Northern blot signal ratios for RNA of MTERF knock down and mock-transfected cells,
probed for mitochondrial tRNAPhe and tRNALeu(UUR) and normalised to the ratio at timepoint -2 d.
C) Northern blot, probed for 16S rRNA and ND1, of RNA from cells knocked down for MTERF or
mock transfected (-). Adjacent panels are from the same exposure of the same gel. Reprinted
from original article (II), copyright (2010), by permission of BioMed Central.
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5.1.6 Altering MTERF levels affects both sense- and antisense-
strand transcription (II)
In order to analyze total sense and antisense transcripts from either side of the MTERF
binding site, cDNA was prepared using specific primers for sense and antisense strand
synthesis. The effect of manipulating MTERF levels was studied in three different cases;
first, cells stably transfected with MTERF were compared to control cells transfected
with the empty vector; second, MTERF was over-expressed in inducible Flp-In™  T-
Rex™ -293 cells and this was compared to non-induced cells; and third, MTERF was
knocked down using shRNA. The positions of the primers used for Q-RT-PCR are shown
in Figure 5.7A. When MTERF was knocked down it was observed that the amount of
anti-16S RNA increased dramatically whereas when MTERF over-expression was
induced in Flp-In™  T-Rex™ -293 cells the anti-16S:anti-ND1 ratio was decreased in a
statistically significant manner. The same effect was seen in cell clones stably transfected
with MTERF: the anti-16S:anti-ND1 ratio was decreased but the effect was statistically
significant only for one of the two clones studied (Figure 5.7B).
Induced over-expression of MTERF yielded 20-fold increase in MTERF mRNA level
(Figure 5.7E) and MTERF knockdown produced a decrease by a factor of 2 at the RNA
level (Figure 5.7F). Induced over-expression caused a dramatic decrease in 16S antisense
transcripts and also a small decrease in the ND1 antisense transcripts (Figure 5.7C).
MTERF knockdown produced mainly a significant decrease in the ND1 antisense
transcripts (Figure 5.7D). Clearly, over-expression and knockdown of MTERF led to
different changes in each RNA transcript when comparing treated cells to untreated
control cells.
92
A B
C D
E F
Figure 5.7. Modulating MTERF levels affects mitochondrial antisense RNA levels. A)
Positions of the primers designed for Q-RT-PCR. B) Q-RT-PCR analysis: two MTERF over-
expressing clones (OE) versus cells transfected with empty vector: MTERF expression construct-
transfected doxycyclin-induced Flp-In™  T-Rex™ -293 cells versus non-induced cells; and
MTERF-targeted shRNA transfected cells versus mock-transfected cells, tested for relative
steady-state levels of anti-16S and anti-ND1 transcripts. Data normalized to corresponding
control cells. Statistically significant difference (*) compared to control cells (t test, p<0.02). C)
Data from panel B was replotted to study relative changes in anti-16S and anti-ND1 transcript
levels separately for Flp-In™  T-REx-293 cells induced to express mTERF. D) Data from panel B
was replotted to study relative changes in anti-16S and anti-ND1 transcript levels separately for
HEK293T cells transfected with mTERF-targeted shRNA versus mock-transfected cells. 18S was
used as internal normalization standard and data were normalized to values of relevant untreated
control cells. E) Q-RT-PCR with hybridization probes (probe sets T1, R2, C1 shown in Table S1
in II) to study relative steady-state levels of 12S, 16S and 18S sense-strand transcripts and of
mTERF mRNA over 18S rRNA (probe sets M1 and C1 shown in Table S1 in II) for Flp-In™  T-
REx-293 cells induced to express mTERF.  F) Q-RT-PCR with hybridization probes (probe sets
T1, R2, C1 shown in Table S1 in II) to study relative steady-state levels of 12S, 16S and 18S
sense-strand transcripts and of mTERF mRNA over 18S rRNA (probe sets M1 and C1 shown in
Table S1 in II) for HEK293T cells transfected with mTERF-targeted shRNA versus mock-
transfected cells. * indicates statistically significant differences between treated and non treated
cells (t test, p < 0.02). Reprinted from original article (II), copyright (2010), by permission of
BioMed Central.
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Different control experiments were carried out to validate the findings. Another
primer/probe set (Figure S3B in II) was used to confirm the main findings and was also
used to study the effects on the relative 16S rRNA and ND1 sense transcript levels, which
were observed not to vary due to these manipulations (Figure S3C in II). This was
supported by the findings from the analysis of mature transcripts by Northern blots
(Figure 5.5B, 5.6C). Also sense transcript level of 12S rRNA (in PH1 transcription unit)
relative to cytosolic 18S rRNA was studied in treated versus untreated cells (Figure 5.7E
and F). The effects were also analyzed on the mitochondrial 16S rRNA sense transcript
level relative to cytosolic 18S rRNA (Figure 5.7E and F). When MTERF was knocked
down there was a significant increase in sense-strand 12S rRNA steady-state transcripts
(Figure 5.7F) whereas MTERF over-expression did not have any effects on the sense-
strand transcripts of 12S rRNA and of 16S rRNA relative to each other or to cytosolic
18S rRNA (Figure 5.7E).
5.1.7 MTERF has multiple novel binding sites in mtDNA (I)
I studied the binding of MTERF to mtDNA by means of EMSA using protein lysates
from crude mitochondrial extracts from MTERF over-expressing cells. Having already
shown that over-expression of MTERF leads to a large increase of binding at the
canonical biding site, it was established that both natural MTERF and the MycHis
epitope-tagged variant were able to bind mtDNA efficiently with the chosen EMSA
conditions. I then designed 150 bp long EMSA probes overlapping each other to cover
the entire non-coding region of the genome (NCR) and adjacent fragments, as well as the
region at OL, the IQM tRNA cluster, the ND1 gene between the IQM tRNA cluster and
the canonical MTERF binding site within the tRNALeu(UUR) coding gene, the ATPase6
coding sequence and the ATPase6/COIII gene junction site, plus other regions of the
genome. A full list of the probes used is presented in Supplementary Table 1 in I.
Binding was scored as positive if EMSA signals were enhanced by both natural
MTERF and MTERF-MycHis, if the complexes migrated at slightly different positions
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due to the presence of the MycHis epitope tag and if the MTERF-MycHis complexes
were shifted by the anti-Myc antibody. The strength of the binding was determined by
actual competition experiments or it was simply based on estimating the EMSA signal by
eye. I identified a cluster of four novel binding sites for MTERF, which I classified as
moderately strong, within the ND1 coding gene and the adjacent tRNA cluster, located
within the probes ND1.1, ND1.2 and IQM2 in addition to the previous ‘canonical’
binding site in the tRNALeu(UUR) (Figure 5.8A and 5.8C). When MTERF binding to the
latter was competed with unlabelled ND1.1 or vice versa, it was estimated that MTERF
binds ND1.1 with an affinity that is 1-2 orders of magnitude weaker than that at the
tRNALeu(UUR) gene (Figure 5.8B). Shorter overlapping fragments were created to cover
the ND1.1 fragment in order to study the binding within this fragment in more detail
(Supplementary Figure 2B in I). This analysis revealed evidence for two distinct binding
sites within the ND1.1 fragment (Supplementary Figure 2D in I).
I identified four other binding sites within the D-loop part of the NCR, one at OL, one
in OH1 fragment adjacent to OH (Figure 5.8A, 5.8C, Supplementary Figure 2E in I). In
addition I found one possible binding site within the OH5 fragment (Figure 5.8C,
Supplementary Figure 2E in I).
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Figure 5.8. MTERF binding to human mitochondrial DNA sequences in vitro. A) EMSA using
150 bp long probes and mitochondrial protein extracts from either induced or non-induced natural
MTERF or MTERF-MycHis transfected Flp-In™  T-Rex™ -293 cells. Supershift was carried out
with anti-Myc monoclonal antibody. Anti-FLAG antibody did not yield supershift nor inhibit the
formation of complexes when used as a control. B) Competition EMSA with mitochondrial protein
extract from MTERF-MycHis over-expressing cells using either 1x, 10x or 100x mass excess of
the cold competitor over the hot probe. C) EMSA results summarized. Strong binding site (filled
circle), moderate (grey circle), weak (open circle), debatable (dotted circle, fragment OH5) no
binding observed (no circle). Reprinted from original article (I), copyright (2007), by permission of
Oxford University Press.
The novel binding sites found in vitro for MTERF using EMSA were studied in vivo by
means of semiquantitative mIP analysis modified from the one published by Lu et al.
(2007). We were successful at amplifying the tRNALeu(UUR) binding site containing
fragment in the immunoprecipitate using anti-Myc antibody whereas it was not
immunoprecipitated by anti-FLAG antibody or no antibody control reactions. Uninduced
cells were used as control and generally the immunoprecipitates from those cells were
negative in the given conditions, but sometimes when excess of anti-Myc antibody was
used, a weak band was detected that correlated with the low level of leaky expression of
96
MTERF-MycHis fusion protein. Fragments that were found to bind MTERF in vitro
based on the EMSA assay and chosen to be further studied by means of mIP, namely
ND1.1, NCR1, NCR5, OH1 and OH5, gave positive signals also in the anti-Myc
immunoprecipitation reactions from induced MTERF-MycHis cells, whereas control
reactions with anti-FLAG antibody or with no antibody gave no such band. In EMSA,
MTERF did not show binding affinity against e.g. ND3.4 which was therefore chosen as
a negative control for the mIP. This fragment gave no band or only a very weak band was
detected. (Figure 5.9)
Figure 5.9. MTERF binding in human mitochondrial DNA in vivo. MTERF-MycHis binding in
human mtDNA was studied by means of mIP. Immunoprecipitation was carried out using either
anti-Myc (M), anti-FLAG (F) or no antibody (-) and the cells used were inducible Flp-In™  T-
Rex™ -293 cells over-expressing MTERF-MycHis. For Leu fragment non-induced cells were also
tested. Reprinted from original article (I), copyright (2007), by permission of Oxford University
Press.
5.1.8 MTERF binding motif (I)
As I had established that MTERF binds several sites in mtDNA, I then proceeded to
study whether there is a sequence MTERF prefers to bind. I established SELEX
(systematic evolution of ligands by exponential enrichment) to identify the consensus
binding sequence for MTERF-MycHis. SELEX consists of several rounds of selecting
and amplifying the most optimal fragments binding the protein of interest the results of
which are shown in Table 5.1. When the SELEX consensus sequence was compared with
the canonical MTERF binding site sequence within the tRNALeu(UUR) coding gene the
minimum binding sequence was found to be GG(N8)GG. After 7 rounds of SELEX 82
clones out of 109 analysed contain a match to TGGT or TYGGT consensus sequence and
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43 clones shared a consensus sequence TGGT(N5)TYGGT or the complement thereof.
(Table 5.1)
Table 5.1. SELEX results for the MTERF binding site analysis. Reprinted from
original article (I), copyright (2007), by permission of Oxford University Press.
5.1.9 The effect of modifying MTERF levels on mtDNA copynumber
(I)
One of the aims of my research was to study whether MTERF has a role in human
mtDNA replication. Therefore, I first studied whether MTERF over-expression has any
effect on mtDNA copynumber and whether it has novel binding sites in mtDNA in
addition to the previously reported canonical binding site. Over-expression or silencing of
MTERF did not affect the mtDNA copynumber (Figure 5.10, Figure 3c in III).
Figure 5.10 The effect of over-expressing MTERF on mtDNA copynumber. Quantitative PCR
was used to analyze the mtDNA copynumber of Flp-In™  T-Rex™ -293 cells transfected with the
MTERF construct and induced for 24 h, 72 h or 6 d. Values were normalized to the mean value
for uninduced cells. Reprinted from original article (I), copyright (2007), by permission of Oxford
University Press.
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5.1.10 Replication pausing at the canonical MTERF binding site (I)
Having found several novel binding sites for MTERF I wished to explore the possible
biological significance thereof. One hypothesis was that some of the replication pause
sites in the human mtDNA actually colocalise with MTERF binding sites. The MTERF
binding site within the tRNALeu(UUR) coding gene is known as the canonical binding site
of MTERF and it was also the first region that was studied by means of 2DNAGE.
mtDNA was isolated from different cell-lines and double digested with PvuII and AccI
restriction enzymes in order to produce a 3.6 kb fragment covering the segment from OL
up until the rDNA (Figure 5.11A). Several pause sites were found and the precision of
the autoradiographic signals was enhanced further by treating the mtDNA with S1
nuclease (Figure 5.12, 5.11B). Four cell lines were studied, namely HEK293T, HeLa,
Jurkat (T-cell leukaemia) and 143B (osteosarcoma) cells, for the replication pause sites
(Figure 5.12). Of these cell lines HEK293T and HeLa gave rather similar patterns, where
pause sites could be clearly distinguished. First we were able to recognise a replication
pause site (a) that maps to the location of tRNALeu(UUR) coding gene, secondly a
replication pause site (b) that maps to the 3’ region of the ND1 gene or the IQM tRNA
cluster next to it, thirdly a replication pause site (d) close to OL and finally one within the
ND2 coding gene (c). Jurkat and 143B cells gave rather similar patterns as the HEK293T
and HeLa cell lines although there were generally less mtDNA replication intermediates
in these two cell lines and S1 treatment did not enhance the separation of the pause sites
in the gel. The replication pause site located in the ND2 coding gene could not be
detected in Jurkat and 143B cells whereas the replication pause site at tRNALeu(UUR) could
be detected in all the cell lines studied (Figure 5.12).
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Figure 5.11. 2DNAGE for MTERF effects on replication pausing at region spanning from
16S rDNA till OL. A) AccI and PvuII restriction sites shown in the map as well as OH and OL sites.
Probe used was ND2, marked with asterisk. Non-coding region (NCR) enhanced bold, dark grey
and rDNA is enhanced bold, pale grey. B) Schematic map of the prominent pause sites a, b, c
and d. Reprinted from original article (I), copyright (2007), by permission of Oxford University
Press.
Figure 5.12. Mitochondrial replication is paused at the canonical MTERF binding site. Four
human cell lines were assayed for PvuII-AccI fragment by means of 2DNAGE and probed with
ND2 probe. S1 nuclease treated samples were compared to non treated ones. The prominent
mtDNA replication pause sites a, b, c and d are denoted with arrows. Reprinted from original
article (I), copyright (2007), by permission of Oxford University Press.
5.1.11 MTERF promotes mtDNA replication pausing (I)
Two approaches were applied to study whether MTERF promotes mtDNA replication
pausing in human mtDNA, namely over-expressing MTERF in inducible cells and on the
other hand knocking down MTERF by means of RNA interference using short interfering
RNAs. mtDNA was extracted from cells over-expressing MTERF and double digested
with PvuII and AccI and compared to similarly treated mtDNA from non-induced cells.
The restriction sites and the binding sites of the probes are illustrated in Figure 5.13A.
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The 3.6 kb fragment containing the canonical MTERF binding site was probed for and
the pause site at tRNALeu(UUR) (a) was observed to be strongly enhanced under condition
of MTERF over-expression. Also the ND1/IQM tRNA cluster (b), OL (d) and ND2 (c)
pause sites were enhanced by MTERF over-expression. X-form intermediates (x) were
also enhanced by MTERF over-expression (Figure 5.13B).
When the effect of over-expressing MTERF on the non-coding region was studied it
was established that it enhances the paused replication intermediates migrating near the
bubble arc (bubble arc denoted as 'f' in the HincII digested fragment and as 'n' in the
equivalent AccI fragment, probed with ‘OH’ probe) (Figure 5.13C). Bubble arc consists of
replication intermediates that contain a bubble. Once bubble exits the fragment studied
the bubble disappears and converts into Y-shaped RIs. Over-expressing MTERF also
decreased the amount of termination intermediates (t) (Figures 5.13C and 5.13D) and on
the other hand generally enhanced the representation of Y-form replication intermediates
(g) (Figure 5.13C).
Human mitochondrial DNA was mapped throughout by means of 2DNAGE to look
for other potential effects caused by MTERF over-expression and it was observed that
MTERF over-expression gave rise to a novel replication pause site at ND3
(Supplementary Figure 4C in I). However, EMSA did not show MTERF binding activity
on this site (Supplementary Figure 2 of I). A prominent pause site (h) close to ND5/ND6
gene junction site was not affected by MTERF over-expression (5.13C).
The effect of MTERF over-expression on human mitochondrial DNA replication was
studied further by means of 2DNAGE (mtDNA digested with a restriction enzyme that
cuts only once in the genome). The findings supported the idea of enhanced pausing in
the ND1/tRNALeu(UUR) region. The effects observed in these gels caused by MTERF over-
expression were site-specific, no general slowing down of replication, that is typical for
non-specific stalling, was observed (Figure 5.13D, Supplementary Figures 4D and 4E in
I).
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When MTERF was knocked down by means of RNAi it inferred replication pausing
was decreased in the ND1/ tRNALeu(UUR) region (Figure 5.14.). When RNAi treated cells
were compared to those not treated, the replication pause site (a) at tRNALeu(UUR)
disappeared and X-form replication intermediates were diminished. Other replication
pause sites seemed to be affected to a lesser degree (Figure 5.14).
Figure 5.13. MTERF promotes mitochondrial replication pausing. Here cells induced to over-
express MTERF are compared to non-induced ones. For clearer visualization of the pause sites
the samples were treated with S1 nuclease where indicated. Pause sites a-d and other replication
intermediates are denoted with arrows. A) Relevant restriction sites and locations of the probes
illustrated in the map. B) Unit-length fragment signal was measured by phosphoimaging and the
induced and uninduced blots were adjusted so as to be comparable. C) Pause site h was not
affected when levels of MTERF were modulated whereas termination intermediates (t) were
decreased and Y form replication intermediates (g) were enhanced. D) In single hitter gels
paused bubble (m) and the double-Y species (j) were upregulated when MTERF was over-
expressed. They both are predicted products yielded by replication pausing at the
ND1/tRNALeu(UUR) site. Also X, double-Y and broken theta molecules are affected and most clearly
putative termination intermediates (t) are suppressed by MTERF over-expression. Uncut and
gapped circles, denoted 'o', were diminished by MTERF over-expression in the PvuII but not NheI
digest. Reprinted from original article (I), copyright (2007), by permission of Oxford University
Press.
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Figure 5.14. Effect of silencing MTERF on human mtDNA replication intermediates. A)
siRNA MTERF.1 transfected cells (cells harvested 48 h after transfection) were compared to
untreated HEK293T cells. PvuII and AccI digested samples were S1 treated and the 3.6 kb
fragment was probed with ND2. Two exposures are shown for both, siRNA MTERF.1 transfected
and the untreated cells. X-spike (x) and pause site 'a' are both suppressed by silencing MTERF
and also pause site 'b' is downregulated when compared to pause site 'c'. B) Uninduced (i) and
induced (ii) MTERF over-expressing cells (reproduction of figure 4B in I) shown alongside with
MTERF silenced cells (iii). Silencing MTERF abolishes pause site 'a' as can be seen from longer
exposure (iv). Reprinted from original article (I), copyright (2007), by permission of Oxford
University Press.
5.2 Functional studies on MTERFD1 and MTERFD3 (III)
5.2.1 MTERFD1 and MTERFD3 are mitochondrial proteins (III)
For MTERFD1 and MTERFD3 studies I established inducible epitope-tagged fusion
protein expressing cell lines using the Flp-In™  T-Rex™ -293 cell system (HEK293T cells
were also transiently transfected with the MTERFD3-FLAG expression construct). The
expression of the epitope-tagged variants of MTERFD1 and MTERFD3 was verified by
means of Western blotting. The size of the MTERFD3-HA or MTERFD3-FLAG protein
was as predicted, roughly 43 kDa, when the epitope tag size has been taken into account
and the mitochondrial targeting sequence has been removed. MTERFD1-FLAG was
observed to migrate slightly slower than expected, approximately 47 kDa (Figure 5.15A).
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The intracellular localization of the fusion proteins was studied by means of
immunocytochemistry of transiently transfected cells. Both FLAG epitope-tagged
proteins were mitochondrially targeted in vivo based on colocalization with Mitotracker
Red. MTERFD1-FLAG but not MTERFD3-FLAG showed a distinctive punctuate
staining pattern that suggested it is localized in nucleoids (Figure 5.15B).
Figure 5.15. Epitope tagged MTERFD1 and MTERFD3 are efficiently over-expressed in
human cells and mitochondrially targeted. A) Flp-In™  T-Rex™ -293 cells were doxycycline
induced for 48 h to express either epitope tagged MTERFD1-FLAG or MTERFD3-HA. HEK293T
cells were transiently transfected (tr) with MTERFD3-FLAG and compared to mock transfected.
Western blots using total protein extracts were probed with anti-FLAG or anti-HA antibodies. B)
HEK293T cells were transiently transfected with MTERFD1-FLAG or MTERFD3-FLAG for
immunocytochemistry and 24 h after transfection probed with anti-FLAG antibody and
counterstained with Mitotracker Red. Merge figure (created using false colours) shows that the
stains colocalise. Reprinted from original article (III), copyright (2010), by permission of Springer.
5.2.2 MTERFD1 and MTERFD3 do not bind mtDNA sequence
specifically (III)
SELEX and EMSA were used to study whether MTERFD1 and MTERFD3 bind DNA in
sequence-specific manner. Previously I used SELEX successfully to look for the
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preferred binding motif for MTERF-MycHis. The same conditions were used to look for
binding motifs for MTERFD1-FLAG and MTERFD3-HA. However, SELEX results
were negative in both cases after 7 rounds of selection. Two independent experiments
were carried out for both proteins. 69 and 15 sequences were obtained for MTERFD1-
FLAG whereas 25 and 29 clones were sequenced for MTERFD3-HA, and these
sequences did not differ from the negative controls (35 clones sequenced).
A series of EMSA assays was carried out using mitochondrial extracts from cells
transiently transfected with either MTERFD1 or MTERFD3 or from induced MTERFD1-
FLAG or MTERFD3-HA Flp-In™  T-Rex™ -293 cells and using the same probes as was
used for MTERF-MycHis EMSAs. The whole non-coding region (NCR) was checked for
MTERFD1-FLAG and MTERFD3-HA binding as well as the canonical MTERF binding
site at the 16S/tRNALeu(UUR)/ND1 gene junction region, the IQM tRNA cluster together
with the C-terminal portion of ND1, OL and the ATPase6/COIII, ND5/ND6 and
tRNAPro/tRNAThr gene junction sites that are all fragments where MTERF and its
homologues or other mtDNA binding proteins have previously been reported or
suggested to bind. However, there was no sign of mtDNA binding activity for either of
the proteins studied, since no novel protein-DNA complexes were observed nor any clear
changes in mobility were visible. Also the effect of over-expressing MTERFD1-FLAG or
MTERFD3-HA on MTERF-MycHis binding was studied but no novel or enhanced bands
compared to control cells were observed. When supershift assays are considered there
were no any changes in mobility of the complexes in MTERFD1-FLAG over-expressing
cells whereas cells over-expressing MTERFD3-HA did yield a supershift with anti-HA
antibody when probed with 4 fragments of the promoter region or with ATPase6/COIII
gene junction site covering fragment. Thus, although neither EMSA nor SELEX revealed
plausible binding sites for either MTERFD1 or MTERFD3, MTERFD3 may associate
with DNA-binding complexes in some specific regions of the genome. My findings
indicate therefore that these proteins do not directly bind mtDNA but might be able to do
so by interacting with other proteins (Figure 5.16).
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Figure 5.16. MTERFD1 and MTERFD3 binding in mitochondrial DNA in vitro. A) 150 bp long
probes used in B) as illustrated. Promoters are denoted as PL, PH1 and PH2. OH is the heavy
strand replication origin and terminus; tRNA coding genes denoted with hatched bars, upper and
lower bars for encoded genes on heavy and light strand, respectively, protein coding gene
denoted with grey bar. B)-F) Series of EMSA gels using crude mitochondrial protein extracts from
Flp-In™  T-Rex™ -293 cells transfected with MTERFD1-FLAG (D1-FLAG) or MTERFD3-HA (D3-
HA) +/- doxycycline induced expression of protein of interest or MTERF-MycHis stably
transfected cells (MTERF-MH) and EMSA probes as indicated. Supershift assay was carried out
using the following antibodies: anti-FLAG (f), anti-HA (h) and anti-Myc (m). E) Complex formed by
ATPase6/COIII oligonucleotide probe (denoted with an arrow) is modestly enhanced by
MTERFD3-HA over-expression and partially supershifted by antibody. F) Arrow indicates the
complex formed by MTERF-MycHis alone. Reprinted from original article (III), copyright (2010),
by permission of Springer.
5.2.3 MTERFD1 and MTERFD3 downregulate mtDNA copynumber
(III)
To investigate whether MTERFD1 and MTERFD3 have any role in mtDNA replication
given the preceding results on MTERF, I tested whether altering the expression levels
thereof affects the mtDNA copynumber. The effect of over-expressing MTERFD1-FLAG
and MTERFD3-HA was studied over 7 days. MTERFD1-FLAG expressing cells showed
progressive downregulation of the mtDNA copynumber which was statistically
significant on day 7 (Figure 5.17A). On the other hand the induction of MTERFD3-HA
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gave only a transient decrease of the mtDNA copynumber, at the boundaries of statistical
significance (Figure 5.17B). When the proteins were knocked down in HEK293T cells
there was no effect on mtDNA copynumber (Figure 5.17C).
Figure 5.17. Effect of modulating MTERFD1 and MTERFD3 levels on mitochondrial DNA
copynumber. A) Relative mtDNA copynumbers measured by means of Q-PCR for Flp-In™  T-
Rex™ -293 cells over-expressing MTERFD1-FLAG or B) MTERFD3-HA. Normalised against
copynumber of the uninduced cells. C) Grey bars show HEK293T cells silenced either for
MTERFD1 or MTERFD3, not treated or transfected with empty shRNA vector (v). Black bars
show MTERF-silenced cells (using siRNAs) in comparison with mock transfected cells. Data was
normalized against relevant untransfected or mock-transfected cells. Here statistical significance
is marked with * (p < 0.01) and borderline significance is denoted with # (p = 0.05, t-test).
Reprinted from original article (III), copyright (2010), by permission of Springer.
5.2.4 MTERFD1 and MTERFD3 influence mtDNA replication
intermediates (III)
To study the role of MTERFD1 and MTERFD3 proteins in mtDNA replication we used
2DNAGE to study the effect of over-expressing MTERFD1-FLAG or MTERFD3-HA in
Flp-In™  T-REx™ -293 cells compared to controls. Over-expression of either MTERFD1-
FLAG or MTERFD3-HA produced a number of changes that indicated that over-
expression of either leads to impaired completion of replication. The over-expression of
MTERFD3-HA had a stronger effect than that of MTERFD1-FLAG (Figure 5.18A).
For this assay mtDNA was digested with PvuII, which cuts mtDNA once, about 2.5 kb
upstream of the replication terminus near OH. Schematic drawings of the replication
intermediates are shown in Figure 5.18C. Multi-junctional molecules, interpreted as
double Y intermediates, were observed to be upregulated, indicating that over-expression
of either of the proteins has effect on the final steps of replication. When MTERFD3 was
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over-expressed uncut or gapped circles (gc), that are released by the resolution step, were
depleted. Lagging-strand DNA synthesis remains unfinished in the uncut circles at the
PvuII restriction site. The bubble arc, represents an intermediate produced at an early
stage of replication, was unchanged (Figure 5.18A).
The effect of over-expressing MTERFD1 and MTERFD3 in mtDNA replication
intermediates was almost opposite to that of over-expressing MTERF. Over-expression
of MTERF led (Figure 5.18A) to accumulation of bubble intermediates that are paused
near the high-affinity MTERF binding site. Conversely both multi-junctional structures
and gapped circles were depleted by MTERF over-expression. When either MTERFD1
or MTERFD3 was knocked down by means of RNAi, most of the mtRIs were preserved,
but incomplete circles accumulated (Figure 5.18B).
Figure 5.18. The role of MTERFD1 and MTERFD3 in mitochondrial replication. A), B) 1 ?g of
total nucleic acids, digested with PvuII and probed with (ND2 + ND4) probe, were analysed by
2DNAGE. Cells were harvested 48 h after induction with 10 ng/ml doxycycline or after
transfection with shRNA constructs. Panels i and ii are reproductions of Figure 4D in I.
Replication intermediates are denoted with arrows and schematic drawings are shown in C),
bubble arc (b), incomplete circles (ic), Y species (Y), broken replication intermediates (br),
complex junctional forms (cj). Red arrows in B) indicate incomplete circles with extensive single-
strandedness. C) Schematic drawings of the mitochondrial replication intermediates. Uncut PvuII
site is marked with red cross. Reprinted from original article (III), copyright (2010), by permission
of Springer.
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5.3 Functional studies on the mitochondrial transcription
factor A (IV)
5.3.1 The effect of altering TFAM levels on mitochondrial transcripts
(IV)
One of the aims was to study how modulating TFAM levels in cultured human cells
affects mitochondrial tRNA transcript levels compared to modulating mTERF levels.
Another aim was to compare the effects of altering TFAM and MTERF levels on mtDNA
replication. I contributed to article IV by studying the effect of modulating TFAM levels
on mitochondrial transcripts by means of neutral acrylamide/urea gel electrophoresis, in
collaboration with Jaakko Pohjoismäki.
The steady-state level of mitochondrial transcript ND3 mRNA (normalized to S5
rRNA) was studied in Flp-In™  T-Rex™ -293 cells stably transfected with either TFAM-
stop or TFAM-MycHis induced to over-express in vivo. Over-expression of TFAM or
TFAM-MycHis induced a clear decrease in the level of ND3 mRNA (Supplementary
Figures 1D and 2D in IV).
We studied also the effect of over-expressing TFAM-MycHis on tRNA levels during
the recovery period after depleting the mtRNA and mtDNA by three days of EtBr
treatment. Over-expressing TFAM markedly slowed down the recovery of the tRNA
levels after the removal of the drug compared to cells not induced to over-express TFAM
(Figure 5.19). The result obtained here contrasts with the minimal effect seen when
MTERF was over-expressed (Figure 5.5C).
Western blotting showed that knocking down TFAM by means of RNAi lead to
progressive reduction of TFAM protein levels and mtDNA copynumber (Supplementary
Figure 3 in IV). When the cells were treated with TFAM specific siRNAs up to 48 h, no
clear effect on the TFAM protein, mtDNA or ND3 mRNA transcript levels (normalized
to the amount of template mtDNA) were detected (Figure 1 in IV).
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Figure 5.19. The effect of over-expressing TFAM-MycHis on mitochondrial tRNA levels.
Cells induced to over-express TFAM-MycHis were treated with EtBr for 72 h in parallel with non-
induced cells after which EtBr was washed away. Mitochondrial tRNA levels were studied during
the five days of induction of TFAM expression compared to non-induced cells by means of
Northern blot and normalized with 5S rRNA. Reprinted from original article (IV), copyright (2006),
by permission of Oxford University Press.
5.3.2 TFAM is a regulator of the mode of mitochondrial DNA
replication (IV)
The effect of modifying the levels of TFAM expression on mtDNA maintenance were
studied in cultured human cells. By means of real-time PCR and Southern blot it was
shown that TFAM-stop over-expression decreased the mtDNA copynumber by 40-60%
(Supplementary Figure 1 in IV) even if the TFAM protein levels did not increase
markedly (Supplementary Figure 1 in IV). Knockdown of TFAM by means of RNAi also
resulted in progressive decrease in mtDNA copynumber (Figure 1 and Supplementary
Figure 3 in IV).
The effect on mitochondrial DNA replication intermediates of over-expressing
TFAM-stop or TFAM-MycHis was studied, which gave a clear overall increase in the
amount of RIs relative to the unit-length restriction fragment (Figure 2 and
Supplementary Figure 5 in IV). When DNA from cells induced to over-express TFAM
was digested with PvuII, an increase in the clubheaded bubble arc (representing
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unidirectional theta replication initiating at OH) was observed and a more prominent
simple Y-arc than in uninduced control cells was detected.
In other digests, conducted to analyse shorter, specific fragments, we observed that S1
nuclease-sensitive RIs were decreased, whereas nuclease-resistant arcs were enhanced by
TFAM over-expression (Figure 2c-e in IV). The strongest effects were observed in the
region spanning from OL through the rDNA (i.e. the so-called minor arc of the genome).
In TFAM over-expressing cells complete Y-arcs were detected already at low exposure
compared to uninduced cells, and the diffuse ‘clouds’ of nuclease-sensitive material were
replaced by two or several nuclease-sensitive slow-migrating Y-shaped arcs.
RIs detected by probes for the NCR were not dramatically affected by TFAM over-
expression, the termination region being the most affected. In this region, the bubble and
X-arcs were diminished, whereas the descending portion of the Y-arc was strongly
increased (Figure 2c in IV). TFAM over-expression also increased replication pausing at
certain pause sites, namely within the ND1 gene, at OL (Figure 3d in IV), within ND5
(Figure 2c in IV) and finally at many weaker pause sites, e.g. in ND4, ND3, COXIII, A6,
A8 and COXII (Figure 3c in IV).
Silencing of TFAM enhanced ribonuclease-sensitive material in the rDNA region and
its mobility was also affected (Figure 4c in IV). Silencing of TFAM also strongly
upregulated the X-arc in the OH –containing fragment (Figure 4b in IV).
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6. Discussion
6.1 The role of MTERF in mitochondrial transcription
termination
6.1.1 Effects of modulating MTERF levels on sense transcripts
One aim of the project was to study the effect of modulating the MTERF level on the
relative activities of the human mitochondrial heavy-strand transcription units by
measuring the relative levels of different mitochondrial transcripts under different
conditions. I did this by means of Northern blot analysis and Q-RT-PCR using cells
either over-expressing MTERF or cells knocked down for MTERF expression.
I studied the effect of over-expressing MTERF on the steady-state
tRNAPhe/tRNALeu(UUR) ratio and established that there is no significant difference in it
when studying different cell clones over-expressing the natural variant of MTERF
compared to the control cells (Figure 5.5A). I also studied the effect of over-expressing
MTERF on the 16S and ND1 transcript levels in Flp-In™  T-Rex™ -293 cells stably
transfected with the MTERF-MycHis construct induced to over-express MTERF
compared to non-induced cells and observed no effect on the relative quantities of the
transcripts in question (Figure 5.5B). Neither did I observe any effect on mitochondrial
RNA levels during the recovery period after EtBr depletion of mitochondrial RNA and
DNA, when cells over-expressing MTERF were studied (Figure 5.5C).
As an opposite approach to MTERF over-expression I studied the effects of silencing
MTERF by means of RNAi on different mitochondrial transcript levels. When the effect
of silencing MTERF was studied 7 days after the initial RNAi treatment there was a
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modest drop detected in the tRNAPhe/tRNALeu(UUR) ratio in HEK293T cells, with a slight
overall increase in mitochondrial transcript levels. Once again, no changes were observed
in similarly treated MTERF-MycHis over-expressing cells (Figure 5.6A). Knocking
down MTERF did not bring about any detectable effects on mitochondrial RNA levels
during the recovery period after EtBr depletion of mitochondrial RNA and DNA (Figure
5.6B).
However, my research produced two pieces of evidence supporting MTERF having a
role in the transcription of the mitochondrial heavy strand. Firstly, after MTERF knock
down in normal cells there was a small increase in the amount of the two mitochondrial
tRNAs representing each of the heavy strand transcription units to be detected, relative to
cytosolic 5S rRNA (Figure 5.6A). Secondly, the levels of sense-strand 12S rRNA relative
to 16S or 18S rRNA gene transcripts, measured by means of Q-RT-PCR, was markedly
increased when MTERF was knocked down (Figure 5.7F). As sense-strand 16S and ND1
transcript levels relative to each other or to 18S were not significantly affected, I suggest
that there exists a compensatory mechanism (Figures 5.7F and S3C in II). According this
suggestion, knocking down MTERF sends out a signal for globally upregulated
mitochondrial transcription or decreased turnover, in order to overcome the potential
impairment in 16S rRNA biogenesis. The degree of MTERF knockdown that was
reached in these experiments was only 50%, for which reason the effects of the
knockdown may be underestimated. It is likely that in these experiments up to half of the
cells still express MTERF normally and in the remaining cells expression is significantly
decreased.
I conclude here that the amount of MTERF in cells does not regulate the relative
steady-state levels of transcripts representing the two heavy-strand transcription units in a
simple manner, but it seems to be modified by compensatory mechanisms. Previous
studies carried out to study the role of MTERF in transcription termination have yielded
diverse and seemingly contradictory results. Martin et al. (2005) and Asin-Cayuela et al.
(2004) reported that MTERF stimulates transcription in vitro from PH1 in a rather crude
system. When purified recombinant proteins (Asin-Cayuela et al. 2005) or crude extracts
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with DNA-affinity purified MTERF were used (Asin-Cayuela et al. 2004), MTERF was
not found to stimulate transcription. Chomyn et al. (1992) studied the effect of the
A3243G mutation on mitochondrial transcript levels and the possible role of MTERF in
the pathogenesis of MELAS syndrome and reported impaired mitochondrial protein
synthesis, defects in respiration and decreased binding affinity of purified MTERF to its
target sequence due to the A3243G mutation; however, no major changes in
mitochondrial rRNA or mRNA levels were observed. Fernandez-Silva et al. (1997)
established in vitro that MTERF alone cannot bring about transcription termination.
Shang and Clayton (1994) studied whether the A3243G mutation impairs transcription
termination in vivo but found no evidence for this even though the mutation caused a
drop in the rate of transcription termination in vitro, supposedly by reducing the MTERF
binding affinity to its target site.
Previously Selwood et al. (2000) reported that TAP (thiamphenicol) treatment does
not affect 12S and 16S rRNA levels in HepG2 cells but instead increases the steady-state
levels of both mRNAs and tRNAs transcribed from the IH2 transcription initiation site of
the heavy strand. Thiamphenicol is an antibiotic which blocks mitochondrial protein
synthesis. Their findings indicate that modulation of MTERF complex could be the
limiting factor determining the mitochondrial gene expression at the level of transcription
termination. The underlying mechanism was proposed to be TAP enhancing
transcriptional initiation from the second HSP (IH2) transcription initiation site, which
was first suggested by Montoya et al. (1983). This would explain the unchanged rRNA
levels and also the enhanced transcription downstream of the MTERF binding site.
Findings from the study of thyroid hormone action (Enriquez et al. 1999) and of the
effects of variation in ATP supply (Micol et al. 1997) are both in agreement with our
results. The molecular mechanism behind suggested is that they have an effect on the
relative rates of transcription of the two differentially transcribed transcription units of
the mitochondrial heavy-strand but no effect on that at the high affinity MTERF binding
site.
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Some of the MTERF homologues in other organisms have been shown to affect
mitochondrial transcription which argues against the idea that the effects on nucleic acid
metabolism caused by altering MTERF levels are incidental while the real biological
function of MTERF is still lurking somewhere else inside mitochondria. The Arabidopsis
thaliana gene SOLDAT10 (singlet oxygen-linked death activator) encodes a protein that
is related to the human MTERF protein. The soldat10 mutation has been reported
specifically to decrease plastid rRNAs which indicates that this mutation does not
universally impair chloroplast RNA accumulation (Meskauskiene et al. 2009). The
soldat10 mutation has been also suggested to have more indirect effect on the ROS
production or the redox state of the plastid. This mutation leads to disturbance of plastid
homeostasis which suppresses ROS-mediated cell death (Meskauskiene et al. 2009). The
MTERF protein homologue in Chlamydomonas reinhardtii, MOC1, on the other hand,
has a role in restoring mitochondrial RNA levels after exposure to light (Schönfeld et al.
2004). MOC1 levels are upregulated after light exposure and the loss of MOC1 leads to
light-sensitive phenotypes as well as impairing the chloroplast transcription and
replication (Schönfeld et al. 2004).
6.1.2 MTERF regulates the levels of anti-sense transcript levels in
human mtDNA
In this project I addressed the question whether MTERF could have a limiting role in
transcription termination in human mitochondrial DNA in vivo. By modulating MTERF
levels and studying the effect on sense and antisense 16S and ND1 transcripts, I found
out that over-expressing MTERF decreases the anti-16S/anti-ND1 transcript ratio and
knocking down MTERF increases it. I therefore established that MTERF regulates
antisense transcript levels consistent with it facilitating of antisense transcription
termination initiated at PL by binding to its canonical binding site. The effect of
modifying MTERF levels on RNA19 (16S + ND1) remains to be studied. It should be
interesting to do so, as it could shed more light on the antisense results.
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Why would MTERF have a role in regulating mitochondrial antisense transcripts that
have no documented function, and which are assumed to be destined for turnover? Asin-
Cayuela et al. (2005) showed, using recombinant human MTERF in a highly purified
reconstituted in vitro transcription system, that MTERF transcription termination exhibits
clear polarity. When bound in the ‘forward’ orientation to its target sequence in the heavy
strand promoter, MTERF arrested transcription completely, but when bound in the
opposite orientation, it arrested transcription only partially. Asin-Cayuela et al. (2005)
also showed that MTERF alone can terminate transcription in vitro and does not need to
be post-translationally modified by phosphorylation. It might be that MTERF actually is
capable of terminating transcription in a bidirectional manner also in vivo and the effects
on the sense transcript levels are masked or complicated due to the post-transcriptional
processing of rRNAs, the stabilization of rRNA into ribosomal subunits or due to
compensatory effects on transcriptional initiation or RNA stability.
The biological significance of the antisense transcripts is still unclear but one
possibility is that they could have a role in providing a stalled replication fork with a
primer that is needed for the re-initiation of the replication machinery. Non-coding
antisense RNA transcripts have been found in normal proliferating cells arising from the
16S rRNA gene, whereas in tumour cell lines the levels of these antisense transcripts are
downregulated (Villegas et al. 2007, Burzio et al. 2009). It therefore seems that the
antisense transcript levels may relate to the tumorigenicity or proliferation status of the
cell. The exact physiological origin of these antisense transcripts is still unknown but they
might be created post-transcriptionally or during transcription by template strand-
switching.
My results suggest that MTERF has a role in mitochondrial transcription in vivo, but it
does not seem to set the levels of mature mitochondrial transcripts encoded by the PH1
and PH2 heavy-strand transcription units in a simple manner. Rather, this is influenced
by compensatory mechanisms.
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6.2 MTERF binding to human mtDNA
Previously, MTERF has been reported to have two binding sites in the human
mitochondrial DNA. The first is canonical binding site, located downstream of the
mitochondrial rRNA coding sequences within the tRNALeu(UUR) gene. A 13 bp fragment
within the MTERF binding site has been reported to be crucial to terminate transcription
correctly from PH1 in vitro suggesting that it may be needed for the formation of the 3’
end of 16S rRNA (Christianson and Clayton 1988). The ability of the MTERF binding
site to work in a bidirectional manner has also been shown to be crucial for accurate
termination of transcription (Christianson and Clayton 1986).
As I was interested in the possible roles of MTERF in human mitochondrial
replication, I first studied whether MTERF has other binding sites in mtDNA than the
previously reported canonical binding site within the tRNALeu(UUR) (Kruse et al. 1989)
coding gene and the other one at the PH1 initiation site for the H strand transcription,
more recently reported by Martin et al. (2005). There are various examples of MTERF
homologues binding to multiple target sites within mtDNA. The MTERF homologue in
sea urchins, mtDBP, binds sea urchin mtDNA at two sites that are located opposite each
other in the circular genome. The MTERF homologue in Drosophila melanogaster,
DmTTF, also has two binding sites in Drosophila mtDNA, both of them located in non-
coding DNA.
The novel binding sites that I found for MTERF, in human mtDNA both in vitro and
in vivo, did not exhibit as high affinity binding as the earlier reported canonical MTERF
binding site. However, these novel binding sites appeared to be clustered in the human
mitochondrial genome indicating that MTERF might bind adjacent target sites in multiple
copies to bring about a physiological effect. Since I used crude mitochondrial protein
extracts for the EMSA experiments, it is also possible that MTERF co-operates with
some other protein e.g. TFAM or one of the novel MTERF protein family members to
bring about more efficient binding. It is also possible that post-translational modification,
e.g. phosphorylation, is needed for MTERF to be biologically active.
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MTERF binds mtDNA as a monomer and it is active in transcription termination in
vitro only when present as a monomer (Asin-Cayuela et al. 2004). The latter authors
further proposed that MTERF is present in mitochondria in two forms, an active
monomer and an inactive homotrimer and that the relative amount of the active MTERF
is regulated by the transition between the two forms. It should be interesting to measure
more carefully the exact MTERF levels in different cell lines and tissues, and determine
the exact nature of these complexes.
It should also be noted that MTERF could be over-expressed at such high excess in the
cell lines I used for my studies that the vast excess of the protein binds mtDNA
unspecifically all around the genome, but that only binding to the canonical site has any
physiologically meaningful effect, whether on transcription or replication. This would of
course require that there is not already an excess of MTERF protein in cells. Clearly
further studies are needed here.
6.3 The physiological significance of multiple MTERF
binding sites in the mtDNA
By means of SELEX I established that the minimum requirement for MTERF binding is
GG(N8)GG. When human mtDNA is studied, there are actually clusters of such minimum
requirement binding sites found. Interestingly there are 12 such sites in the NCR alone,
all in the same orientation. Christianson and Clayton (1986) previously reported possible
binding sites within the NCR for MTERF. There is also a cluster of seven similar binding
sites, again all in the same orientation, near the 3’ end of the ND1 coding sequence,
spanning the IQM tRNA gene cluster adjacent to it. Curiously, the sequence at the
canonical binding site shows the opposite orientation and overlaps on each side two other
similarly oriented minimal MTERF binding sequences. Orientation-dependent
termination activity has later suggested to be due to MTERF preferring to bind to the
light strand of the mitochondrial DNA (Nam and Kang 2005). Clearly, MTERF binding
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sites are not in random orientation or location in the mtDNA (Supplementary Figure 6 in
I).
Prieto-Martin et al. (2004b) reported that the rat MTERF protein binds the
mitochondrial transcription initiation site but did not detect any complex bringing
together the rat mtDNA transcription initiation and termination sites and the rat MTERF.
Martinez-Azorin (2005) had already introduced the idea that regulation of different
mitochondrial transcripts is brought about by looping of mitochondrial DNA, when
Martin et al. (2005) published a report of MTERF binding simultaneously at two sites in
the mtDNA and therefore creating a loop in the mtDNA bringing together the
transcription initiation and termination sites. According to Martin et al. (2005) this could
explain the difference between the synthesis rates of mitochondrial rRNAs and mRNAs;
namely, that rRNA is synthesized 15-60 times more than mRNA. However, my findings
do not provide any support for this model in vivo, although one has to keep in mind that I
did not measure synthesis.
6.4 Physiological significance of MTERF levels
The physiological amount of MTERF molecules present in mitochondria remains to be
determined. There might, for example, be a large pool of inactive MTERF trimers present
(Asin-Cayuela et al. 2004). If this were the case, over-expressed MTERF such as in my
experiments would simply end up adding further to the inactive pool of MTERF. On the
other hand, RNAi may not lead to detectable effects since a substantial or at least
adequate pool of MTERF may remain; thus my negative results could also be explained
away. Since all the cells used in this study are derived from one cancer cell line the
possibility must also be considered, that our cells do not behave in a physiologically
similar manner as non-cancer cells and might already have a higher level of MTERF.
Therefore, altering MTERF levels could have a more profound effect on mitochondrial
transcription in some other cell-types. Gene expression data from biogps.gnf.org does not
support this idea, but shows that rather MTERF is expressed in HEK293T cells at very
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close to the median level of all cell lines studied. The range of expression according to
biogps.gnf.org is approximately 2-5 fold, whereas I achieved greater than 10-fold
expression changes in my cells which is probably higher than in any normal
physiological situation and therefore should be sufficient to yield detectable effect, if any
could be produced.
It is also possible that MTERF is constitutively inactivated in HEK293T cells no
matter what the expression level is. For example Prieto-Martin et al. (2004a) established
that in order to be active in transcription termination in vitro rat MTERF needs to be
phosphorylated. Asin-Cayuela et al. (2005) on the other hand reported that human
recombinant MTERF does not need to be post-translationally phosphorylated, in order to
carry out transcription termination in vitro. Therefore it would be interesting to check if
over-expressed human MTERF is phosphorylated (or modified in some other way),
whether it trimerizes or is held in complexes with other proteins or, indeed, whether it is
cleaved to the active form.
6.5 A possible role of MTERF in mitochondrial DNA
replication
6.5.1 MTERF has a dual role in transcription and replication arrest
One aim of my project was to establish whether MTERF has another role(s) in mtDNA
maintenance relating to its novel binding sites. I addressed the question by studying the
effects of MTERF in mtDNA replication by means of 2DNAGE. The outcome of the
study was that, when over-expressed in inducible T-Rex cells, MTERF was demonstrated
to promote replication pausing at several sites. In addition I documented novel replication
pause sites in human mtDNA.
My results indicate that MTERF does not directly regulate the relative rates of PH1
and PH2 transcription. Since the different quantities of mRNA and rRNA transcripts in
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human mitochondria can be explained based on their different half-lives and RNA
processing efficiency, and considering also that the A3243G MELAS mutation does not
affect mtRNA levels in vivo, it is thus possible that MTERF has another principal role in
mitochondria than transcriptional regulation as such. My findings suggest that MTERF
might have a dual role in transcription and replication arrest and may even coregulate
these processes.
The light strand promoter (LSP) has been suggested to provide RNA primers for DNA
replication because it is located near to the origin of heavy-strand replication. Light
strand transcripts initiating from the non-coding region were initially found by Wallberg
and Clayton (1983). Later it was established that the LSP transcription unit provides
replication with RNA primers (Chang and Clayton 1985). The primer for the initiation of
mtDNA replication is proposed to be synthesized by transcription from PL, but with the
transcript remaining annealed to the template-strand. Yasukawa et al. (2006) reported
results indicating that the vertebrate mtDNA lagging strand is first copied as extended
RNA segments which are then matured to DNA. The lagging-strand priming described
above is hypothesized to require either a primase that can synthesize extended RNA
primers or alternatively it can happen via the so-called bootlace model. In the bootlace
model the preformed L-strand RNA is hybridized with the displaced H-strand in a 3´ to
5´ direction as the replication fork proceeds. The bootlace model is supported by the
MTERF enhanced replication pausing. By catalyzing a coincidental arrest of both
transcription and replication machineries, MTERF might provide the replication
machinery with a 3´ end that is capable of priming lagging-strand DNA synthesis and
simultaneously providing a new RNA bootlace so that the replication fork can continue
replication in the forward direction.
6.5.2 A possible role for MTERF in preventing the head on collision
of the transcription and replication machineries
The sea urchin MTERF homologue mtDBP exhibits bidirectional contrahelicase activity,
suggesting that it might act as a negative regulator of replication fork progression. This
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raises the question of whether, human MTERF might have an analogous function in
mtDNA metabolism in addition to any possible role in transcription termination
(Loguercio Polosa et al. 2005). mtDBP regulates transcription termination in vitro only
when the enzyme approaches the DNA bound mtDBP from the L-strand direction and
therefore mtDBP is suggested to act as a polar termination factor.
I therefore propose that MTERF promotes replication pausing on a template molecule
while transcription is occurring at the same time. MTERF could therefore be acting as a
“traffic signal” regulating the orderly passage of the replication and transcription
machineries. Such regulation maybe important since unregulated collisions can create
recombinogenic ends and lead to genomic instability. Such a regulation mechanism has
been reported at least in Escerichia coli (Neylon et al. 2005, Mulcair et al. 2006).
Loguercio Polosa et al. (2005) suggested that in sea urchin the passage of the RNA
polymerase through the DNA-mtDBP complex abrogates the mtDBP contrahelicase
activity.
The Escerichia coli Tus protein provides an excellent model for studying the human
MTERF protein despite the lack of structural homology. E. coli has several replication
fork arrest sites (Hill et al. 1988) which act in a polar manner, as in prokaryotes generally
(Hill et al. 1989). Replication forks are arrested by the terminator protein, Tus, binding to
its target site (Hill et al. 1989, Neylon et al. 2005). Tus shows contrahelicase activity
only in one direction and has also been shown to act as a polar block for elongating
transcripts in vitro (Mulcair et al. 2006). The physiological significance of this polar
RNA chain blocking activity lies in its ability to abrogate contrahelicase activity, as
observed in vitro (Mohanty et al. 1996). In vivo migration of a transcription complex
through the ter sequence also abrogates the contrahelicase activity, and replication forks
are subsequently enabled to progress. On the other hand replication fork arrest is not
abrogated when transcription approaches the ter site towards the blocking end (Mohanty
et al. 1996). Similarly to Escerichia coli Tus protein, MTERF binds on both sides of the
replication terminus region and is here proposed to regulate the passage of
transcription/replication machineries approaching the terminus region from opposite
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directions, thus preventing them colliding with each other head-on. Unregulated head-on
collision of two protein machineries can lead to genomic instability in prokaryotic
genomes (Takeuchi et al. 2003, Prado and Aguilera 2005) and prevents DNA replication
whereas in the nucleus of mammalian cells it leads to formation of HSRs
(homogeneously staining regions of chromosomes) (Hashizume and Shimizu 2007).
DmTTF has two binding sites in Drosophila mtDNA and transcription termination has
been shown to take place at these sites. In vitro studies carried out on DmTTF have
shown that it is capable of terminating transcription. However, silencing DmTTF has
shown that it has no role in generating the 3´ ends of the mature transcripts. Roberti et al.
(2005) reported that in vitro DmTTF has bidirectional transcription termination activity
with biased polarity. DmTTF protein was therefore found to act asymmetrically so that it
exposes different faces to RNA polymerases that approach it from different directions
(Roberti et al. 2005). Thus it is possible that DmTTF could have a role in mtDNA
replication as well, as hypothesized for mtDBP (Loguercio Polosa et al. 2005) and here
for MTERF.
6.6 Does MTERF have a role in MELAS pathogenesis?
The functional role of MTERF is interesting because the A3243G MELAS mutation is
situated in the middle of its canonical binding site within the tRNALeu(UUR) gene. The
mutation has been shown, in vitro, to dramatically reduce the binding of MTERF to its
target site and to suppress transcription termination efficiency (Hess et al. 1991, Chomyn
et al. 1992). However, it remains to be established whether MTERF finally has a role in
MELAS pathogenesis. Some MELAS-causing mutations in the tRNALeu(UUR) gene are not
located within the MTERF binding sequence and some of them are even located in other
genes where no alteration in MTERF binding is seen. Nevertheless, it is possible that
when the A3243G MELAS mutation is considered, interaction with MTERF might still
be necessary. I showed that altering MTERF expression levels affects antisense transcript
levels; it is possible that these antisense transcripts might play a role in MELAS
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pathogenesis. It should be interesting to study whether antisense transcript levels in
A3242G mutation carrying cells differ from those in normal cells.
The A3242G MELAS mutation and silencing of MTERF by RNAi lead to the same
end result, namely the MTERF binding to its target sequence is potentially decreased. My
results indicate that MTERF does influence mitochondrial transcription in vivo and thus it
cannot be ruled out that some of the pathological effects seen in MELAS may be due to
impaired transcription termination or modified relative amounts of sense- and antisense-
strand transcripts.
6.7 The physiological role of MTERF and its crystal
structure
The MTERF structure has been solved only recently and it has further elucidated the
possible biological significance of the MTERF protein and also other members of the
MTERF protein family since they also have the MTERF motif. The MTERF structure
consists of nine left-handed helical MTERF motifs that form a solenoid structure which is
further twisted to the right. MTERF apparently has two DNA binding sites and it binds
one continuous DNA strand creating a bend in DNA (Jiménez-Menéndez et al. 2010).
DNA bending has been shown to be important for transcription termination. One other
transcription termination factor, TTF1, has been reported to induce DNA bending of 40°
(Smid et al. 1992) and similarly to bring about transcription termination (Kuhn et al.
1990). TTF1 has also been reported to show contrahelicase activity (Pütter and Grummt
2002), like the sea urchin MTERF homologue mtDBP (Loguercio Polosa et al. 2005).
We have shown that over-expressing MTERF promotes mtDNA replication pausing and
therefore implicating it in replication as well. The MTERF molecular structure and its
ability to bend DNA are consistent with the idea that it might indeed have a dual role in
mtDNA transcription and replication.
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Jiménez-Menéndez (2010) established that repeats I-VI of the full length MTERF
protein bind one half of the binding site oligonucleotide and that repeats VIII and IX bind
the other half of it. They showed that two conserved guanines contact two arginines at
positions 169 and 202. These guanine residues are G12 from strand C and G3 from strand
B which I established to be part of the minimal binding site of MTERF by means of
SELEX. In addition G4 from strand B contacts Glu165. It appears that full length
MTERF protein binds YGGY at both ends of its minimal binding site, thus creating a
bend in the mtDNA.
Since full length MTERF protein is able to bind DNA at two sites it is conceivable
that it can create a loop in mtDNA and might therefore have a role in regulating the
relative activities of the PH1 and PH2 transcription units and explain the difference in
rRNA and mRNA levels in mitochondria after all as proposed by Martin et al. (2005).
Jiménez-Menéndez et al. (2010) also reported that MTERF protein has a shorter
variant that is due to spontaneous proteolysis of the full length MTERF protein. This
shorter version of MTERF, MTERF-DN, is also capable of binding DNA but does so in a
sequence non-specific manner contacting the DNA in the major groove. It is possible that
MTERF-DN somehow interacts with the full-length protein that binds DNA in a sequence
specific manner.
6.8 MTERFD1 and MTERFD3 binding to human mtDNA
The third aim of my study was to investigate two recently identified members of the
human MTERF protein family. MTERFD1 and MTERFD3 were found to be efficiently
expressed in the inducible Flp-In™  T-Rex™ -293 cells and were mitochondrially targeted
as predicted. I was not able to establish any sequence-specific DNA binding activity for
either of the proteins, which is consistent with other published data which showed little or
no sequence-specific binding for either factor in vitro or in vivo (Park et al. 2007,
Pellegrini et al. 2009, Wenz et al. 2009). Nevertheless, I detected that the over-expressed
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MTERFD3-HA complex was supershifted with the anti-HA antibody when probed with
four separate probes located at the OH/promoter region, with which TFAM has also been
shown to interact. It is therefore possible that MTERFD3 interacts with the TFAM-DNA
complex. Over-expressing MTERFD3-HA did not enhance the signal. However,
MTERFD3 is already an abundant protein and this might explain the absence of any
visible effect on the signal seen in EMSA.
6.9 Physiological role of MTERFD1 and MTERFD3 in
human mitochondrial DNA maintenance
I investigated the effect of modulating MTERFD1 and MTERFD3 protein levels on
mtDNA copynumber. Over-expression of either of the proteins leads to mtDNA
copynumber depletion, suggesting that they might have a role in mtDNA replication. I
continued by studying the effect of over-expressing the epitope-tagged proteins on
mitochondrial DNA replication intermediates by means of 2DNAGE. The effect of over-
expressing either of the proteins was distinct from the one due to MTERF over-
expression; complex junctional molecules were upregulated whereas the amount of
gapped circles was downregulated when the DNA was analysed by PvuII digestion.
Conversely, when either of the two proteins was silenced by means of RNAi, incomplete
circles were increased compared with other replication intermediates.
There are also earlier studies suggesting that MTERFD1 might play a role in mtDNA
replication since Mterfd1-mice do not survive past embryonic stage (Park et al. 2007).
This is also supported by my mtDNA copynumber analysis data. On the other hand,
knocking out Mterfd3 in the mouse did not result in a dramatic outcome but a mild, rather
late-onset pathology (Wenz et al. 2009) which is again consistent with my mtDNA
copynumber data. Given the similar effects on replication intermediates, I suggest that
these two proteins might co-operate in some way. One possible molecular mechanism for
that would be that MTERFD3 is actually an accessory protein for MTERFD1.
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Above I introduced the idea that MTERF, like mtDBP, might have contrahelicase
activity. My findings on the biological role of MTERFD3 suggest that it could also
regulate replication fork passage, but immediately upstream of the replication terminus,
since it appears to interact preferentially with the NCR at the OH/promoter region,
causing an accumulation of pre-termination mtRIs. As over-expressing MTERFD1 leads
to similar but less dramatic changes in the mtRIs, I suggest that it could cause a similar
kind of effect but more widely in the genome. RNAi of either MTERFD1 or MTERFD3
yielded results that are in accordance with the possibility that these proteins show
contrahelicase activity; the above mentioned gapped circles being exactly what we would
expect to see if replication fork impedance in the pre-termination zone is alleviated.
6.10 TFAM and MTERF have distinct effects on
mitochondrial transcription and replication
intermediates
We studied the effect of modulating TFAM levels on mitochondrial transcription and
replication. We established that both over-expression and silencing TFAM decrease
mtDNA copynumber whereas modulating MTERF levels did not affect mtDNA
copynumber and that over-expression of TFAM down regulates mitochondrial
transcripts. When over-expressed, TFAM led to an increase in the amount of RIs in
general, most clearly in the rDNA region, and it also caused a decrease in replication
termination intermediates. When TFAM was silenced it led to enhancing of termination
intermediates but RIs did not shift from the ribosubstituted type more generally. Treating
cells with dideoxycytidine led to a generally similar phenotype as TFAM over-
expresssion at large.
Many conflicting findings have been published on the proposed role of TFAM in
packaging the mtDNA (Takamatsu et al. 2002, Alam et al. 2003, Ekstrand et al. 2004,
Kanki et al. 2004a, Kanki et al. 2004b, Wiesner et al. 2006, Cotney et al. 2007). One
theory is that the mtDNA is packed with TFAM and saturated with it (Takamatsu et al.
2002, Alam et al. 2003, Kanki et al. 2004a, Kanki et al. 2004b). Takamatsu et al. (2002)
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reported that the human TFAM:mtDNA ratio is 1700:1 which they find to be of the same
order of magnitude as in Xenopus laevis oocytes (2000:1). Cotney et al. (2007) reported a
TFAM:mtDNA ratio of 50±8:1, i.e. of the same order of magnitude as the 35:1 reported
by Wiesner et al. (2006). There are also many contradictory findings about the effect of
manipulating TFAM levels on mitochondrial transcription. Originally TFAM was
characterized to be a mitochondrial transcription factor (Fisher and Clayton 1988).
Upregulating TFAM has been reported to increase in vitro the levels of run-off transcripts
from mtDNA promoters (Parisi and Clayton 1991, Falkenberg et al. 2002) but, but now it
seems that when expressed at very high levels it can also suppress transcription
(Falkenberg et al. 2002, Maniura-Weber et al. 2004). Our findings on the effect of over-
expressing TFAM in transcription are supported by those of Falkenberg et al. (2002) and
Maniura-Weber et al. (2004). However, if the mtDNA was already packed with TFAM
our findings could possibly be difficult to explain. Namely, if the mtDNA was already
heavily saturated with TFAM, the overexpression of TFAM should not have any effect
on transcript levels. However, it is possible that a simple titration model cannot be
directly applied to explain the mechanism by which TFAM regulates mtDNA
copynumber. It has been observed that, during the recovery period after ethidium
bromide-induced mtDNA depletion in cultured cells, the mtDNA levels recovered faster
than TFAM levels, suggesting that the packing ratio of TFAM on mtDNA may actually
vary and also affect mtDNA replication (Seidel-Rogol and Shadel 2002). Finally, Shutt et
al. (2010) showed that specific transcription initiation can occur in vitro from both LSP
and HSP1 independently of TFAM. Clearly, further studies need to be carried out to
elucidate the role of TFAM in mitochondrial transcription.
Both TFAM and MTERF seem to have different roles in mitochondrial transcription,
opposing the ideas previously presented. Similarly, the role of MTERF in transcription
termination should be reconsidered, as modulating MTERF levels had a clear effect only
on antisense transcript levels and the effects on mature mitochondrial transcripts in vivo
appear to be negated or modified by compensatory mechanisms.
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TFAM does not show sequence specificity when binding mtDNA but binds
preferentially to branched DNA structures (Ohno et al. 2000) and to cisplatin-damaged or
oxidized DNA (Chow et al. 1994, Chow et al. 1995, Yoshida et al. 2002). However,
TFAM also shows preferential binding to the region upstream of the LSP, giving a
footprint (Fisher and Clayton 1988, Ghivizzani et al. 1994), but both mature human and
mouse TFAM proteins also bind dsDNA nonspecifically with high affinity (Ekstrand et
al. 2004). Even if TFAM does not bind DNA in a sequence-specific manner, it is possible
that it could enhance replication pausing by causing a bend in DNA like
Schizosaccharomyces pombe Sap1p has been suggested to do (Krings and Bastia 2005).
The pause sites TFAM over-expression enhances are rather diffuse compared to pause
sites enhanced by MTERF over-expression. Generally over-expressing MTERF has more
site specific effects on mitochondrial replication than TFAM as it binds mtDNA in a
sequence specific manner in contrast to TFAM. MTERF and TFAM enhance replication
pausing at some of the same sites; however, it remains to be investigated whether, and if
so how, they interact in regulating transcription and replication pausing.
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ABSTRACT
The mammalian mitochondrial transcription termi-
nation factor mTERF binds with high affinity to a
site within the tRNALeu(UUR) gene and regulates
the amount of read through transcription from the
ribosomal DNA into the remaining genes of the
major coding strand of mitochondrial DNA (mtDNA).
Electrophoretic mobility shift assays (EMSA) and
SELEX, using mitochondrial protein extracts from
cells induced to overexpress mTERF, revealed
novel, weaker mTERF-binding sites, clustered in
several regions of mtDNA, notably in the major non-
coding region (NCR). Such binding in vivo was
supported by mtDNA immunoprecipitation. Two-
dimensional neutral agarose gel electrophoresis
(2DNAGE) and 5’ end mapping by ligation-mediated
PCR (LM-PCR) identified the region of the canonical
mTERF-binding site as a replication pause site. The
strength of pausing was modulated by the expres-
sion level of mTERF. mTERF overexpression also
affected replication pausing in other regions of
the genome in which mTERF binding was found.
These results indicate a role for TERF in mtDNA
replication, in addition to its role in transcription.
We suggest that mTERF could provide a system
for coordinating the passage of replication and
transcription complexes, analogous with replication
pause-region binding proteins in other systems,
whose main role is to safeguard the integrity
of the genome whilst facilitating its efficient
expression.
INTRODUCTION
The mitochondrial genome of animals is organized in a
highly compact manner, with virtually no non-coding
information between or within its 37 genes. The circular
genome is transcribed by a phage-type RNA polymerase
into polycistronic transcripts which, in mammals, encom-
pass the entire genome on both strands (1,2). Production
of these transcripts depends upon a set of closely spaced
promoters located in the major non-coding region (NCR).
The primary transcripts are then processed to mature
mRNAs, rRNAs and tRNAs via a series of enzymatic
steps requiring the tRNA-processing endonucleases
RNase P and tRNAse Z, as well as other enzymes. The
major coding strand (informationally the L-strand, but for
the purposes of transcription conventionally referred to by
the name of the template, H-strand) is transcribed
from two distinct initiation sites at the heavy-strand
promoter (HSP), PH1 and PH2, separated by 100 bp. The
PH2-derived precursor transcript covers virtually the entire
genome and can give rise to all of the transcription
products of the heavy-strand except tRNAPhe, whose
coding sequence overlaps the PH2 initiation site. The
PH1 initiation site gives rise to a truncated transcript
encompassing just the rRNAs (plus two tRNAs) and thus
deﬁnes a distinct mitochondrial rDNA transcription unit.
Termination at the 30 end of the rDNA is brought about
by a transcription termination factor, mTERF (3–6),
which has also been proposed to interact with the RNA
polymerase in initiation site selection (2,7). Recent data
suggest that this involves formation of a DNA loop in
which RNA polymerase complexes are recycled around
the rDNA segment of the genome after terminating (7).
mTERF binds sequence speciﬁcally with high aﬃnity to a
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sequence element within the coding sequence of
tRNALeu(UUR), located immediately downstream of the
rDNA (4). Current evidence indicates that mTERF
interacts with its asymmetric-binding site as a monomer
(8), although the tertiary structure of the protein and the
structural basis of its interaction with DNA are unknown.
mTERF belongs to a recently identiﬁed superfamily of
proteins whose functions are largely unknown (9–11).
Homologues in Drosophila and in sea urchins have
variously been implicated in transcriptional termination
(12–14), regulation of DNA replication (15) and even
mitochondrial protein synthesis (11). The sea urchin
mTERF homologue mtDBP (D-loop-binding protein)
has recently been shown to terminate transcription in a
polar manner (14,16), analogous with the activity of
mTERF (5). However, mtDBP is also a contrahelicase
(15), and has been proposed to play a role in regulating
the expansion of the short D-loop of sea urchin mtDNA
and thus the initiation of productive replication of the
genome.
Transcription and replication of mtDNA have long
been regarded as interlinked processes. The primer for
initiation of DNA replication has been assumed to be a
product of transcription by the mitochondrial RNA
polymerase. However, there is no consensus concerning
the mechanism by which 30 ends are generated for
extension by DNA polymerase, variously proposed to be
RNA processing by endonuclease MRP (17) or protein-
independent termination at one of the conserved sequence
blocks of the NCR (18). The exact site of replication
initiation is also unclear, and may vary between cell-types.
A prominent cluster of 50 ends in H-strand DNA,
designated as OH, is generally regarded as the major
origin of (unidirectional) replication. However, there is no
direct experimental evidence that it functions thus, and
bidirectional initiation clearly occurs in some molecules at
sites downstream of OH, both in cultured cells (19),
especially when recovering from drug-induced mtDNA
depletion (20), and in solid tissues (21,22). In a minority of
molecules (21) these initiation sites can encompass the
entire genome (in birds) or almost the entire genome
(in mammals).
Mitochondrial DNA (mtDNA) was for over 25 years
assumed to replicate by a unique, strand-asynchronous
mechanism (23). However, more recent analysis of
mtDNA replication intermediates (RIs) by two-
dimensional neutral agarose gel electrophoresis
(2DNAGE) failed to detect the extensively single-stranded
products of such a replication mechanism (19–22,24–26)
and instead revealed two classes of double-stranded RIs.
One class consists of the predicted products of conven-
tional strand-coupled replication (19,21,24,25); the other
contains extended RNA segments (26) encompassing the
entire lagging strand (RITOLS, ‘RNA incorporation
throughout the lagging strand’, 19). Maturation of the
lagging strand to DNA appears to occur with diﬀerent
kinetics and distinct sites of initiation in diﬀerent
organisms (19), and some RIs of the ﬁrst class could be
interpreted as molecules in which lagging-strand DNA
synthesis has eﬀectively caught up with the advancing
fork, as a result of replication pausing. The mechanism by
which the RNA lagging strand is created is unknown.
mtDNA replication also depends on the HMG-box
protein TFAM, named for its essential role as a cofactor
for eﬃcient and speciﬁc transcriptional initiation. TFAM
is required for mtDNA maintenance (27) and appears to
have several distinct roles in mtDNA metabolism. It is a
major structural protein of the mitochondrial chromo-
some, but also inﬂuences mtDNA replication in ways
connected with transcription. Overexpression of TFAM
leads to a drop in mitochondrial transcript levels and a
pronounced shift toward conventional, strand-coupled
RIs (28). This could represent either a general slowing or
stuttering of fork advance, attributable to a decreased
availability of RNA to form the lagging strand (i.e. in
which lagging-strand maturation frequently catches up
with fork advance) or else a programmed switch to
standard DNA synthesis.
As a factor aﬀecting the outcome of mitochondrial
transcription, mTERF might be expected also to have
some inﬂuence over mtDNA replication if, as suggested,
replication is intimately connected with transcription.
We therefore embarked on a series of experiments to
document the eﬀects on mtDNA replication of modulat-
ing the expression of mTERF in cultured human cells.
To this end, we set out initially to characterize better the
binding speciﬁcity of mTERF, especially given recent
reports of possible additional binding sites for mTERF
in vivo (6,29). Electrophoretic mobility shift assays
(EMSA) using mitochondrial protein extracts from cells
induced to overexpress mTERF revealed additional,
though weaker mTERF-binding sites clustered in strate-
gically important regions of the mitochondrial genome.
2DNAGE and lagging strand 50 end mapping by ligation-
mediated PCR (LM-PCR) identiﬁed the canonical
mTERF-binding site as a replication pause site, with the
frequency of pausing subject to the expression level of
mTERF. Replication pausing in other regions of the
genome, notably the NCR, was also aﬀected by mTERF
overexpression. These results indicate a role for mTERF
in mtDNA replication, in addition to its role in
transcription.
MATERIALS AND METHODS
Cells and cell culture
Human embryonic kidney-derived HEK293T cells, Flp-
InTM T-RexTM-293 cells (Invitrogen), 143B osteosarcoma,
Jurkat and HeLa cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Sigma) containing
4.5 g/l of D-glucose, 10% foetal calf serum (Sigma),
50 mg/ml uridine (Sigma) and 2mM L-glutamine
(BioWhittaker/Cambrex) at 378C in an incubator with
5% CO2 in air. Flp-In
TM T-RexTM-293-derived cell-lines
were cultured under selection with blasticidin and
hygromycin according to the manufacturer’s protocol.
Expression of mTERF or mTERF-MycHis (C-terminally
tagged) was induced in transfected Flp-InTM T-RexTM-
293 cells with 10 ng/ml doxycyclin (Sigma-Aldrich), which
was replenished every 48 h. Cells were passaged routinely
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every 3–4 days at 1:10 or 1:20 dilution. Adherent cells were
detached either by pipetting alone or, for HeLa cells, by
treatment with Trypsin-EDTA (Bio-Whittaker/Cambrex).
Suspension cells (Jurkat) were passaged by centrifugation
and resuspension in fresh medium.
Oligonucleotides and plasmids
Oligonucleotides used to create EMSA or hybridization
probes by PCR from puriﬁed human mtDNA or cloned
segments thereof are listed in Supplementary Table 1. The
mTERF coding region, including the mitochondrial
targeting signal and 24 nt of the 50 untranslated region, a
total of 1221 bp, was ampliﬁed from HeLa cell cDNA (30)
using the following chimeric primer pairs (all sequences
shown 50 to 30, restriction sites used for cloning under-
lined): BamHI-mTERF F1, CGCGGATCCCTGTTCTC
CAGCCTTTCTGG plus HindIII-mTERF R1, CCC
AAGCTTGGCAAATCTGCTTAACTTTTT to create
an in-frame C-terminal fusion to the Myc epitope tag;
BamHI-mTERF F1 plus HindIII-mTERF R STOP,
CCCAAGCTTTCAGGCAAATCTGCTTAACTTTTTC
to create an mTERF expression construct containing the
stop codon at the natural position (shown in italics,
underlined, complementary strand). After sequence
veriﬁcation PCR products were digested with BamHI
and HindIII (Fermentas, manufacturer’s recommended
conditions) and ligated to similarly digested pcDNA3.1(-)/
Myc-His A (Invitrogen) vector DNA to create the
mTERF and mTERF-MycHis expression constructs.
For induced expression using the Flp-InTM T-RExTM-
293 cell system these plasmids were digested with PmeI
(New England Biolabs), which cuts on either side of the
insert, ligated into PmeI-digested DNA of the vector
pcDNA5/FRT/TO (Invitrogen), and stably transfected
into the recipient cells as previously (31).
DNA and siRNA transfections
HEK293T cells were transfected either with 3 mg of
plasmid DNA and 30 ml of LipofectAMINE (Invitrogen)
or 10 mg of DNA and 40 ml of TransFectinTM Lipid
Reagent (Bio-Rad), according to manufacturers’ proto-
cols. Transiently transfected cells were subsequently
harvested for diﬀerent assays, or placed under selection
using 2mg/ml G418 Sulfate (Calbiochem), in order to
select clones of stably transfected cells expressing
mTERF-MycHis. mTERF-speciﬁc siRNAs were synthe-
sized by means of in vitro transcription using the
SilencerTM siRNA construction kit (Ambion). Candidate
target sites for speciﬁc mTERF silencing were chosen
using a prediction programme provided by Ambion
(http://www.ambion.com/techlib/misc/siRNA_ﬁnder.html).
One out of ﬁve tested siRNAs was found to be eﬃcient
in mTERF silencing (see Results section), the relevant
target site in mTERF mRNA being nt 585–605
(50-AAGCGGGUGAAAGCUAACAUU-30). To knock-
down mTERF expression, HEK293T cells (with or with-
out prior stable transfection with the mTERF-MycHis
expression construct) were transfected with 10 nM (ﬁnal
concentration) of mTERF-speciﬁc siRNA molecules using
LipofectamineTM 2000 transfection reagent (Invitrogen),
as per manufacturer’s recommendations. An siRNA
reagent targeted on 50-GGAGAAGGUACGAGGGGC
AUU-30 (siRNA Control) was used as a negative control.
Immunocytochemistry
For immunocytochemistry cells were grown on coverslips,
seeded at low density. Twenty-four hours after transfec-
tion or induction with doxycyclin, cells were washed with
DMEM and then incubated in fresh medium containing
100mMMitoTracker Red CMXRos (Molecular Probes)
at 378C for 10min, then washed twice with PBS. After
incubation in fresh medium at 378C for 2 h, cells were
again washed twice with PBS and ﬁxed in 4% formalde-
hyde/5% sucrose in PBS at 378C for 15min. After three
further PBS washes cells were permeabilized by incubation
in 0.5% Triton X-100 in PBS at 378C for 15min, washed
twice with PBS, incubated in blocking solution (5% w/v
non-fat milk powder in PBS) at room temperature for
45min, then again washed three times with PBS. After
incubation in primary antibody solution, mouse anti-
Myc monoclonal 9E10 (Roche Molecular Biochemicals,
stock 5mg/ml) 1:1000 in PBS for 1 h at room temperature,
cells were washed three times with PBS, then incubated
for 1 h at room temperature in a 1:200 dilution of
secondary antibody, ﬂuorescein-conjugated horse anti-
mouse IgG (Vector Technologies, stock 1.5mg/ml). After
three ﬁnal PBS washes the coverslips were mounted on
slides using Vectashield with DAPI (Vector Technologies).
Cells were visualized and photographed using an Olympus
IX70 inverted confocal microscope at 100 magniﬁcation,
with excitation at 568 nm (emission 607/45) for
Mitotracker Red and 488 nm (emission 525/50) for
ﬂuorescein, using an Andor iXon DV885 front-illumi-
nated CCD camera.
Western blotting
SDS–PAGE used 12% polyacrylamide gels under stan-
dard conditions (32). Protein extraction and western
blotting were carried out essentially as described pre-
viously (30). Primary antibodies used were mouse anti-
Myc monoclonal 9E10 (as above, diluted 1:15000) and
rabbit anti-human mTERF antibody, custom-supplied
(Invitrogen) as an anti-peptide (KLH-conjugated
CSNDYARRSYANIKE) antibody, 1mg/ml, diluted
1:5000. Kodak BiomaxTM ML X-ray ﬁlm was exposed
to the ﬁlter membrane for between 5 s and 5min.
Preparation of mitochondrial lysates
Cells were harvested without trypsinization, resuspended
in 1ml (per 10 cm plate of cells) of resuspension buﬀer
(0.133M NaCl, 5mM KCl, 0.7mM Na2HPO4, 25mM
Tris–HCl pH 7.5) and centrifuged at 1200gmax for 2min at
48C. The pellet was resuspended in 0.5ml of swelling
solution (10mM NaCl, 1.5mM CaCl2, 10mM Tris–HCl
pH 7.5) and incubated on ice for 15min. After swelling,
the cells were dounce-homogenized (20–25 strokes, tight-
ﬁtting pestle) on ice and breakage of the cells was checked
microscopically. An equal volume of sterile ﬁltered
sucrose/EDTA buﬀer (0.68M sucrose, 2mM EDTA,
20mM Tris–HCl pH 7.5) was added immediately after
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breaking the cells. Nuclei and debris were pelleted
by centrifugation at 1200gmax for 10min at 48C. The
supernatant was transferred to a fresh tube and centrifu-
gation was repeated. The supernatant was collected and
recentrifuged at 16 000gmax for 30min at 48C. The
mitochondrial pellet was washed once with 200 ml of
PBS and frozen at 808C or lysed immediately. For
processing large quantities of cells the volumes were scaled
up. Mitochondrial lysates were prepared essentially as
described by Fernandez-Silva et al. (33), except using
‘Complete, Mini protease inhibitor cocktail’ (Roche)
instead of PMSF.
EMSA
DNA fragments for EMSA were PCR ampliﬁed using
mtDNA as template and primer pairs shown in
Supplementary Table 1, followed by sequence veriﬁcation
of the product. dsDNA oligonucleotide probes for EMSA
(Supplementary Table 1) were prepared by mixing equal
amounts of complementary oligonucleotide pairs in 500 ml
of H2O to a ﬁnal concentration of 2mM, followed by
incubation for 5min at 1008C and cooling to room
temperature on the bench. Total of 300 ng of each PCR
fragment or 20 pmol of each dsDNA oligonucleotide
were labelled using 8U of T4 polynucleotide kinase
(Fermentas) and 15 mCi of [g-32P] ATP (Amersham
Pharmacia Biotech, 3000Ci/mmol) in 15 ml ﬁnal volume
of PNK buﬀer (MBI Fermentas). Reactions were stopped
on ice and diluted to 100ml with H2O. EMSA was carried
out in 20 ml binding reactions according to Fernandez-
Silva et al. (33) with minor modiﬁcations. Reactions
contained at least 10 ml of the binding buﬀer (25mM
HEPES–KOH, pH 7.5, 12.5mM MgCl2, 20% glycerol,
0.1% Tween-20, 1mMDTT), 0.2 pmol of labelled dsDNA
oligonucleotide or 3 ng of labelled PCR product as probe,
5 mg of mitochondrial lysate, 100mM KCl, 5 mg BSA and
5 mg of non-speciﬁc competitor DNA poly(dI-dC)–(dI-dC)
(Amersham Pharmacia Biotech). Reactions were incu-
bated at room temperature for 20min and terminated on
ice with addition of 0.25 volumes of 30% glycerol.
Competition EMSA reactions contained also up to
100-fold excess of the non-labelled competing probe.
Supershift EMSA reactions contained 0.5mg of anti-Myc
antibody (as above), or 1 mg of anti-FLAG M2 antibody
(Sigma), which was added 30min prior to the labelled
probe. Depending on the length of the fragment, reaction
products were analysed on 5–10% non-denaturing poly-
acrylamide TBE gels, pre-run at 48C in 2.2 TBE at 100V
for 1 h at 48C, then run at 100V for 30min and 175V for
3–5 h depending on the size of the probe fragment. Gels
were dried and autoradiographed using KODAK
BioMaxTM MS ﬁlm.
SELEX
Creation of a randomized DNA ligand library was carried
out essentially as described by Blackwell (34). The 46 nt
long oligonucleotide template contained 14 internal
random nucleotides, ﬂanked on either side by 16 nt ﬁxed
ends corresponding with standard primers, containing
recognition sites for BamHI and EcoRI, respectively.
Second-strand synthesis was carried out in a reaction
volume of 20 ml containing 1.6 mg of template, 500 mmol of
primer, 2mM dNTPs and 5U of Klenow fragment
(Fermentas) in Klenow fragment buﬀer at 468C for
1min, followed by 378C for 7.5min. The reaction was
stopped by heating at 758C for 10min and the dsDNA
ligand library was gel-puriﬁed from an EtBr-stained 14%
native polyacrylamide gel using the QIAEX kit
(QIAGEN) according to the manufacturer’s protocol.
Ligand selection was carried out in 25 ml reactions under
essentially the same conditions as EMSA, using 10 mg of
mitochondrial protein lysate from mTERF-MycHis
expressing Flp-InTM T-RexTM-293-cells, 0.8 mg of the
ligand DNA and 6.25 mg of non-speciﬁc competitor
DNA poly(dI-dC)–(dI-dC) incubated for 20min at room
temperature. Pre-swollen anti-myc-Sepharose beads
(Amersham Biosciences) were suspended in EMSA
buﬀer (25mM HEPES–KOH, pH 7.5, 12.5mM MgCl2,
20% glycerol, 0.1% Tween-20, 1mM DTT, 100mM KCl,
0.2mg/ml BSA), washed once in the same buﬀer and
resuspended in 1.5 volumes of the same buﬀer containing
0.25mg/ml poly(dI-dC)–(dI-dC). To each binding reaction
was added 100 ml of the bead suspension, followed by
gentle rotation for 2 h at 48C. Beads were then washed in
EMSA buﬀer containing 0.25 mg/ml poly(dI-dC)–(dI-dC),
followed by a further seven times in the buﬀer without
poly(dI-dC)–(dI-dC) and gentle rotation overnight in
100 ml of K buﬀer (10mM Tris–HCl, 0.5mM EDTA
50mM NaCl, pH 8.0) containing 100 mg/ml of freshly
dissolved proteinase K (Fermentas). DNA was recovered
from the beads by extraction with phenol–chloroform–
isoamyl alcohol (25:24:1) and ethanol precipitation,
washed once with 70% ethanol and resuspended in a
minimal volume of H2O (7.5 ml). PCR was then carried
out using 2 ml of this template in a 50 ml reaction volume
containing 0.2 mM of each SELEX primer (GGTGAAT
TCGCTCACG and GAACGGATCCCTTTCG, both
shown 50 to 30, with restriction sites for cloning under-
lined) and 2.5U of Pfu DNA polymerase (Promega).
Thirty ampliﬁcation cycles were carried out using a 15 s
extension step, after which the enriched ligand DNA was
gel-puriﬁed from an EtBr-stained 12% native polyacryl-
amide gel as above. After seven such enrichment cycles,
the ligand DNA was cloned into pCR4Blunt-TOPO
vector (Invitrogen) and individual clones were sequenced
using standard primers on an ABI 3100 sequencer using
the BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems).
DNA extraction and mtDNA copy number estimation
For the preparation of mtDNA (mitochondrial nucleic
acids) for analysis of RIs from cultured cells, mitochon-
dria were isolated and processed as described by
Pohjoisma¨ki et al. (28). Total DNA for analysis of
mtDNA copy number was extracted from cells by stan-
dard methods (35), and copy number was determined
using quantitative PCR, as described previously (28), with
amyloid precursor protein (APP) as a single-copy nuclear
DNA standard. Human placental mtDNA was prepared
as previously (24). Total DNA for analysis of mtDNA RIs
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was extracted from frozen human tissue blocks 7  7 
7mm3) obtained via forensic autopsies. The samples
were taken as part of the Tampere Coronary Study,
approved by the Ethics Committee of Tampere University
Hospital (DNO 1239/32/200/01) and the National
Authority for Medicolegal Aﬀairs. Heart, brain, skeletal
muscle and kidney tissue samples were cut into thin slices
with a sterile blade and suspended in 2ml DNA extraction
buﬀer (28). One-tenth volume of 10% SDS and 0.5mg
proteinase K were added. The crude homogenate was
passed several times through a 5ml pipette tip with a
sawn-oﬀ end, to disperse the larger tissue fragments.
The homogenate was incubated overnight with gentle
swirling at 378C. After incubation, 2 volumes of phenol–
chloroform–isoamylalcohol (25:24:1) were added, and the
mixture was shaken gently for 1 h. The mixture was then
transferred to Eppendorf 15ml Phase Lock GelTM Heavy
tubes and centrifuged at 5000gmax for 15min. The aqueous
phase was recovered and the extraction step repeated.
DNA was precipitated by the addition of 0.2 volumes of
10M ammonium acetate and 2 volumes of ethanol. The
mixture was incubated on ice for 10min and DNA was
spooled out using a glass rod, washed once with 70%
ethanol, air dried gently and resuspended in 300–700ml TE
buﬀer (10mM Tris–HCl, 1mM EDTA, pH 8.0), depend-
ing on the pellet size. 2DNAGE analysis used 10 mg
aliquots of heart and brain DNA and 20 mg aliquots of
kidney and skeletal muscle DNA.
Two-dimensional neutral agarose gel electrophoresis
One microgram of total mitochondrial nucleic acids was
used per analysis. Restriction digestions were performed
following manufacturers’ recommendations, except for
BclI which was carried out at 378C for double the usual
reaction time. If subsequent treatment with S1 nuclease
was used, DNA was ﬁrst recovered by ethanol precipita-
tion and resuspended in the appropriate reaction buﬀer,
before treatment with 50U S1 Nuclease (Promega) for
30 s. Reactions were stopped by the addition of an equal
volume of phenol–chloroform–isoamyl alcohol (25:24:1,
pH 8.0) and immediately extracted. 2DNAGE was
performed as described previously [(28), note diﬀerent
gel conditions for fragments in diﬀerent size classes).
Radiolabelled probes and blot hybridization
For Southern hybridization, probes were created by
Pfu-PCR, using cloned segments of human mtDNA as
template (see Supplementary Table 1), and subse-
quently sequenced to conﬁrm their identity. Probes were
labelled using RediprimeTM II random prime labelling
kit (Amersham) and [a-32P] dCTP (Amersham;
3000Ci/mmol).
LM-PCR
LM-PCR was carried out as described by Yasukawa et al.
(20), using oligonucleotide primer sets as indicated in
ﬁgure legends and as detailed in Supplementary Table 2.
Mitochondrial DNA immunoprecipitation
Cells were processed for mitochondrial DNA immuno-
precipitation (mIP) essentially as described by Lu et al.
(36). The mtDNA was sheared to fragments of average
size 500–600 bp using a Sonics Vibra-Cell sonicator, 3mm
tip at 25% power for 3 20 s (1 s on, 1 s oﬀ) with
incubation on ice for 30 s between. Complete, Mini
protease inhibitor cocktail (Roche) was included in the
lysis buﬀer. Lysates were pre-cleared with pre-swollen
Protein A Sepharose (Amersham Biosciences) and immu-
noprecipitations were carried out with 5 mg mouse anti-
Myc monoclonal 9E10 (Roche Molecular Biochemicals)
or anti-FLAG M2 antibody (Sigma) overnight at 48C.
Final PCR reactions used primers listed in Supplementary
Table 1 and the minimum number of ampliﬁcation cycles
required to generate substantial product bands from the
input DNAs (generally 25–26 cycles, depending on the
fragment, based on preliminary tests), thus avoiding
saturation.
RESULTS
mTERF has multiple binding sites in the human
mitochondrial genome
In order to study the eﬀects of mTERF on mtDNA
replication, we established HEK293-derived cells expres-
sing both natural mTERF and C-terminally Myc epitope-
tagged mTERF. Mitochondrial targeting was veriﬁed
by immunocytochemistry of transiently transfected
HEK293T cells expressing mTERF-MycHis (Figure 1a).
Induction of protein expression in Flp-InTM T-RexTM-293
cells stably transfected with the mTERF or mTERF-
MycHis constructs was veriﬁed by western blotting
(Figure 1b). Protein levels were the same after 24 or 48 h
of induction. Prolonged overexpression of mTERF
(6 days) had no signiﬁcant eﬀect on mtDNA copy
number as estimated by Southern blotting (data not
shown) or by quantitative PCR (Supplementary
Figure 1a).
Since the main aim of the study was to determine the
eﬀects of altered mTERF expression on mtDNA replica-
tion in vivo, we ﬁrst tested the eﬀects of mTERF
expression on protein binding to mitochondrial DNA,
using EMSA with mitochondrial protein extracts from
cells overexpressing mTERF. In contrast to earlier studies
using puriﬁed, bacterially expressed mTERF, this tests the
eﬀects of altered mTERF expression level on protein–
DNA interactions in the mitochondrial milieu, in which
other mitochondrial proteins, including TFAM, are
present and may inﬂuence binding.
Using EMSA with probes covering the previously
identiﬁed, canonical mTERF-binding site in the
tRNALeu(UUR) gene, we conﬁrmed that overexpression
of natural mTERF, whether by transient or stable
transfection (data not shown), or under tetracycline
induction (Figure 1c), leads to a large increase in
sequence-speciﬁc binding activity. The protein complex
formed from the Myc epitope-tagged protein migrated
slightly slower than the complex formed by endogenous
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or overexpressed natural mTERF, and was supershifted
by an anti-Myc monoclonal antibody (Figure 1c), but not
by other antibodies (e.g. anti-FLAG, Supplementary
Figure 1b). The anti-Myc antibody did not supershift
the complex formed by endogenous or overexpressed
natural mTERF (Supplementary Figure 1b).
These properties next allowed us to test other regions of
the mitochondrial genome for speciﬁc binding of mTERF
to DNA, using EMSA. Using overlapping fragments of
150 bp, we scanned the major NCR and its ﬂanking
sequences, the minor NCR (OL), its surrounding tRNA
gene cluster, the region extending from OL to the
canonical mTERF-binding site in the tRNALeu(UUR)
gene, the ATPase 6 gene and its junction with the COIII
gene and several other segments of the genome (Figure 2,
Supplementary Figures 2 and 3). We estimated relative
binding aﬃnities using competition EMSA against the
tRNALeu(UUR) gene fragment and vice versa. As shown in
Figure 2 and Supplementary Figure 2, we identiﬁed a
cluster of four moderately strong mTERF-binding sites
within the ND1 coding sequence and the adjacent IQM
tRNA gene cluster (see Figure 2e for summary).
Competition EMSA indicated that the binding to frag-
ment ND1.1 (Figure 2b) was between one and two orders
of magnitude weaker than to the canonical binding site
in tRNALeu(UUR). Binding to the ND1.1 fragment was
tested further, using shorter, overlapping fragments
(Supplementary Figure 2d). The results suggest that
fragment ND1.1 contains two distinct binding sites.
We also identiﬁed a binding site adjacent to OH (fragment
OH1) at least two orders of magnitude weaker than the
canonical binding site, based on competition EMSA data
(data not shown), as well as four other binding sites in the
D-loop portion of the NCR and one at OL, plus a possible
site at the HSP (fragment OH5, see Supplementary
Figure 2e).
Alignment of the sequences of these binding sites
suggested a consensus which was veriﬁed by SELEX
(Table 1). Most of the SELEX output clones analysed
(82/109) contained at least one match to the consensus
TGGT or TYGGT, and 43 clones showed an identical or
almost identical (8/9) match to the extended consensus
TGGT(N5)TYGGT (or its complement). Of 28 control
clones analysed, subjected to the same number of
ampliﬁcation cycles but without antibody selection, none
matched this consensus. Comparing the SELEX consen-
sus with the canonical mTERF-binding site in the
tRNALeu(UUR) gene, and with the ﬁndings of an earlier
application of PCR-based selection on a smaller scale
using only EMSA (37), the invariant features of the
binding site would appear to be two pairs of G residues on
the same strand, separated by eight nucleotides (see also
Supplementary Table 3).
In order to verify that mTERF is able to bind to at least
some of its non-canonical binding sites in vivo, we carried
out semi-quantitative mIP, using a minor adaptation of
the method recently published by Lu et al. (36). For this
assay we used cells inducibly expressing mTERF-MycHis,
and carried out immunoprecipitation using anti-Myc
antibody, as well as a control antibody (anti-FLAG) or
no antibody.
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Figure 1. Overexpression of mTERF in cultured cells. (A) Immunocy-
tochemistry of HEK293T cells transiently or stably transfected with
mTERF-MycHis, using anti-Myc monoclonal antibody, counterstained
with Mitotracker Red. (B) Western blots of mitochondrial protein
extracts from Flp-InTM T-RExTM-293 cells transfected with the
mTERF or mTERF-MycHis constructs and induced for expression as
indicated (0, 24, 48 h) or from transiently transfected (t) HEK293T
cells, probed with anti-Myc or anti-mTERF antibodies, as indicated.
The endogenous mTERF protein detected by the anti-mTERF
antibody is singly arrowed. The mTERF-MycHis fusion protein
detected by the same antibody is indicated by a double arrow.
(C) EMSA using Leu-short dsDNA oligonucleotide probe and
mitochondrial protein extracts from Flp-InTM T-RExTM-293 cells
transfected with the mTERF or mTERF-MycHis constructs and
induced for expression as indicated. EMSA was carried out with or
without anti-Myc antibody as shown (left-hand panel), or (right-hand
panel) in the presence of an increasing amount of cold Leu-short
dsDNA oligonucleotide competitor (1-, 10-, 100- and 1000-fold mass
excess) or without competitor (). The free probe (F), complexes
formed by natural mTERF (BN) or the mTERF-MycHis fusion protein
(BF), and the antibody-supershifted complex (S) are indicated. See also
Supplementary Figure 1.
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Figure 2. EMSA and mIP analysis of alternate mTERF-binding sites in human mtDNA. (A) Schematic diagram of regions of the mitochondrial
genome in which binding was detected, showing NCR (white box), 16S and 12S rRNA genes (pale grey boxes), protein-coding genes ND1, ND2,
COI and cyt b (darker grey boxes), tRNA genes (cross-hatched boxes), OH, OL and the promoters/transcriptional initiation sites of the two strands
(PL, PH1 and PH2). Genes transcribed to the right shown above the centre line, genes transcribed to the left shown below. Nucleotide coordinates are
as Ref. (82). Black bars indicate the positions of the 150 bp probe fragments which were found by EMSA to contain strong or moderate binding sites
for mTERF, as shown in panels b and c. (B) Competition EMSA using the probes and competitors as shown, plus mitochondrial protein extract
from cells induced to express mTERF-MycHis. The amounts of cold competitor represent 1-, 10- and 100-fold mass excess over the probe. Similar
results were obtained using extracts from cells overexpressing natural mTERF (data not shown). (C) EMSA analyses of binding to 150 bp probe
fragments as indicated, using mitochondrial protein extracts from Flp-InTM T-RExTM-293 cells transfected either with natural mTERF or with
mTERF-MycHis (mTERF-mh) and induced for expression (or not) as indicated. Supershifting with the anti-Myc monoclonal antibody was
performed for the lanes indicated. Supershifted complexes are denoted by arrows. Although the supershifted complex is minor in some cases, the
main complex is always eﬃciently removed by the antibody, conﬁrming the presence of mTERF-MycHis. Other antibodies tested (e.g. anti-FLAG)
gave no supershifting and did not inhibit the formation of these complexes. For further experiments conﬁrming speciﬁcity of binding and negative/
weak ﬁndings using other fragments, see Supplementary Figures 1 and 2. (D) mIP analysis of mTERF-MycHis binding in vivo. Immunoprecipitation
used anti-Myc (M), anti-FLAG (F) or no antibody (). Ampliﬁcation of immunoprecipitates alongside corresponding input DNAs used the same
primer pairs as were employed to generate the corresponding fragments for EMSA (see Supplementary Table 1), Samples were from Flp-InTM
T-RExTM-293 cells induced for mTERF-MycHis expression, except for fragment Leu, where extracts from uninduced cells were also tested.
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Induction of mTERF-MycHis expression enabled
immunoprecipitation of several key fragments of the
mitochondrial genome in which binding was found
in vitro (Figure 2d) The fragment containing the canonical
mTERF-binding site in the tRNALeu(UUR) gene was
routinely detected in the anti-Myc immunoprecipitate
from induced cells, but was not immunoprecipitated
by control antibody (anti-FLAG) or no antibody.
Immunoprecipitates from uninduced cells were negative
under comparable conditions, but using excess anti-Myc
antibody we sometimes observed weak ampliﬁcation of
this fragment (data not shown), consistent with a low level
of leaky expression of the mTERF-MycHis transgene and
the high aﬃnity of the protein for the canonical binding
site. Consistent positive signals were also seen in the anti-
Myc immunoprecipitate from induced cells, but not
control immunoprecipitates, for the HSP-containing frag-
ment OH5 and for the three D-loop fragments (NCR1,
NCR5 and OH1) which gave the strongest EMSA signals
in vitro (Figure 2c). The ND1.1 fragment internal to
the ND1 coding sequence was also weakly ampliﬁed
from anti-Myc immunoprecipitates from induced cells
(Figure 2d). Fragments from the ND3 gene (e.g. ND3.4),
or others which were negative for binding in vitro using
EMSA, gave either very faint signals or no signal at all
after immunoprecipitation. Overall, these ﬁndings are
consistent with the proposition that mTERF, when
overexpressed, can bind in vivo to speciﬁc, non-canonical
binding sites, which correspond with binding sites detected
in vitro.
Replication pause sites map close to sites of mTERF
binding in human mtDNA
In previous studies using 2DNAGE we noted the
occurrence of a number of stereotypic pause sites in
mitochondrial DNA of both sea urchins (38) and
vertebrates (21,24). In sea urchins, pause sites corres-
pond with sites of speciﬁc protein binding (39–41). We
therefore considered the hypothesis that some of the
replication pause sites in human mtDNA may map to
locations of mTERF binding.
We initially analysed the region of the genome in which
the canonical mTERF-binding site in the tRNALeu(UUR)
gene is located. 2DNAGE analysis of the PvuII–AccI
fragment covering this site, extending from OL into the
rDNA, in several diﬀerent cell lines and tissues (Figure 3),
revealed a number of pause sites of varying prominence.
To visualize their positions more clearly we treated
parallel samples with S1 nuclease, thus digesting partially
degraded RITOLS intermediates, including any attached
RNA tails. The two epithelia-derived cell-lines, HEK293T
and HeLa, gave very similar patterns, with a clear,
though relatively weak pause site signal in the region
of the tRNALeu(UUR) gene (designated ‘a’ in Figure 3b),
a second, more prominent pause located in the 30 part
of the ND1 gene or in the adjacent IQM tRNA cluster
(designated ‘b’), a third, near OL (designated ‘d’), and
accumulated material in a broad region of ND2
(designated ‘c’).
In 143B (osteosarcoma) and Jurkat (T-cell leukaemia)
cells the steady-state abundance of all mtDNA RIs was
quantitatively less, though the patterns were qualitatively
similar to those seen in HEK293T or HeLa cells.
In S1-untreated material the pause sites were poorly
resolved, and the descending segment of the Y-arc was
very weak. Region ‘c’ was not seen as a discrete species,
even after S1 treatment. Following S1 treatment, the ratio
of the other pauses diﬀered between cell-types: for
example, pause ‘b’ was much more prominent than
pause ‘d’ in Jurkat cells, whereas in 143B cells they were
at similar abundance. The tRNALeu(UUR) gene pause ‘a’
was seen clearly in all cell-lines tested.
In tissue samples (Figure 3c), pause ‘a’, near to the
canonical mTERF-binding site, was most prominent
in the brain, but weak in other tissues tested. Pause ‘d’
was more prominent than pause ‘b’ in heart and brain,
but weaker than pause ‘b’ in skeletal muscle and in
kidney. Pause ‘c’, was seen only in kidney, where both
it (and pause ‘b’) appeared to be even more diﬀuse
than in other tissues or cell-lines. An additional pause
site was seen in brain, between ‘c’ and ‘d’ (denoted ‘d’).
Pause ‘d’, near OL, was also detected as an extended
pause region in human placenta [(24), Supplementary
Figure 3].
Pausing near two other sites at which mTERF binding
to DNA was seen both in vitro and in vivo (Figure 2),
namely OH and the TAS region, is already well
documented from previous studies, and further examples
are seen in Figure 4 (see also Supplementary Figures 3
and 4). Although originally proposed as a unique
unidirectional origin, recent data indicate that OH also
functions as a site of fork arrest when bidirectional
replication initiates elsewhere, and may thus also be
considered as the terminus of replication [(20–22,24), see
also Supplementary Figure 3]. The TAS region is, by
deﬁnition, adjacent to the termination site for the
synthesis of D-loop 7S DNA.
mTERF overexpression enhances replication pausing in
human mtDNA
In order to test whether the level of mTERF expression
inﬂuences replication pausing we carried out 2DNAGE
(E) Summary of EMSA results combining the data from this ﬁgure, Supplementary Figure 2, and other (negative) data not shown. The regions of the
genome which were probed are reproduced from part (a) of the two ﬁgures, plus the ND5-ND6 gene junction which was probed using a dsDNA
oligonucleotide. Binding is denoted as strong (ﬁlled circles), moderate (grey circles), weak (open circles), questionable (dotted circle, fragment OH5,
as discussed in the text and legend to Supplementary Figure 2) or absent (no circles). Our inference of binding is based on the fact that EMSA signals
were enhanced by induction of expression of both mTERF and mTERF-MycHis, that the complexes migrated at slightly diﬀerent positions
consistent with the presence of the epitope tag in the latter case, and that the complexes formed by mTERF-MycHis were supershifted by the anti-
Myc antibody. The assertion that binding is strong, moderate or weak is based either on actual competition experiments (OH1 and ND1.1), or
simply on the strength of the EMSA signal. Where the above criteria were not fulﬁlled, binding was scored as negative. In summary, the ND1 coding
region and following IQM tRNA cluster contain at least four weak binding sites for mTERF. The NCR contains three weak binding sites, as well as
three additional sites which showed very weak or questionable mTERF binding, as shown. A weak binding site was also found in the vicinity of OL.
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analysis of RIs in mtDNA extracted from cells induced to
overexpress mTERF, compared with uninduced cells
(Figure 4, Supplementary Figure 4). Within the 3.6 kb
PvuII–AccI ND2-containing fragment (Figure 4b), pause
site ‘a’ (tRNALeu(UUR), mapping near the canonical site of
mTERF binding) was strongly enhanced by mTERF
overexpression, compared with the unit-length restriction
fragment (denoted 1n in Figure 3d). Pause sites ‘b’ (ND1/
IQM tRNA cluster) and ‘d’ (OL) were also enhanced,
as was the more diﬀuse pause region ‘c’. In mTERF-
overexpressing cells we also detected a more prominent
X-form intermediate (designated ‘x’ in Figure 4b,
Supplementary Figure 4a) in restriction fragments
(e.g. HincII or AccI) containing the tRNALeu(UUR) gene
at a central location.
Within the NCR mTERF overexpression enhanced the
abundance of a paused intermediate migrating near or
beneath the bubble arc (designated ‘f’ in the HincII
fragment and ‘n’ in the AccI fragment, OH probe), as well
as the arc leading to it from the unit-length fragment
(Figure 4c, Supplementary Figure 4b). These forms were
sensitive to S1 nuclease (Supplementary Figure 4b) and are
probably equivalent to the classical D-loop. mTERF
overexpression also appeared to increase the relative
amount of 7SDNAas well as introducing subtle alterations
to the various forms of mtDNA resolved on 1D gels
(Supplementary Figure 4f). mTERF overexpression also
diminished the relative abundance of termination inter-
mediates (designated ‘t’ in Figure 4c and d) and increased
that of Y-form intermediates in which a single fork appears
to have paused when approaching OH (designated ‘g’). The
distribution of material on the termination arc also
appeared to be subtly diﬀerent from that of uninduced cells.
In other regions, a prominent pause site (‘h’, Figure 4c),
located near to the ND5/ND6 gene boundary, was
unaﬀected by mTERF overexpression, whereas a novel
pause was induced in the coding region of ND3
(Supplementary Figure 4c). Note, however, that strong
mTERF binding was not found in vitro in either region
(Supplementary Figure 2 and other data not shown).
Digestion of mtDNA from mTERF-overexpressing
cells with restriction enzymes having only a single
recognition sequence in the genome generated 2DNAGE
patterns consistent with enhanced pausing in the
region of ND1/tRNALeu(UUR) and consequent delayed
resolution in the NCR (Figure 4d, Supplementary
Figure 4d and e). Note that mTERF overexpression
produced subtle, site-speciﬁc eﬀects, rather than a
general slowing of replication e.g. as would be attributable
due to non-speciﬁc stalling.
mTERF knockdown diminishes replication pausing
in the ND1/tRNALeu(UUR) region
To test whether the modulation of replication pausing
resulting from mTERF overexpression represents the
signature of a ﬁnely tuned physiological process rather
than just an overexpression artefact, we downregulated
the expression of mTERF by RNA interference. This
produced a reciprocal eﬀect on mtDNA replication
pausing at the canonical mTERF-binding site. We ﬁrst
tested several diﬀerent mTERF-directed siRNAs in
transient transfection assays, using cells stably transfected
with the mTERF-MycHis expression construct, enabling
us to evaluate knockdown at the protein level by western
blotting (Figure 5a). One particular siRNA (mTERF.1)
gave consistently strong knockdown, as judged also by
immunocytochemistry on mTERF-MycHis-expressing
cells (Figure 5b) and EMSA (Figure 5c). Based crudely
on the autoradiographic EMSA signals, functional
knockdown of >90% was routinely achieved 48 h after
transfection with siRNA mTERF.1. The eﬀects of
mTERF knockdown on replication pausing in the ND1/
tRNALeu(UUR) region were then studied using 2DNAGE
(Figure 5d). Pause site ‘a’ (tRNALeu(UUR)) was no longer
detectable, even on long autoradiographic exposure, and
the prominence of X-forms was also diminished by
mTERF knockdown. The abundance of other pauses
was altered less substantially, though the relative
amount of species ‘b’ compared with ‘c’ appeared to be
decreased.
mTERF overexpression enhances lagging strand 5’ ends
near to specific replication pause sites
One signature of increased replication pausing during
strand-coupled DNA replication should be the enhance-
ment of persistent, lagging strand 50 ends adjacent to
pause sites (Supplementary Figure 5). We used LM-PCR
to map such ends in the vicinity of the major pauses
regulated by mTERF, and to determine the eﬀects upon
them of mTERF overexpression. Comparing mtDNA
from cells overexpressing mTERF with that from unin-
duced cells, we analysed 50 ends on the L-strand near the
canonical tRNALeu(UUR) binding site, as well as in the
whole of ND1 and the adjacent tRNA genes, and also on
the H-strand in the NCR. A cluster of L-strand 50 ends in
or adjacent to the tRNALeu(UUR) gene, notably at np 3211,
Table 1. SELEX analysis of the mTERF-binding site
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Occurrencesa
A 0 0 0 3 30 17 23 21 1 0 0 0 0 2
C 0 0 0 7 4 6 1 3 0 0 15 0 0 0
G 8 43 43 2 4 16 6 16 31 0 0 43 43 0
T 35 0 0 31 5 4 13 3 11 43 28 0 0 41
Consensusb t G G t a r a r g T Y G G t
aOut of 43 clones analysed which matched a clear consensus (see text).
bNucleotides found in 43/43 clones shown in upper case, others in lower case, Y=pyrimidine, R=purine.
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3234 and 3310, were strongly enhanced during 72 h of
induction of mTERF overexpression (Figure 6a,
Supplementary Figure 5b). In the vicinity of the IQM
tRNA gene cluster, LM-PCR revealed L-strand 50 ends
enhanced by mTERF overexpression at np 4476 (close to
the 50 end of ND2 mRNA) and np 4434 (within the
tRNAMet gene), against a background of heterogeneous 50
ends that were generally unaﬀected by mTERF over-
expression (Figure 6b and c). The signiﬁcance of this
heterogeneous background of abundant 50 ends is unclear,
although the two sites enhanced by mTERF overexpres-
sion lie in the vicinity of pause ‘b’. Within the remainder of
the ND1 and ND2 coding regions (Supplementary
Figure 5c–h) we detected only weak LM-PCR signals
which were not aﬀected by mTERF overexpression. The
prominent 50 ends in the tRNACys gene adjacent to OL
were also unaﬀected by mTERF overexpression.
In the NCR, H-strand 50 ends at OH, as well as those
clustered in the distal region of the D-loop (np 16 311,
16 337, 16 370, 16 411 and more weakly at np 16 197) were
strongly induced by mTERF overexpression. This is
consistent with delayed resolution, arising from more
frequent pausing at the canonical mTERF-binding site.
H-strand 50 ends in the NCR are on the lagging strand for
initiation events outside of the NCR, and thus may also be
enhanced by pausing of replication forks entering the
NCR from the ‘cytochrome b side’.
DISCUSSION
mTERF is a modulator of replication as well as transcription
In this study, we showed that mTERF binding at its
canonical binding site in the tRNALeu(UUR) gene
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inﬂuences replication pausing near to this site.
Overexpression of mTERF enhanced this pausing and
increased the steady-state abundance of lagging strand 50
ends adjacent to the binding site, whereas mTERF
knockdown by RNA interferences decreased pausing in
the tRNALeu(UUR) gene region. In addition, based on
studies in vitro (EMSA, SELEX) and supported by
ﬁndings in vivo (mIP), we identiﬁed novel sites of
mTERF binding, elsewhere in the genome. Binding at
these sites was weaker than in the tRNALeu(UUR) gene, but
replication pausing in these regions was nevertheless
inﬂuenced by mTERF overexpression. The data support
a role for mTERF as a modulator of replication, especially
at its canonical binding site. Close parallels with the
properties of replication pause-region binding proteins in
bacteria and eukaryotic nuclei provide some intriguing
hypotheses which we now discuss.
mTERF binding to additional sites in human mtDNA
The present study revealed novel sites of mTERF binding
in the NCR and ND1 gene. mIP assays were consistent
with binding at least at some of these sites by over-
expressed mTERF in vivo. mTERF homologues in
invertebrates, such as DmTTF in Drosophila (12) or
DBP in sea urchins (39,41), also have diverse and multi-
ple binding sites, typically demarcating the 30 ends of
oppositely transcribed gene clusters. Although mTERF
binding to the novel binding sites appeared weaker than at
the canonical binding site, many of them are clustered,
suggesting that cooperative binding might promote site
occupancy in vivo, consistent with the results of mIP. The
binding we observed in vivo might also depend on other
mitochondrial nucleoid proteins, including TFAM, as well
as possible post-translational modiﬁcations.
The eﬀects of mTERF overexpression on mtDNA RIs
from the NCR (Figure 4c and d), suggest that mTERF
may interact with this region in vivo to promote fork arrest
at the replication terminus. The termination zone for
mtDNA replication appears not to be a single point (OH),
but an extended region of the NCR (Figure 4c). mTERF
overexpression resulted in increased stalling of replication
forks as they approach OH from the ‘cytochrome b side’.
It also appeared to elevate the abundance of 7S DNA
(Supplementary Figure 4f) and of S1 nuclease-sensitive
species probably equivalent to the classical D-loop
(Figure 4c), consistent with increased pausing in the
TAS region. Protein-binding sites within the TAS region
were previously mapped by in vivo footprinting (42)
and by EMSA (43), and mTERF might be one of the
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proteins involved. The D-loop remains enigmatic.
DNA synthesis arrest at TAS might be a switching
mechanism relevant to copy number control, or may
have other purposes, such as mitochondrial nucleoid
organization (44).
The Escherichia coli Tus protein, which regulates the
termination of chromosomal DNA replication, may
represent a useful paradigm for mTERF. Tus binds
multiple copies of the Ter sequence ﬂanking the termi-
nator region, and acts directionally as a contrahelicase
(45) to trap replication forks in this region (46). The sea
urchin mTERF homologue DBP has also been shown to
function as a contrahelicase in vitro (15). Like Tus,
mTERF binding to sites on both sides of the replication
terminus region might regulate the entry of oppositely
moving replication forks into the region, facilitating their
orderly synopsis. Increased mTERF expression resulted in
elevated levels of persistent H-strand 50 ends in the NCR
(Figure 6d), an expected signature of delayed resolution
if fork passage through rDNA is more restricted. The
orientation of potential mTERF-binding sites in the
genome appears highly non-random. Taking the simpliﬁed
sequence GG(N8)GG as the minimal binding site, its 12
occurrences in the NCR all bear the same orientation. The
same applies to the cluster of seven such sites in the 30
portion of ND1 and the adjacent tRNA gene cluster. In
contrast, the canonical binding site shows the opposite
orientation, although is ﬂanked on each side by two
oppositely oriented copies of the minimal binding site
(Supplementary Figure 6).
Although we detected only ambiguous mTERF binding
in vitro in the H-strand transcriptional initiator region,
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Figure 5. Downregulation of mTERF expression by RNA interference. (A) Western blot assay of mTERF knockdown by siRNA mTERF.1
(directed against mTERF mRNA) and siRNA Control. HEK293T cells were either untransfected (), transiently transfected (t) or stably (+)
transfected with an mTERF-MycHis expression construct. Cells were then assayed 24, 48 and 72 h following siRNA transfection or else without such
transfection (). The arrowed band is the mTERF-MycHis fusion protein, migrating between two background bands which appear in all westerns
and thus provide an internal loading control. Note that the sample from untransfected, non-siRNA-treated cells in the upper panel (penultimate lane)
is approximately 3-fold overloaded. (B) Immunocytochemistry of HEK293T cells stably transfected with mTERF-MycHis expression construct and
then either mock transfected or transiently transfected with siRNA mTERF.1. Immunocytochemistry used the anti-Myc monoclonal antibody, and
counterstaining with Mitotracker Red. (C) EMSA using Leu-short dsDNA oligonucleotide probe and mitochondrial protein extracts from HEK293T
cells with or without stable transfection of mTERF-MycHis expression construct, followed by transient transfection for 48 h with or without siRNA
mTERF.1. Despite the apparent diﬀerence in signal, the experimental conditions are the same as in Figure 1c: only the exposure time is diﬀerent, and
the amount of background signal in the gel. (D) 2DNAGE of mtDNA from untreated HEK293T cells or cells transfected with siRNA mTERF.1 for
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(Supplementary Figure 2e, EMSA probe OH5), mIP
ﬁndings suggest that the site is eﬃciently bound in vivo
by overexpressed mTERF. The latter is consistent with
previous ﬁndings that recombinant mTERF (7,29) binds
only weakly to this site, whereas partially puriﬁed,
endogenous mTERF binds more strongly and establishes
a DNA loop required for eﬃcient rDNA transcription (7).
This may require a post-translational modiﬁcation or
limiting accessory factor found only in vivo. mTERF exists
in multiple isoforms with distinct properties (4,47), and
has been reported to convert to an inactive trimeric form
in vitro (48). The initiator fragment also contains binding
sites for TFAM, which may promote binding but may also
interfere with the interpretation of the EMSA assay (see
Supplementary Figure 2e).
Regulated passage of replication and transcription complexes
The role of mTERF as a transcriptional terminator
is well established from in vitro studies, and DmTTF
also functions thus in vivo in Drosophila (13).
However, there is no compelling evidence that mTERF
regulates mitochondrial RNA levels physiologically.
The disparity in relative abundance between mRNAs
and rRNAs in mammalian mitochondria can largely
be accounted for by post-transcriptional regulation,
notably diﬀerences in half-life (49) and RNA processing
eﬃciency (50). Despite causing reduced mTERF-binding
aﬃnity and terminator activity in vitro, the 3243A>G
MELAS mutation has almost no eﬀect on mitochondrial
RNA levels in vivo (5). Moreover, manipulation of
mTERF levels in vivo by overexpression or RNA
interference has remarkably little eﬀect on steady-state
mitochondrial RNA levels (Hyva¨rinen et al., manuscript
in preparation). The observation that mTERF also
modulates mtDNA replication pausing suggests a diﬀer-
ent physiological meaning for its action as a transcrip-
tional terminator, i.e. it coregulates replication and
transcription.
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Figure 6. LM-PCR analysis of DNA 50 ends. (A–D) Analysis of L-strand 50 ends in the ND1-ND2 region, using primer sets TL1/TL2/TL7, TL8/
TL9/L11 and TL8/TL9/TL11, respectively, shown alongside sequencing ladders for the corresponding segments. Samples analysed represent a time-
course of induction of mTERF overexpression from 0–72 h (d). Analysis of H-strand 50 ends in the OH region using primer set H1/H2/H5. (E) and
(F) Schematic summary diagrams of the LM-PCR ﬁndings in the 16S rRNA-OL and OH regions, respectively. Shown below the scale lines are the
positions (vertical lines) of the major 50 ends detected, with those exhibiting clearly increased abundance in mTERF-overexpressing cells also
indicated by ﬁlled circles. Gene locations shown below (12S and 16S rRNA in light grey, cyt b, ND1, ND2 and COI protein-coding genes in dark
grey, tRNAs cross-hatched, non-coding DNA in NCR and at OL in white). LM-PCR data are compiled from parts (a–d) of this ﬁgure, plus parts
(b–i) of Supplementary Figure 5. Above the scale lines are indicated the positions of mTERF-binding sites and replication pauses inferred from other
experiments: in (e) reproduced from Figure 3d, and in (f) compiled from data of Figures 2 and 4, plus Supplementary Figure 2. Based on the data of
Figure 4, the OH pause region enhanced by mTERF overexpression extends across most of the NCR. The white box in (f) indicates the assumed
position of the pause site giving rise to species ‘n’ in Figure 4c, i.e. assuming initiation close to OH. The open circle denotes the minor lagging strand
50 end mapping in this region (np 16197), which was enhanced by mTERF overexpression. The positions of the various mTERF-binding sites in the
NCR were inferred from EMSA using overlapping 150 bp fragments, as shown.
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The unregulated collision of oppositely moving tran-
scription and replication complexes drastically inhibits
DNA replication and provokes genomic instability in both
bacteria (51,52) and yeast (53,54). In E. coli, head-on
collision of the transcription and replication machineries
severely impedes the progress of the replication fork (51)
whereas codirectional transcription has no eﬀect. Within
the E. coli chromosome almost all essential genes are
oriented such that transcription and replication are
codirectional (55), which is proposed to minimize the
mutagenic eﬀect of repeated replication stalling and
recombinational restart, following head-on collisions
(51,56). In bacterial or yeast plasmids, or yeast rDNA,
such head-on collisions can trigger genomic instability
(53,57,58), e.g. due to knotting of daughter duplexes (59).
In mammalian nuclei, head-on collisions can trigger the
formation of HSRs (homogeneously staining regions of
chromosomes), the signature of massive gene ampliﬁca-
tion events (60).
Proteins with dual roles in replication and transcrip-
tional arrest are well documented. The E. coli Tus protein,
described in the preceding section, preferentially blocks
transcription with a similar polarity as DNA replication
(61,62). Passage of a transcription complex from the
permissive direction relieves the block on DNA synthesis
(61) by provoking the dissociation of bound Tus (63). The
mouse TTF-I protein binds at the 30 end of the rDNA
transcription unit, where it terminates transcription by
RNA polymerase I (64) and arrests replication forks
arriving from the other direction (65,66), via its polar
contrahelicase activity (67). This organization of the
rDNA locus is relatively conserved throughout eukary-
otes, although in some species the TTF-I homologue
co-operates with or depends upon other proteins to
maintain the replication fork barrier (RFB), including
Sap1p and Reb1p in Schizosaccharomyces pombe (68–70),
with involvement of Swi1p and Swi3p to stabilize the
stalled forks (71), or Fob1p in Saccharomyces cerevisiae
(72,73), with Sir2p regulating recombination at the stalled
forks (74).
The entry of replication forks into the mtDNA
termination zone around OH requires traversal of the
heavily transcribed rDNA region in the antisense direc-
tion, with potentially catastrophic consequences if a
transcription complex is encountered. By binding at the
rDNA boundary, mTERF may thus serve a function
related to those of both Tus and TTF-I, facilitating the
regulated passage of oppositely moving transcription and
replication machineries, and regulating fork access to the
termination zone.
The passage of a transcriptional complex in the
permissive direction may also serve a regulatory role,
such as hypothesized for mtDBP in relieving the block on
D-loop expansion in sea urchins (15).
mTERF overexpression enhanced X-like species in
fragments where the canonical mTERF-binding site was
centrally located (Figure 4b, Supplementary Figure 4a),
whereas mTERF knockdown by RNA interference
depleted such species (Figure 5d). Although these may
be recombination intermediates (see below), they might
also comprise termination complexes centred on the
mTERF-binding site. If increased mTERF activity
enhances rDNA transcription (6), it may also restrict the
entry of replication forks into rDNA in the antisense
direction and perhaps even shift the resolution site in some
molecules from the NCR to the tRNALeu(UUR) gene.
However, this must be a very minor fraction of molecules,
since we did not see a complete Y-arc in OH-containing
fragments.
Transcription termination and the bootlace model
Previous studies of vertebrate mtDNA replication indi-
cated that, in the majority of molecules, the lagging strand
is initially laid down in the form of extended RNA
segments which are subsequently converted to DNA via a
maturation step (19). We hypothesized that the RNA
lagging-strand may arise via either of two highly
unorthodox mechanisms: either via a primase capable of
synthesizing extended RNA primers, or by the hybridiza-
tion of preformed L-strand RNA with the displaced
H-strand in a 30 to 50 direction as the replication fork
advances, the so-called bootlace model.
mTERF-dependent replication pausing may be con-
strued as circumstantial evidence supporting the bootlace
model. Transcriptional termination by mTERF adjacent
to a paused replication complex would provide a 30 end
capable of priming lagging-strand DNA synthesis, at the
same time as delivering a fresh RNA bootlace to enable
the replication fork to proceed in the forward direction.
The mTERF-dependent enhancement of lagging strand
50 DNA ends near the canonical (and some other)
mTERF-binding sites, (Figure 6), supports this idea.
In sea urchin mtDNA, the major replication pause-
region, which interacts with at least two DNA-binding
proteins (38,40,41), also appears to be a major lagging-
strand origin, as well as a site of transcriptional
termination and/or RNA processing.
The eﬀect of overexpression of mTERF is much more
site-speciﬁc than that produced by overexpression of
TFAM (28), by treatment with mtDNA replication
inhibitors such as dideoxycytidine (28), or by expression
of dominant-negative versions of the mtDNA helicase
Twinkle (31). Unlike these treatments, mTERF over-
expression did not cause a general slowing of replication,
and did not alter globally the ratio of strand-coupled and
RITOLS type RIs. By facilitating lagging-strand matura-
tion, mTERF may serve merely to minimize the extent of
the region of mtDNA maintained in the more vulnerable
RNA-DNA hybrid form, thus contributing to genome
stability.
Recombination at the mTERF-binding site
An alternate interpretation of the X-like molecules centred
on the tRNALeu(UUR) gene region, which were enhanced
by mTERF overexpression and depleted by mTERF
knockdown, is that they represent true recombination
intermediates. Such forms would be expected to arise if
persistent mTERF binding and consequent prolonged
pausing entrain fork collapse, requiring either a double-
strand break or fork regression to generate a recombino-
genic end for restart of replication. We previously
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noted that the canonical mTERF-binding site was a
frequent break-point in rearranged mtDNA molecules
(‘sublimons’) detectable at a low level in all cell-types,
but especially prominent in human heart (75), and also in
mice expressing a disease-equivalent version of the
Twinkle helicase(76) associated with autosomal dominant
external ophthalmoplegia (PEO). It is tempting to ascribe
such molecules to aberrant recombination following
pausing and fork collapse at the tRNALeu(UUR) gene.
In yeast, double-strand breaks at the site of the RFB in
rDNA, giving rise to low-level genomic rearrangements
implicated in ageing, are evident even in wild-type strains
(54). However, in strains defective for the DNA helicase
Rrm3p, which is required for the processing of paused
replication forks at sites of protein binding (77,78), the
frequency of such events is greatly increased. If the
balance between the pause-inducing and pause-processing
machineries is disturbed, recombinational mechanisms
must be employed to restart replication, with the
concomitant risk of genomic instability. Thus, even
though replication pausing systems such as mTERF may
have evolved to limit genomic instability by preventing
collisions of the replication and transcription machineries,
their dysregulation, including by overexpression, could
itself lead to instability. It follows that mTERF is a
candidate gene for involvement in those cases of genetic
disorders mediated by mtDNA rearrangements (e.g.
PEO), whose genetic basis has not yet been elucidated.
In some cases replication pausing is merely a signature
of defective replication (79,80). In others it is clearly a
programmed event which facilitates other processes and
preserves genome stability (81). As indicated by our
ﬁndings (Figure 3), the phenomenon of pausing in human
mtDNA is not conﬁned to just one cell-type, nor is it an
in vitro artefact seen only in cultured cells. The fact that it
exhibits diﬀerences between cell-types and tissues strength-
ens the proposition that it is of physiological signiﬁcance.
The involvement of mTERF in modulating mtDNA
replication pausing in human mtDNA, and the analogies
with programmed replication pausing in other systems,
support the idea that mTERF represents a system for
safeguarding the integrity of the mitochondrial genome,
whilst facilitating its eﬃcient expression.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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LEGENDS TO SUPPLEMENTARY FIGURES
Supplementary Figure 1
Effects of overexpression of mTERF on mtDNA copy number and sequence-specific protein binding
activity.  (a) Q-PCR analysis of mtDNA copy number of Flp-In™  T-REx™ -293 cells transfected with
the mTERF construct and induced for the times indicated, normalized to the mean value for uninduced
cells (means + S.D.  of 3 independently isolated DNA samples). The analysis compared the level of
mtDNA (cytochrome b probe) with that of amyloid precursor protein (APP), as a single copy nuclear
DNA standard, as previously (28).  (b) EMSA supershift assay of protein binding to the tRNALeu(UUR)
gene-containing fragment Leu (see Fig. 2 and Supplementary Table 1) using mitochondrial protein
extract from Flp-In™  T-REx™ -293 cells, with (+) or without (–) induced overexpression of mTERF
or the mTERF-MycHis fusion protein, as indicated.  Supershift was carried out using anti-Myc (m) or
anti-FLAG (f) antibodies as shown (see Materials and Methods).  The supershifted complex formed
using the anti-Myc antibody, but not the anti-FLAG antibody, is arrowed.  This supershifting property
makes it possible to distinguish complexes actually containing the over-expressed mTERF-MycHis.
Note also the low mobility bands visible at this exposure in the left-hand panel, which are probably
due to binding by TFAM.   Similar complexes are revealed in the gel shown in the right-hand panel
(mTERF-MycHis expressing cells), at longer (more comparable) exposures.  Their appearance is
dependent on the fragment tested and the autoradiographic exposure used, not on the expression of any
transgene.
Supplementary Figure 2
EMSA analysis of mTERF binding.  See Figure 2 of the main paper for other data.  (a) Schematic
diagram of regions of the mitochondrial genome in which binding was tested using 150 bp fragments,
nomenclature as in Fig. 2a, with additional segments of protein-coding genes A8, A6, COIII, ND3 and
ND4L as shown.  The overlap between A8 and A6 is shown in black.  [The additional regions
analysed for binding were selected, based on the data of the main paper, as regions showing enhanced
replication pausing in mTERF-overexpressing cells].  (b) Map showing overlapping, shorter fragments
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used in EMSA to localize the binding sites within fragment ND1.1 (see below, part d).  (c) Further
detail of binding to 150 bp fragments shown in Fig. 2. Mitochondrial protein extracts were from cells
induced (or not) to over-express natural mTERF, with or without 100-fold mass excess of cold
competitor.  (d) Localization of mTERF binding sites within fragment ND1.1 using shorter,
overlapping fragments (see part b), and supershifting.  Cold competitor was present, where indicated,
in several-fold mass excess.  The simplest interpretation is that there are two mTERF binding sites
within ND1.1, one located in fragments ND1.12 and ND1.13 but absent from ND1.11 and ND1.16,
i.e. lying between np 3830-3855, the second located within ND1.14 but absent from ND1.13, i.e. lying
between np 3880-3907.  Within each of these short segments a good match to the SELEX consensus is
found (see Table 1). (e) EMSA analyses of binding to 150 bp probe fragments in addition to those
shown in Fig. 2. Nomenclature as for Fig. 2.  A very high molecular weight mTERF-dependent
complex (arrowed) was formed by fragment OH5.  Since fragment OH5 also contains an identified
binding site for TFAM, this complex may contain TFAM as well as mTERF, and could correspond
with the large complex visualized by Martin et al (6) at the initiator site for rDNA transcription.  Other
fragments gave no reproducible EMSA signals indicative of mTERF binding.  The ND5-6 dsDNA
oligonucleotide covering the ND5-ND6 gene junction (Supplementary Table 1, data not shown) also
gave no signal.
Supplementary Figure 3
Examples of replication pausing near mTERF binding sites.  (a) Schematic map of human mtDNA
showing relevant restriction sites, OH, OL, the approximate locations of the probes used (OH and COI,
see Materials and Methods), denoted by asterisks, the NCR (bold, dark grey) and rDNA (bold, pale
grey). (b) 2DNAGE analysis of OH- and OL-containing fragments from human placental mtDNA.
Panels i and ii were treated, after digestion, with S1 nuclease and are images of gels already published
in Ref. 24.  Pause zones near OH and OL arrowed.
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Supplementary Figure 4
Further 2DNAGE data showing effects of mTERF overexpression.  (a) Comparable exposures of
ND2-containing AccI fragment, treated with S1 nuclease, in which pause site ‘a’ (tRNALeu(UUR)) is
centrally located, showing enhancement of the species at the tip of the X-arc (‘x’), as well as of the
double-Y arc leading to it,  in mtDNA from cells in which mTERF overexpression was induced for 48
h.  (b) Longer exposure of panels i and ii from Fig. 4c, plus similar gels of material treated with S1
nuclease. Nomenclature as Fig. 4c.  (c) BclI digest (treated with S1 nuclease), probed for the 3.3 kb
ND3-containing fragment (ND4 probe).  Novel pause in mTERF-overexpressing cells arrowed.  (d)
BamHI digest probed as for the gels shown in Fig. 4d, using similar nomenclature.  The steeply
descending trajectory of the ‘eyebrow’ (broken-theta) arc, denoted ‘e’, is due to compression.  i –
initiation (bubble) arc, o – uncut circles, dY – double-Y molecules.  Pausing in the ND1/tRNALeu(UUR)
region generates complex double-Y or broken-theta species in this digest (region of the gel designated
‘l’), whose migration and interconversion depends on the timing of lagging-strand maturation to
dsDNA at the BamHI site.  The enhanced pausing when mTERF is overexpressed is proposed to
facilitate the more complete maturation of the lagging strand, such that the termination forms in the
BamHI digest are resolved mainly as double-Y molecules (in which the site is cut on both daughter
duplexes), denoted ‘u’, as opposed to the more electrophoretically retarded broken-theta molecules,
denoted ‘s’, in which the site is cut only on one daughter branch, as seen in uninduced cells. (e)
Illustration of the prominent intermediates generated by pausing in the ND1/tRNALeu(UUR) region,
which were detected in single-hitter digests (Fig. 4d and part (d) of this figure), as indicated.  Filled
and open ovals denote OH and the ND1/tRNALeu(UUR) pause region, respectively.  (f) One-dimensional
agarose gel-blot of undigested mtDNA, with or without heating to 95 ºC for 30 s to release 7S DNA
(arrowed) by branch migration, as indicated.  DNA was from cells induced for 24 h (ind) or not
induced (unind) to overexpress mTERF.  Lower panel indicates 7S DNA region of the gel (longer
exposure).  The upper panel indicates approximately equal loading and reveals subtle differences
resulting from mTERF overexpression, in the molecular forms of mtDNA resolved on 1-D gels.
Brackets indicate areas of the gel in which the migration of various forms of mtDNA from mTERF-
overexpressing cells differed from those seen in uninduced cells.
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Supplementary Figure 5
LM-PCR analysis of additional 5  ´ends. (a) Schematic diagram indicating that sites of replication
pausing, such as may result from a bound protein (filled oval), correspond also with persistent 5  ´ends
on the lagging strand.  Nascent strands are shown with arrowheads to denote the 5  ´to 3  ´direction of
synthesis.  (b)-(i) LM-PCR reactions using the following primer sets: (b) TL1/TL2/TL7,  (c)
TL1/TL2/TL6, (d) TL1/TL2/TL5, (e) TL1/TL2/TL4, (f) TL1/TL2/TL3, (g) TL8/TL9/TL12, (h)
TL8/TL9/TL10 and (i) L1/L2/L3, alongside sequencing ladders of the corresponding segments.
Samples were as in Fig. 6.  Amount of input DNA for uninduced cells in part (b) was 50% more than
for other samples analysed in parallel.  Note that the 5  ´end at np 3211 does not increase uniformly
during the time-course of mTERF over-expression, a curious but consistent anomaly (see also Fig. 6a)
for which do not have any explanation.  The minor bands, which differ in prominence between the
genomic regions analysed, are unlikely to be due to nonspecific DNA nicking or polymerase stalling
since there is no obvious reason why this would affect some portions of the mitochondrial genome
more than others.  It may be that they represent genuine DNA ends on the nascent lagging strand.
Supplementary Figure 6
Proposed minimal mTERF binding sites in the 16S/tRNALeu(UUR)/ND1 boundary region.  The
canonical binding site (highlighted in orange) is the only one in which the pairs of GG residues are on
the top (L-) strand. This site is flanked on each side by pairs of binding sites in the opposite orientation
(highlighted in yellow).  The tRNALeu(UUR) gene sequence is boxed.  Numbering as Ref. 82. The gap
represents the original nt 3107, which was later deleted from the sequence upon revision, the gap
having been inserted to preserve the original numbering.
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SUPPLEMENTARY TABLES
SUPPLEMENTARY TABLE 1: EMSAa and hybridization probesb
Name of probe Coordinates Length (bp) Use Genes or sequence features covereda
TP 15829-15978 150 EMSA Cyt b, tRNAThr, tRNAPro
NCR1 15959-16108 150 EMSA NCR, tRNAPro, NCR, ETAS1
NCR2 16089-16238 150 EMSA NCR, ETAS1, TAS, mt5 element
NCR3 16219-16368 150 EMSA NCR, ETAS2
NCR4 16349-16498 150 EMSA NCR
NCR5 16479-58 150 EMSA NCR
NCR 35-611 576 Hybridization NCR,
OH1 41-190 150 EMSA NCR, OH, CSB1, CSB2, CSB3, PL, PH1, PH2 , 12 S rRNA
OH2 171-310 140 EMSA NCR, OH, CSB1, TFAM binding sites
OH3 291-440 150 EMSA NCR, CSB2, CSB3, PL
OH4 421-570 150 EMSA NCR, PL, TFAM binding sites
OH5 520-669 150 EMSA NCR, TFAM binding sites, PH1, PH2  12S rRNA
Leu 3193-3342 150 EMSA 16S rRNA, tRNALeu(UUR), ND1
Leu-short 3230-3256 27 EMSA (ds oligo) tRNALeu(UUR)
ND1.4 3312-3490 179 EMSA ND1
ND1.5 3451-3600 150 EMSA ND1
ND1.6 3581-3730 150 EMSA ND1
ND1 3601-4080 481 Hybridization ND1
ND1.7 3711-3860 150 EMSA ND1
ND1.1 3800-3950 150 EMSA ND1
ND1.2 3931-4080 150 EMSA ND1
ND1.11 3800-3839 40 EMSA ND1
ND1.12 3800-3873 74 EMSA ND1
ND1.13 3813-3893 81 EMSA ND1
ND1.14 3813-3907 95 EMSA ND1
ND1.15 3813-3927 115 EMSA ND1
ND1.16 3847-3950 104 EMSA ND1
ND1.3 4061-4210 150 EMSA ND1
                          Supplementary data, Hyvärinen et al (2007)
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IQM1 4201-4350 150 EMSA ND1, tRNAIle, tRNAGln
IQM2 4331-4480 150 EMSA tRNAIle, tRNAGln, tRNAMet, ND2
ND2 4480-4988 589 Hybridization ND2
ND2.1 5161-5310 150 EMSA ND2
ND2.2 5221-5370 150 EMSA ND2
OL 5685-5834 150 EMSA tRNAAsn, OL, tRNACys, tRNATyr
COI 5831-6244 414 Hybridization tRNATyr, COI
A8A6 8475-8625 150 EMSA A8, A6
A6.1 8501-8650 150 EMSA A6
A6.2 8631-8780 150 EMSA A6
A6.3 8761-8910 150 EMSA A6
A6.4 8891-9040 150 EMSA A6
A6.5 9021-9170 150 EMSA A6
A6.6 9151-9300 150 EMSA A6
ND3.1 9961-10110 150 EMSA ND3
ND3.2 10091-10240 150 EMSA ND3
ND3 3 10221-10370 150 EMSA ND3
ND3.4. 10351-10500 150 EMSA ND3
ND3.5 10481-10630 150 EMSA ND3
ND4 11161-11640 480 Hybridization ND4
ND5-6 14134-14160 27 EMSA (ds oligo) ND5-ND6 gene junction
aLeu-short and ND5-6 were dsDNA oligonucleotides (see text).  All other EMSA probes were created by PCR using two 20 nt oligonucleotide primers
commencing at the coordinates indicated (82), except for the H-strand primers for ND1.5, ND3.5, A6.1 and IQM1 (17 nt), NCR3, A6.3, A6.4, A6.6 and A8A6
(18 nt), ND3.1, Leu and OL (19 nt), ND3.2 (26 nt) and ND3.4 (27 nt), the L-strand primers for ND1.6 (16 nt), NCR4, A6.5  and OH5 (18  nt), ND3.3 (24 nt)
and ND3.5 (27 nt), and both primers for probes ND1.11-16 (all 27 nt).
bHybridization probes were synthesized by PCR using two 20 nt oligonucleotide primers commencing at the coordinates indicated (82).
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SUPPLEMENTARY TABLE 2: Oligonucleotides used in LM-PCR
aCoordinates as in Ref. 82.
Name of
oligonucleotide
Oligonucleotide sequence (5´ to 3´) Coordinates
TL1 TTAGCGCTGTGATGAGTGTG 4536-4517
TL2 AGTGTGCCTGCAAAGATGGTAG 4522-4501
TL3 TGCTAGGGTGAGTGGTAGGAAGTTTTT 4203-4177
TL4 CGGCTATGAAGAATAGGGCGAAG 3985-3963
TL5 AGTGTGCCTGCAAAGATGGTAG 3812-3788
TL6 AAATAGGAGGCCTAGGTTGAGGTTGA 3618-3593
TL7 GGGCCTTTGCGTAGTTGTATATAGCC 3416-3391
TL8 TCATGTTAGCTTGTTTCAGGTG 5186-5165
TL9 GCTTGTTTCAGGTGCGAGAT 5178-5159
TL10 GGGGTGCCTTGGGTAACCTC 4837-4818
TL11 TGGCAGCTTCTGTGGAACGA 4638-4619
TL12 GGGTATGGGCCCGATAGCTTATT 4438-4416
TL18 GGGTTGATTGCTGTACTTGC 16223-16204
TL19 AGGGGGTTTTGATGTGGATT 16189-16170
TL21 ATGAGGATGGATAGTAATAGGGCAAGG 15645-15619
L1 TAGAGCTGTGCCTAGGACTC 6002-5983
L2 CAGCTCATGCGCCGAATAATAGG 5982-5960
L3 GGTATAGTGTTCCAATGTCTTTGTGGTTTGTAG 5961-5929
H1 CCTCCTAGGCGACCCA 15490-15505
H2 AGACAATTATACCCTAGCCA 15505-15524
H3 CACACGTTCCCCTTAAATAAGACATCACGATG 16537-16569
H5 TCCACCATTAGCACCCAAAGCTAAGATTCT 15976-16005
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SUPPLEMENTARY TABLE 3
SELEX analysis of the mTERF binding site and possible binding sites in mtDNA
Position 1 2 3 4 5 6 7 8 9 10 11 12  13 14
SELEX Consensusa t G G t a r a r g T Y G G t
Actualb
Leuc T G G C A G A G C c C G G T
ND1.12d a G G G T C A T G a T G G c
ND1.14e G G G G T T C G G T T G G T
OH1f a G G A T G A G G c a G G A
aSee Table 1 of main paper
bBest matches to consensus within several of the inferred binding-site regions of human mtDNA, based on EMSA
cCanonical binding site for mTERF within tRNALeu(UUR) gene
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dProposed binding site in ND1 gene between np 3830-3855; see Supplementary Fig. 2d.
eProposed binding site in ND1 gene between np 3880-307; see Supplementary Fig. 2d.
fPossible binding site within fragment OH1; see Fig. 2
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3001 ggacatcccg atggtgcagc cgctattaaa ggttcgtttg ttcaacgatt aaagtcctac
3061 gtgatctgag ttcagaccgg agtaatccag gtcggtttct atctac-ttc aaattcctcc
3121 ctgtacgaaa ggacaagaga aataaggcct acttcacaaa gcgccttccc ccgtaaatga
3181 tatcatctca acttagtatt atacccacac ccacccaaga acagggtttg ttaagatggc
3241 agagcccggt aatcgcataa aacttaaaac tttacagtca gaggttcaat tcctcttctt
3301 aacaacatac ccatggccaa cctcctactc ctcattgtac ccattctaat cgcaatggca
3361 ttcctaatgc ttaccgaacg aaaaattcta ggctatatac aactacgcaa aggccccaac
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Effects on mitochondrial transcription of
manipulating mTERF protein levels in cultured
human HEK293 cells
Anne K Hyvärinen1, Mona K Kumanto1, Sanna K Marjavaara1,2, Howard T Jacobs1*
Abstract
Background: Based on its activities in vitro, the mammalian mitochondrial transcription termination factor mTERF
has been proposed to regulate mitochondrial transcription by favouring termination at its high-affinity binding
immediately downstream of the rDNA segment of mitochondrial DNA, and initiation selectively at the PH1 site of
the heavy-strand promoter. This defines an rDNA transcription unit distinct from the ‘global’ heavy-strand
transcription unit initiating at PH2. However, evidence that the relative activities of the two heavy-strand
transcription units are modulated by mTERF in vivo is thus far lacking.
Results: To test this hypothesis, we engineered human HEK293-derived cells for over-expression or knockdown of
mTERF, and measured the steady-state levels of transcripts belonging to different transcription units, namely
tRNALeu(UUR) and ND1 mRNA for the PH2 transcription unit, and tRNAPhe plus 12S and 16S rRNA for the PH1
transcription unit. The relative levels of 16S rRNA and ND1 mRNA were the same under all conditions tested,
although mTERF knockdown resulted in increased levels of transcripts of 12S rRNA. The amount of tRNAPhe relative
to tRNALeu(UUR) was unaffected by mTERF over-expression, altered only slightly by mTERF knockdown, and was
unchanged during recovery from ethidium bromide-induced depletion of mitochondrial RNA. mTERF
overexpression or knockdown produced a substantial shift (3-5-fold) in the relative abundance of antisense
transcripts either side of its high-affinity binding site.
Conclusions: mTERF protein levels materially affect the amount of readthrough transcription on the antisense
strand of mtDNA, whilst the effects on sense-strand transcripts are complex, and suggest the influence of
compensatory mechanisms.
Background
Mammalian mitochondrial DNA is organized into three
multicistronic transcription units (reviewed in [1], Fig.
1A), which give rise to the mature RNAs encoded by
the circular genome: two ribosomal RNAs, 22 tRNAs
and 11 mRNAs (2 of them bicistronic). Each strand is
transcribed in its entirety, employing closely spaced pro-
moters located within the major non-coding region of
the genome, namely LSP, the promoter of the light-
strand, with a unique initiation site designated PL, and
PH1 and PH2, the alternate transcription start sites of
the heavy-strand promoter (HSP), which give rise to
partially overlapping transcripts. Based on metabolic
labeling studies, PH1 and PH2 have been inferred to
give rise to distinct primary transcripts of the heavy-
strand [2]. PH1 is located within the non-coding region
and generates a primary transcript comprising both
rRNAs and two tRNAs (-Phe and -Val), terminating at
the end of the rDNA region, mainly within the 5’ end of
the tRNALeu(UUR) gene [3]. PH2 is located within the
coding sequence of tRNAPhe and generates a primary
transcript comprising all of the remaining heavy-strand
encoded genes. PL generates a primary transcript com-
prising the entire light strand.
The mechanism by which the transcriptional machin-
ery selects between these different initiation sites, and
also effects selective termination at the end of the
rDNA, in the case of transcripts initiated at PH1, is
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incompletely understood. It can be manipulated in orga-
nello by various drugs and by ATP [4-6]. The mitochon-
drial RNA polymerase comprises a single catalytic
subunit, MTRPOL, plus an accessory factor, TFB2M,
required for formation of the initiation complex in vitro
at both HSP and LSP [7,8], together with mitochondrial
transcription factor A (TFAM), which is needed for pro-
moter-dependent transcription in vitro [7,9]. TFAM has
a natural binding affinity for DNA and has been sug-
gested also to play a more general role in organizing the
mitochondrial chromosome, analogous with bacterial
HU or eukaryotic and archaeal histones. A third factor,
mTERF, with sequence-specific binding affinity for a
sequence located within the tRNALeu(UUR) gene immedi-
ately downstream of the rDNA [10,11], has been pro-
posed to play a key role in both initiation and
termination of the PH1 transcription unit [12].
mTERF has selective termination activity in vitro on
templates containing its high-affinity binding site in the
tRNALeu(UUR) gene [10,13]. In crude extracts [14], as
well as in a reconstituted system based on recombinant
proteins [15], this activity appears to be bidirectional,
but operates in the latter case more efficiently in the
reverse direction, i.e. to terminate transcription initiating
from the LSP side more efficiently than from HSP [15].
Based on the fact that it has weak binding to other sites
Figure 1 Manipulation of mTERF expression has minimal effects on steady-state levels of mature mitochondrial RNAs. (A) Schematic
diagram of the promoter and rDNA region of human mtDNA. Because mTERF binding dictates the use of alternate transcriptional start sites and
terminators, tRNAPhe and tRNALeu(UUR) fall into separate transcription units (PH1 and PH2 respectively). (B) Relative expression of mitochondrial
transcripts in cells overexpressing mTERF, based on phosphorimaging of Northern blots probed successively for mitochondrial tRNAPhe and
tRNALeu(UUR) and for 5S rRNA. Data (means ± SD) are signal ratios of tRNAPhe to tRNALeu(UUR) (F/L) and tRNAPhe to 5S rRNA (F/5S) for the mTERF-
overexpressing clones shown in Additional File 1, Fig. S1, normalized to the corresponding ratio in cells stably transfected with empty-vector.
Bars shown alongside are based on single reference experiments, using HEK293T cells transiently transfected with the same construct, or mock-
transfected. (C) Q-RT-PCR analysis (means ± SD) of mitochondrial transcript levels, plus cytosolic18S rRNA, as indicated, in Flp-In™ T-Rex™-293 cells
over-expressing mTERF-MycHis after doxycyclin induction for 3 d (or not induced). Data were normalized, in each case, to the corresponding
ratio for uninduced cells. (D) Relative expression of mitochondrial transcripts in cells knocked down for mTERF, as indicated. – denotes mock-
transfection. Northern blot probed successively for 16S rRNA and ND1 mRNA, as shown. The panels represent non-adjacent pairs of lanes from
the same exposure of the same gel. (E) Relative expression of mitochondrial transcripts in cells knocked down for mTERF, as indicated, calculated
from Northern blot data as in (B), normalized to the corresponding ratio in mock-transfected HEK293T cells. * indicates significant differences
from the corresponding mock-transfected cells, and # a significant difference between cell-lines (t-test, p values as in text). For original blots see
Additional File 1, Fig. S1C. Note that additional Q-RT-PCR data on levels of 12S rRNA gene transcripts are shown in Fig. 3.
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in mtDNA, including the promoter region [12,16,17], it
has been proposed that mTERF favours transcription of
the PH1 transcription unit by simultaneous binding to
the promoter and to the terminator region, creating a
loop structure that can be visualized in vitro [12]. The
level of active mTERF would thus act as a fine tuning of
the relative production of rRNA and mRNA.
There are, however, some problems associated with
this model. First, efficient transcription from PH1 in
vitro does not require mTERF (although does appear to
be stimulated by it [18]), whereas transcription from
PH2 in vitro is weak [18]. Second, measurements of the
relative half-lives of mitochondrial rRNAs and mRNAs
in cultured cells [19] indicate that post-transcriptional
regulation is substantial and may in fact be sufficient to
maintain the different transcript levels seen in vivo,
without the need for any differential regulation of tran-
scription from the PH1 and PH2 transcription units.
Note that, although the synthesis rates of mitochondrial
rRNAs and mRNAs appear to be very different in both
cultured cells [19] and rat liver [20], ‘synthesis rate’ here
includes RNA processing as well as transcription. In
organello, the combined rate of accumulation of pre-
rRNA plus mature rRNA is, in fact, lower than that of
mRNA [6]. Third, no modulation of transcription from
the two initiation sites correlating with mTERF activity
has ever been convincingly demonstrated in vivo.
Fourth, in cells bearing the 3423A > G mutation, which
greatly impairs mTERF binding in vitro, there is no
alteration in the relative levels of 16S rRNA and ND1
mRNA [21,22], and no alteration in site occupancy in
vivo, based on footprinting studies [21]. Fifth, decreased
levels of mTERF expression in Mpv17 knockout mice
are associated with globally increased mitochondrial
transcription [23], suggesting rather than mTERF may
function in vivo as a negative but general regulator of
transcription. Finally, whilst recombinant mTERF is
active in a reconstituted system in vitro [15], its activity
in the presence of less pure mitochondrial extracts is
subject to post-translational modifications and/or the
presence of other proteins [11-13,18,24], raising doubts
as to whether and how it influences transcription in
vivo.
mTERF is a member of a family of organellar proteins
proposed to interact with DNA to produce a variety of
outcomes [25]. In mammals, two homologues of
mTERF, MTERFD1 (mTERF3) and MTERD3
(mTERF2), have been shown to influence mitochondrial
RNA levels and have been proposed to act as regulators
of transcription from LSP [26,27], with consequent
effects on oxidative phosphorylation mediated brought
about by altered translation, as seen also in Drosophila
[28]. However, neither mTERF homologue has been
conclusively demonstrated to have high-affinity
sequence-specific binding to DNA [26,27,29]. Homolo-
gues of mTERF in invertebrates have been demonstrated
to influence both RNA and DNA synthesis in vitro, but
here too, there is only weak evidence for a specific role
in vivo. The mTERF-homologue in sea urchins, mtDBP,
binds to at least two sites in the mitochondrial genome
[30] and exhibits bidirectional transcription termination
activity in vitro in the presence of human mitochondrial
RNA polymerase, although it acts unidirectionally in
combination with phage polymerases [31]. It also
impedes the progress of DNA polymerase bidirection-
ally, acting as a contrahelicase in vitro [32], suggesting a
possible role in DNA replication. A role for mTERF in
mammalian mtDNA replication is also suggested by the
observation that the level of mTERF expression in cul-
tured human cells influences replication pausing in the
vicinity of mTERF binding sites [16]. The Drosophila
mTERF homologue mTTF binds to two putative tran-
scriptional terminators [33], acting in vitro with similar
directional properties to mtDBP [34]. Manipulation of
DmTTF levels in cultured cells leads to effects on tran-
script levels consistent with it acting in the manner
hypothesized for mTERF, i.e. as a regulator of termina-
tion (bidirectionally) and also of promoter activity [35].
The difficulty of interpreting in vitro experiments, and
the open questions regarding the role of mTERF in vivo,
prompted us to address the issue of whether and how
mTERF activity influences mitochondrial RNA levels in
cultured human cells. Clearly, if mTERF is a regulator
of mitochondrial transcription in vivo, via a model as
proposed, up- or down-regulation of its expression
should influence mitochondrial RNA levels in a predict-
able fashion. We therefore undertook a study of mito-
chondrial transcripts in cells over-expressing or knocked
down for mTERF. Surprisingly, we found that varying
the level of mTERF over a wide range has only a small
effect on the levels of sense-strand transcripts of the
mitochondrial genome in the rDNA region. Conversely,
we detected a clear effect on the relative amounts of
antisense transcripts on the two sides of the high-affinity
binding site. These findings support a role for mTERF
in influencing mitochondrial transcription in vivo, but
not in setting the levels of mature mitochondrial
transcripts.
Results
Over-expression of mTERF does not alter steady-state
levels of mature mitochondrial RNAs
To evaluate whether the expression level of mTERF
influences the steady-state levels of the mature mito-
chondrial transcripts encoded on either side of its high-
affinity binding site, we generated a series of transfected
HEK293T cell clones stably over-expressing the natural
mTERF protein. Expression of the mTERF transgene
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was verified at the RNA level by Q-RT-PCR (Additional
File 1, Fig. S1A) and at the protein level by the substan-
tial increase in DNA-binding capacity at the high-affinity
mTERF binding site, as judged by EMSA (electrophore-
tic mobility shift assay, Additional File 1, Fig. S1B).
We analysed two parameters which we considered
diagnostic for the relative utilization of the two heavy-
strand transcription units predicted by the classic model
of mammalian mtDNA transcription (Fig. 1A). The first
is the relative amounts of tRNAs -Phe and -Leu(UUR),
which are exclusively produced by transcription from
PH1 and PH2, respectively, according to the classical
model. The second is the relative amounts of mature
16S rRNA and ND1 mRNA. The latter is synthesized
via transcription from PH2, whereas the former has
been proposed to be generated mainly or exclusively
from transcription initiating at PH1, although it has not
been formally excluded that transcription from PH2 also
contributes some of the 16S rRNA. We found that the
relative amounts of tRNAs -Phe and -Leu(UUR) in dif-
ferent cell-clones over-expressing natural mTERF was
indistinguishable from that in control cells transfected
with empty vector (Fig. 1B), and was also unchanged in
cells transiently transfected with the mTERF overexpres-
sion construct (or mock transfected cells). The global
amount of mitochondrial transcription, as measured by
the ratio of tRNAPhe to cytosolic 5S rRNA was more
variable, but showed no systematic relation to mTERF
overexpression (Fig. 1B). We also found no detectable
alteration in the relative amounts of mature NDI1
mRNA and 16S rRNA between mTERF over-expressing
clones and control cells, based on Northern blots (Fig.
1D: compare lanes 1 of panels i and ii [control cells]
with lanes 1 of panels iii and iv [over-expressing cells]).
In an effort to quantify any such effect and avoid possi-
ble influences of cell background, we also used Q-RT-
PCR to analyse transcripts of the 16S and ND1 genes in
RNA extracted from Flp-In™ T-Rex™-293 cells stably
transfected with the mTERF-MycHis construct, in which
expression of mTERF can be induced by doxycycline
(Fig. 1C). We found no differences in the relative
amounts of transcripts from these two genes, nor in the
ratio of either to cytosolic 18S rRNA transcripts.
Effects of mTERF knockdown on steady-state levels of
mature mitochondrial RNAs
In previous studies [16] we noted that transfection with
an siRNA directed against mTERF suppressed most of
the binding activity at the high-affinity mTERF binding
site, as judged by EMSA [16]. We therefore compared
the relative levels of mitochondrial transcripts in cells
knocked down for mTERF. Northern blots probed suc-
cessively for 16S rRNA and ND1 mRNA showed no dif-
ference in the relative levels of these mature transcripts
in HEK293T cells after prolonged treatment (7 d) with
an mTERF-specific siRNA (Fig. 1D: compare lanes 1
and 2 of panels i and ii), nor in mTERF-MycHis over-
expressing cells knocked down for mTERF (Fig. 1D:
compares lanes 1 and 2 of panels iii and iv). mTERF
knockdown in HEK293T cells did, however, produce a
small but significant decrease in the relative amount of
tRNAPhe compared with tRNALeu(UUR), (Fig. 1E, t-test, p
< 0.05), accompanied by an increase in the overall
amount of mitochondrial tRNAs, represented by the
ratio of mitochondrial tRNAPhe to cytosolic 5S rRNA (t-
test, p < 0.01). siRNA treatment of mTERF-MycHis
overexpressing cells caused no significant alteration in
mitochondrial tRNAs (Fig. 1E), compared with mock-
transfected cells. Note also that cells overexpressing
mTERF-MycHis showed no clear difference from
HEK293T cells in the relative levels of mitochondrial
tRNAPhe and tRNALeu(UUR) (Fig. 1E), although mito-
chondrial tRNA levels globally were lower than in
untransfected HEK293T cells (t-test, p < 0.01).
Manipulation of mTERF expression does not alter the
relative levels of mitochondrial tRNAs during recovery
from mitochondrial RNA depletion
Reasoning that the steady-state levels of mature mito-
chondrial transcripts may not accurately reflect their
transcription rates in vivo, due to the influence of post-
transcriptional processing, we set out to study whether
the level of mTERF expression can influence the re-
accumulation of tRNA transcripts belonging to the PH1
and PH2 transcription units during recovery from ethi-
dium bromide (EtBr)-induced depletion of mitochon-
drial RNA. We compared the ratio of mitochondrial
tRNAs -Phe and -Leu(UUR) in stably transfected cells
overexpressing mTERF-with that in empty vector-trans-
fected cells over 2 days of EtBr treatment followed by 5
days of recovery (Fig. 2A, Additional File 1, Fig. S2A). In
both cell lines the ratio fell substantially during deple-
tion, reflecting the much shorter half-life of tRNAPhe,
but then recovered to levels higher than those seen in
untreated cells, before decreasing again gradually,
towards the starting value. This may indicate that the
PH2 transcription unit is used preferentially during
recovery from depletion. However, this did not appear
to be influenced by the level of mTERF, since the same
pattern was seen in control cells and in three separately
analysed overexpressor cell lines, as well as in cells
knocked down for mTERF by treatment with the
mTERF-specific siRNA, which behaved indistinguishably
from mock-transfected cells (Fig. 2B). The overall
kinetics of recovery of mitochondrial transcripts com-
pared with cytosolic 5S rRNA was also similar, compar-
ing cells over-expressing mTERF with control cells
(Additional File 1, Fig. S2B), and comparing cells
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knocked down by mTERF-specific siRNA with mock-
transfected cells (Additional File 1, Fig. S2C).
Manipulation of mTERF expression influences both sense-
and antisense-strand transcription
Since the effects of manipulating mTERF expression
on the levels of mature 16S rRNA and ND1 mRNA
did not reveal any significant changes, we used strand-
specific quantitative RT-PCR to analyse effects on the
levels of both sense-strand and antisense-strand tran-
scripts derived from specific regions of these genes
either side of the high-affinity mTERF binding site. We
analyzed the relative levels of antisense transcripts
from portions of the ND1 and 16S genes in three con-
texts in which mTERF expression was manipulated
(Fig. 3B). In cell clones stably overexpressing mTERF
the relative level of anti-16S to anti-ND1 RNA was
decreased compared to control cells transfected with
the empty vector, although this difference was only
statistically significant in one of the two clones studied.
Induction of mTERF expression in Flp-In™ T-Rex™-293
cells stably transfected with the mTERF construct also
resulted in a substantial and statistically robust
decrease in the anti-16S:anti-ND1 ratio, whereas trans-
fection of HEK293T cells with an shRNA targeted on
mTERF resulted in the opposite effect, i.e., a significant
Figure 2 Manipulation of mTERF expression has minimal effects on levels of mature mitochondrial RNAs during recovery from EtBr-
induced depletion. Relative expression of mitochondrial transcripts in cells overexpressing mTERF, based on phosphorimaging of Northern
blots probed successively for mitochondrial tRNAPhe and tRNALeu(UUR). Data (means ± SD) are ratios of tRNAPhe to tRNALeu(UUR) (F/L) normalized
to the ratio at the start of the experiment (time-point –2 d). (A) Cells stably transfected with empty-vector (as shown in Additional File 1, Fig.
S1B) or mTERF overexpression (OE) construct (clone 3, as shown in Additional File 1, Fig. S1). Overexpressor clones 1 and 2 gave similar results:
sample blots shown in Additional File 1, Fig. S2A. (B) Cells treated with mTERF-specific siRNA (or mock-transfected) prior to the addition of EtBr
(day –2) and again 2 days after removal of EtBr (day 2). Days 1-5 indicate the period of subsequent recovery. For equivalent data on ratio of
tRNAPhe to 5S rRNA from the same experiment see Additional File 1, Fig. S2B, C.
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large increase in the relative amount of anti-16S RNA.
Notably, the pattern of changes in each RNA differed
in the two cases (over-expression and knockdown),
when comparing its level in treated versus untreated
cells (Fig. 3C, D). Induced overexpression, which
resulted in a 20-fold increase in mTERF mRNA (Fig.
3E), produced a severe decrease in antisense tran-
scripts from the 16S gene, but also a small decrease in
the level of anti-ND1 (Fig. 3C). mTERF knockdown
(by a factor of 2 at the RNA level: Fig. 3F) produced
no significant effect on antisense transcripts of 16S,
but a sharp drop in the level of anti-ND1 (Fig. 3D).
We validated the main findings using a second primer
set (Additional File 1, Fig. S3B), which was also used to
test effects on the relative amounts of sense-strand tran-
scripts from the 16S and ND1 genes, which were found
to be unaffected by these manipulations, as expected
from the analysis of mature transcripts by Northern
blots (Fig. 1). In addition, we analysed effects on sense-
strand transcript from the 12S rRNA gene, and
Figure 3 Manipulation of mTERF expression affects relative levels of antisense transcripts of the 16S rRNA and ND1 genes. (A)
Schematic diagram of 16S rDNA-ND1 region of human mtDNA. For full details of primer sequences and location, see Additional File 1, Table S1.
(B) Relative steady-state levels of anti-16S and anti-ND1 transcripts, determined by Q-RT-PCR using proximity probe hybridization (probe sets R1,
N1 and C1 for normalization), after various manipulations of mTERF expression, i.e. two mTERF overexpressor clones (OE) compared with vector-
transfected cells, doxycyclin-induced versus uninduced Flp-In™ T-Rex™-293 cells transfected with mTERF expression construct, and HEK293T cells
transfected with mTERF-targeted shRNA versus mock-transfected cells. In each case, data were normalized to the corresponding control cells.
* denotes statistically significant differences from control cells (t test, p < 0.02). (C, D) Relative changes in anti-16S and anti-ND1 transcripts, based
on replotting of data from the experiment of panel B for each transcript individually, (C) following induced expression of mTERF in Flp-In™ T-
Rex™-293 cells and (D) in HEK293T cells transfected with mTERF-targeted shRNA versus mock-transfected cells. Data were normalized to values
for corresponding untreated control cells, using 18S as internal normalization standard. * denotes statistically significant differences from
corresponding control cells (t test, p < 0.01). (E, F) Relative steady-state levels of 12S, 16S and 18S sense-strand transcripts, as determined by
Q-RT-PCR using of proximity probe hybridization (primer sets T1, R2, C1 respectively, as described in Additional File 1, Table S1), and of mTERF
mRNA relative to 18S rRNA (probes sets M1 and C1, see Additional File 1, Table S1), (E) following induced expression of mTERF in Flp-In™
T-Rex™-293 cells and (F) in HEK293T cells transfected with mTERF-targeted shRNA versus mock-transfected cells. * denotes statistically
significant differences (t test, p < 0.02). See also Additional File 1, Fig. S3.
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determined the levels of sense-strand transcripts of both
mitochondrial rRNAs relative to cytosolic 18S rRNA
(Fig. 3E, F). Under conditions of induced over-expres-
sion of mTERF, sense-strand transcripts of 12S rRNA
and of 16S rRNA were unchanged relative to each other
and to cytosolic 18S rRNA (Fig. 3E). However, we did
detect a significant increase in sense-strand 12S rRNA
transcripts in cells knocked down for mTERF (Fig. 3F).
Discussion
mTERF and heavy-strand promoter modulation
In this study we investigated the effects of manipulating
the expression level of mTERF on the relative levels of
different mitochondrial transcripts. Under all conditions
tested we failed to detect any significant effects on the
relative levels of mature 16S rRNA and ND1 mRNA
(Fig. 1C, 1D, Additional File 1, S3C). Over-expression of
a tagged mTERF variant, which resulted in the greatest
increase in DNA-binding activity that we were able to
generate (Fig. 5C of [16]), produced no significant
change in the relative levels of the mitochondrial tRNAs
tested, with only a minor decrease in their overall abun-
dance (Fig. 1E). Induced 20-fold over-expression of nat-
ural mTERF in a controlled nuclear background also did
not alter the ratio of mature 16S rRNA to ND1 mRNA,
nor were the levels of 16S or ND1 transcripts affected
relative to transcripts of cytosolic 18S rRNA or 12S
rRNA (Fig. 1C, 3E). Knockdown of mTERF resulted in a
very modest decrease in the level of tRNAPhe relative to
tRNALeu(UUR). However, this was not sufficient to gener-
ate any significant change in the kinetics of recovery of
mitochondrial tRNA levels following EtBr-induced
depletion.
We did, however, obtain two piece of evidence that
mTERF knockdown is not inert as regards transcription
of the mitochondrial heavy strand. Firstly, we observed,
by Northern blots, a small increase in the amount of
mitochondrial tRNAs belonging to each of the heavy-
strand transcription units, relative to cytosolic 5S rRNA
(Fig. 1E) in normal cells after mTERF knockdown. Sec-
ondly, the level of sense-strand 12S rRNA gene tran-
scripts analysed by quantitative RT-PCR was
significantly increased relative to sense-strand 16S rRNA
or cytosolic 18S rRNA gene transcripts (Fig. 3F), in nor-
mal cells knocked down for mTERF. However, the levels
of sense-strand 16S and ND1 transcripts relative to each
other or to 18S were not significantly affected (Fig. 3F).
This suggests the existence of a compensatory mechan-
ism, whereby decreased mTERF levels, which might
otherwise impair 16S rRNA biogenesis, generate a signal
for globally increased mitochondrial transcription (or
decreased turnover) to overcome any such defect. It
may also be noted that the effects of knockdown may be
underestimated due to the rather limited decrease in
mTERF mRNA level that we were able to achieve in
these experiments. A 50% decrease is not untypical in
cultured mammalian cells in cases where knockdown of
a given gene may provoke a growth defect, even just a
transient one, compared with untransfected cells in the
culture. Thus, the effects we observed may likely repre-
sent a combination of normal expression in almost half
the cells, plus greatly reduced expression in the remain-
ing cells.
Nevertheless, our findings imply that the expression
level of mTERF does not determine, in a simple manner,
the relative steady-state levels of transcripts belonging to
the two transcription units of the heavy-stand. Although
mTERF was previously shown to stimulate transcription
in vitro from PH1 in a comparatively crude system
[12,18], it may be noted that no such effect was seen
when purified, recombinant proteins were used [15], or
even in crude extracts using DNA-affinity purified
mTERF [18].
Our results indicate that even if mTERF levels do
influence transcriptional readthrough, a compensatory
response nevertheless adjusts the relative output of dif-
ferent transcripts belonging to the two heavy-strand
transcription units. This may involve the modulation of
transcriptional initiation, post-transcriptional processing
or RNA turnover. Our findings are consistent with pre-
vious reports of the action of thyroid hormone [36] or
variation in ATP supply [37], both of which can influ-
ence the relative rates of transcriptional of initiation at
PH1 and PH2 without any effect on that at the high-
affinity mTERF binding site. It is also possible that
mTERF might have a different physiological function,
and that its effects on transcription are accommodated
by modulating other components of the mitochondrial
RNA synthesis machinery.
Is mTERF activity in HEK293 cells physiological?
All of the current study was conducted in one cell-line
and its derivatives which, as a cancer cell-line, may not
behave in a physiologically normal manner. We consid-
ered the hypothesis that mTERF levels may, in other
cell-types, have a more profound effect on mitochon-
drial transcription but that, in HEK293 cells, mTERF
could be present in such excess that neither over-
expression nor any amount of knockdown achievable by
RNAi technology influences its functional level. How-
ever, from available gene expression data (biogps.gnf.
org) the range of expression of mTERF in different cell-
types in vivo, plus primary tumours and cell-lines
including HEK293 and its derivatives, is only of the
order of 2-5 fold. Furthermore, in HEK293T cells
mTERF is expressed at very close to the median level
for all cells investigated. Therefore, the range of expres-
sion achieved in the present study (~40-fold at the RNA
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level, Fig. 3E, F) far exceeds that known to be experi-
enced in vivo.
Another possibility, given the wealth of previous data
indicating possible post-translational regulation of the
transcriptional activity of mTERF, is that mTERF is con-
stitutively inactivated in HEK293T cells, regardless of its
expression level. Although we analysed DNA-binding
activity as well as RNA levels, some mTERF prepara-
tions that are competent for DNA binding are neverthe-
less unable to influence transcription in vitro [11,24].
This is unlikely, however, since the patterns of mito-
chondrial transcripts in HEK cells, and their responses
to other manipulations, such as increases in the level of
TFAM [38], are similar to other cultured cells and in
vivo tissues.
Thiamphenicol treatment, which alters the representa-
tion of PH1- and PH2-derived transcripts in a manner
similar to thyroid hormone treatment, is able to modify
the EMSA signal at the high-affinity mTERF binding
site, whilst leaving the actual levels of mTERF polypep-
tide unaffected [39]. This may indicate that a post-trans-
lational modification of mTERF could modulate both its
DNA-binding and its transcriptional properties in vivo,
but is equally consistent with the notion that another
factor, capable of binding in this region, is involved.
Final resolution of these issues will require the crea-
tion of an in vivo model in which mTERF levels can be
manipulated over at least as great a range in a tissue-
selective manner. The possibility of redundancy between
mTERF and other members of the mTERF family in
regulating read-through transcription at the 16S/tRNA-
Leu(UUR) gene boundary needs also to be considered.
Modulation of antisense-strand transcripts
We found that alterations in mTERF expression pro-
duced systematic changes in the extent of read-through
transcription in the antisense direction, as inferred from
the relative levels of anti-16S to anti-ND1 transcripts.
Increased levels of mTERF, resulting from stable over-
expression or from induction of Flp-In™ T-Rex™-293
cells transfected with an mTERF expression construct,
shifted the balance of antisense transcripts in the anti-
ND1 direction, whereas mTERF knockdown had the
opposite effect, shifting the balance in favour of anti-
16S. These findings are consistent with the notion that
mTERF, bound to its high affinity binding site in the
tRNALeu(UUR) gene, promotes termination of antisense
transcription initiated at PL, which has traversed most
of circular genome. Increased termination at this site
should deplete the representation of anti-16S, whereas
decreased termination should increase the amount of
anti-16S, consistent with our observations. However, the
effects seen are more complex than implied by this sim-
ple model. Specifically, the shift towards anti-ND1
under conditions of over-expression consists of a rather
drastic decrease in the amount of stable anti-16S, com-
bined with a much smaller decrease in the amount of
anti-ND1 (Fig. 3E). Since there are additional, weaker
binding sites for mTERF in the IQM tRNA cluster and
ND1 coding sequence [16], our finding supports the
idea that a high level of mTERF leads to increased occu-
pancy also of these weaker affinity binding sites,
restraining readthrough into anti-ND1 as well as the
more dramatic effect on readthrough into anti-16S
further downstream. On the other hand, mTERF knock-
down resulted in a clear decrease in the level of anti-
NDI1 but only a small change in anti-16S (Fig. 3F).
These findings imply that maintenance of the physiolo-
gical level of mTERF is important for the formation of
stable antisense transcripts of ND1, by preventing read-
through into the rDNA. If this interpretation is correct,
one in vivo role of mTERF is thus inferred to be the
regulation of antisense transcriptional termination, for
an unknown physiological reason.
In vitro, mTERF exhibits bidirectional termination
activity [15]. If this applies also in vivo, it may be that
the primacy of post-transcriptional processing, the stabi-
lization of rRNA into ribosomal subunits, and compen-
satory effects on transcriptional initiation or RNA
stability, mask or complicate the effects on sense-strand
transcripts. Conversely, antisense transcripts, which are
destined only for turnover (or for some unknown phy-
siological function) would appear to be regulated more
straightforwardly by mTERF.
A somewhat different interpretation arises from the
recent, and thus far unexplained reports of hairpin-loop
transcripts deriving from the 16S rRNA gene, whose
levels appear to reflect the proliferation status and
tumorigenicity of cells [40,41]. It is not yet known how
these transcripts arise. Possibilities are that they are cre-
ated post-transcriptionally by trans-splicing or RNA
ligation, or else that they arise by template strand-
switching during transcription. Our antisense results
could thus imply that mTERF influences the rate of
their production in ways related to or even independent
of its binding to mitochondrial DNA.
Physiological function(s) of mTERF
Given that the effects of mTERF manipulation on the
levels of mature mitochondrial transcripts in vivo appear
to be negated or modified by compensatory mechan-
isms, it may be that the principal physiological function
of this evolutionarily conserved protein is something
other than transcriptional regulation as such. In our pre-
vious study [16] we speculated that mTERF might play
some role in regulating collisions between oppositely
moving transcription and replication machineries, facili-
tating their orderly passage, whilst minimizing the risk
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of stalled replication giving rise to recombinogenic 3’
ends. A requirement for such activity is well established
in both prokaryotic and eukaryotic DNA replication
[42,43], and other members of the mTERF family have
been inferred to play a role in the completion of DNA
replication in human cells [44]. The presence of a tran-
scriptional terminator at a replication pause site more-
over provides a potential primer of lagging-strand
synthesis commencing immediately from the pausing
site, ensuring that no region remains single-stranded
and hence susceptible to DNA damage during pausing.
The RITOLS model of mtDNA replication [45] postu-
lates that the entire lagging strand is laid down initially
as RNA, which might be facilitated by such a mechan-
ism. However, the lagging strand for mtDNA replication
is the same strand as the rRNA. Therefore, if bound
mTERF were to deliver the 3’ end of a paused transcript
to an arriving replication complex, this would be as a
result of its activity in the sense direction. The role of
attenuation on the antisense strand is less clear,
although this might provide a primer required for re-
initiation of the replication machinery at a stalled repli-
cation fork, especially since the former leading strand 3’
end may be unavailable, e.g. due to fork regression. A
role for DnaG primase in replication restart at stalled,
gapped forks has been identified in E. coli [46], serving
as a precedent for primer-dependent restart. Codirec-
tional collisions between the transcription and replica-
tion machineries in E. coli also generate leading-strand
gaps, with the nascent RNA being recruited as a new
primer by the replisome [47].
Another possibility which should be seriously consid-
ered is that mTERF’s effects on nucleic acid metabolism
are incidental to its real biological function inside mito-
chondria, which may be something completely different.
However, arguing against this is the fact that other
members of the mTERF family also affect mitochondrial
transcript levels, including a recently reported case of
the SOLDAT10 protein in Arabidopsis chloroplasts, a
mutation in which appears to activate retrograde signal-
ing by decreasing plastid rRNA synthesis [48]. MOC1,
an mTERF family homologue in Chlamydomonas, is
required for maintaining mitochondrial RNA levels after
exposure to light, although its mechanism of action is
unknown and the broader phenotype of the mutant sug-
gests that the effect might be indirect [49].
Conclusions
In summary, our findings support a role for mTERF in
influencing mitochondrial transcription in vivo, even
though it does not appear to set the levels of mature
mitochondrial transcripts encoded by the PH1 and PH2
heavy-strand transcription units in a simple manner. It
appears to modulate the levels of antisense transcripts,
by implication regulating the extent of readthrough by
the transcriptional machinery of its high-affinity binding
site in the tRNALeu(UUR) gene, as well as other, weaker
mTERF binding sites in the vicinity. Further experi-
ments will now be required to resolve the functional sig-
nificance of this regulation, and its possible relevance to
DNA replication and other processes.
Methods
Cell-lines and cell culture
HEK293T cells and derivatives were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM, Sigma) as pre-
viously [16]. HEK293T-derived cell-clones over-
expressing natural mTERF were created by recloning
the mTERF coding sequence, including its natural stop
codon, into the expression vector pcDNA3.1/hygro(-)
(Invitrogen) as a BamHI/HindIII fragment. Aliquots of
the sequence-verified plasmid DNA (1 μg) were trans-
fected into HEK293T cells using Lipofectamine™ (Invi-
trogen) diluted in 1 ml of Opti-MEM® (Invitrogen)
according to the manufacturer’s protocol. Twenty four
hours later cells were either harvested (for transient
transfection) or placed under hygromycin selection (Cal-
biochem, 200 μg/ml). Hygromycin-resistant colonies
were grown up and tested for expression of the mTERF
transgene by reverse transcriptase (RT)-PCR and by
electrophoretic mobility shift assay (EMSA) as described
in Additional File 1. Flp-In™ T-Rex™ 293 cells trans-
fected with expression constructs for natural mTERF
and for epitope-tagged mTERF-MycHis, as well as their
induction by doxycycline, were as described previously
[16]. mTERF-specific RNA interference was induced by
siRNA for 48 h as described previously [16] or by trans-
fection (using Lipofectamine™ 2000, Invitrogen, manu-
facturer’s protocol) with a customized shRNA construct
(10 μg) targeting the following sequence within mTERF
mRNA (5’ to 3’): GCUGUAACUUGAGUACUUU, Open
Biosystems Expression Arrest™ pSM2 Retroviral shRNA-
mir Library, Oligo ID V2HS_95064 (Thermo Fisher
Scientific, Huntsville, AL, USA). shRNA-transfected cells
were harvested 48 h after transfection.
Depletion of mitochondrial RNA
Cells were passaged one day before adding ethidium
bromide (EtBr) so that the 60 × 15 mm plates were
approximately 50% confluent on the day of experiment.
EtBr was added to the medium to 250 ng/ml and the
cells were incubated for 48 h, after which the plates
were approximately 90% confluent. Cells were then pas-
saged at different densities so that each re-seeded plate
would reach approximately 70-80% confluence when
harvested for RNA extraction. RNA samples were col-
lected before EtBr treatment (day -2), on the day when
drug was washed away (day 0) and 24, 48, 72, 96 and
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120 h after removing EtBr (days 1-5). To ensure com-
plete removal of EtBr the medium was changed 3 h and
6 h after passaging the cells, and then again every day.
Where depletion was carried out in combination with
mTERF-directed RNA interference, siRNA transfection
was carried out prior to the addition of EtBr (day -2)
and was repeated 2 d after removal of the drug (day 2).
RNA extraction, electrophoresis and Northern blotting
Total RNA was extracted from cells using TRIzol®
Reagent (Invitrogen) according to the manufacturer’s
instructions. Any traces of DNA were removed by treat-
ment with RNase-free DNase I (GE Healthcare, manu-
facturer’s recommended conditions), followed by
standard acid phenol/chloroform extraction and isopro-
panol precipitation. For Northern blotting to tRNA
probes RNA samples were electrophoresed at 4°C over-
night at 100 V in neutral 12% acrylamide/7 M urea gels
in TBE buffer, electroblotted onto Zeta-Probe GT mem-
brane (Bio-Rad) at 4°C, u.v.-crosslinked and processed
as described previously [50]. Oligonucleotide probes for
mitochondrial tRNAs and cytosolic 5S rRNA were radi-
olabeled using T4 polynucleotide kinase (PNK, MBI Fer-
mentas) according to the manufacturer’s protocol and
[g-32P] ATP (Amersham Pharmacia Biotech, 3000 Ci/
mmol) and purified using mini Quick Spin Columns
(Roche). The probe oligonucleotide sequences were as
follows (all 5’ to 3’): 5S - GGGTGGTATGGCCGTA-
GAC, tRNALeu(UUR) - GTTTTATGCGATTACCGGGC
and tRNAPhe - CTAAACATTTTCAGTGTATTGC.
Hybridization, washing, autoradiography and phosphori-
maging (Phosphorimager SI, Molecular Dynamics) were
as described previously [51]. For re-probing, the mem-
branes were stripped by boiling in 0.5% SDS solution for
3 min and cooled to room temperature. For Northern
blotting to 16S rRNA or ND1 probes, RNA samples
were fractionated on formaldehyde agarose gels and pro-
cessed for blotting and hybridization as described pre-
viously [51], using probes labelled by random-priming
[50]. The template used for synthesis of the ND1 probe
was as described previously [50]; that for 16S rRNA was
the shorter ApaI digestion product (230 bp) from the
same fragment.
Quantitative RT-PCR
Quantitative RT-PCR was used to estimate the relative
amounts of 12S and16S rRNA, ND1 mRNA, cytosolic
18S rRNA and mTERF mRNA. For cDNA synthesis, 5
μg of RNA was reversed transcribed using 40 units of
M-MuLV reverse transcriptase (Fermentas), primed by
0.2 μg random hexamers (Pharmacia) in a 20 μl reaction
according to manufacturer’s instructions. Three dilu-
tions of each cDNA sample (1:10, 1:20 and 1:50) were
analysed, and each reaction was performed in three
technical replicates. PCR reactions were performed in a
LightCycler™ apparatus using LightCycler FastStart DNA
Master SYBR Green I kit (Roche) according to the man-
ufacturer’s instructions, with the following primer pairs
(all 5’ to 3’) and annealing temperatures: for 18S rRNA,
18Sfor3 - GACGATCAGATACCGTCGTA and 18Srev3
-TGAGGTTTCCCGTGTTGAGT, 52°C; for 16S rRNA,
16Sfor1 - GGTAGAGGCGACAAACCTACCG and
16Srev1 - TTTAGGCCTACTATGGGTGT, 50°C; for
ND1 mRNA, ND1for1 - GGCCAACCTCCTACTCC
and ND1rev1 - GATGGTAGATGTGGCGGGTT, 50°C.
cDNA synthesized from 5 μg of RNA pooled from dif-
ferent cell-lines was used to prepare the standard curve,
based on a five-fold dilution series. The homogeneity of
all products was checked after each run by melting
curve analysis. For strand-specific analysis to distinguish
antisense from sense transcripts, 20 pmol of specific pri-
mer (TIB MOLBIOL, Berlin, Germany, see Additional
File 1, Table S1) were used in the RT step. The PCR
step used custom-designed sets of primers and proxi-
mity-hybridization probes (TIB MOLBIOL, Berlin, Ger-
many, see Additional File 1, Table S1), with LightCycler
(R) FastStart DNA Master HybProbe kit (Roche),
according to manufacturer’s instructions, and annealing
temperatures listed in Additional File 1, Table S1 for
each primer pair. The homogeneity of the products was
checked after each run by melting curve analysis,
according to the annealing temperatures of the hybridi-
zation probes as listed in Additional File 1, Table S1.
Three dilutions (1:10, 1:20 and 1:50) were analysed from
each cDNA. The level of mTERF mRNA relative to 18S
rRNA was measured similarly, using hybridization probe
sets M1 and C1 (see Additional File 1, Table S1), except
that cDNA primed with random hexamers was used as
template.
Additional material
Additional file 1: Supplementary text, Table (S1) and Figures (S1,
S2, S3). All supplementary data is supplied as a single PDF file
containing the following items: Supplementary Methods, Legends to
Supplementary Figures, Supplementary Table (Table S1), Supplementary
Figures S1, S2 and S3.
Acknowledgements
We thank Academy of Finland, Sigrid Juselius Foundation and Tampere
University Hospital Medical Research Fund for financial support, and Outi
Kurronen, Merja Jokela and Tea Tuomela for technical assistance. We also
thank Hans Spelbrink, Ian Holt, Marina Toompuu, Gertjan Hakkaart, Anja
Rovio, Kia and Esko Kemppainen and Rimmy Manjiry for advice and useful
discussions.
Author details
1Institute of Medical Technology and Tampere University Hospital, FI-33014
University of Tampere, Finland. 2Research Program of Molecular Neurology,
FI-00014 University of Helsinki, Finland.
Hyvärinen et al. BMC Molecular Biology 2010, 11:72
http://www.biomedcentral.com/1471-2199/11/72
Page 10 of 12
Authors’ contributions
AKH performed the experimental work, assisted by MKK for Q-RT-PCR,
analyzed the data and co-drafted sections of the manuscript (Results,
Materials and Methods, Figure Legends). SKM co-designed the project and
co-supervised its initial stages. HTJ co-designed and supervised the project,
compiled the figures and drafted the manuscript. All authors saw and
approved the final version of the manuscript.
Received: 4 March 2010 Accepted: 16 September 2010
Published: 16 September 2010
References
1. Asin-Cayuela J, Gustafsson CM: Mitochondrial transcription and its
regulation in mammalian cells. Trends Biochem Sci 2007, 32:111-117.
2. Montoya J, Gaines GL, Attardi G: The pattern of transcription of the
human mitochondrial rRNA genes reveals two overlapping transcription
units. Cell 1983, 34:151-159.
3. Van Etten RA, Bird JW, Clayton DA: Identification of the 3’-ends of the two
mouse mitochondrial ribosomal RNAs. The 3’-end of 16 S ribosomal RNA
contains nucleotides encoded by the gene for transfer RNALeuUUR. J Biol
Chem 1983, 258:10104-10110.
4. Gaines G, Attardi G: Intercalating drugs and low temperatures inhibit
synthesis and processing of ribosomal RNA in isolated human
mitochondria. J Mol Biol 1984, 172:451-466.
5. Gaines G, Rossi C, Attardi G: Markedly different ATP requirements for
rRNA synthesis and mtDNA light strand transcription versus mRNA
synthesis in isolated human mitochondria. J Biol Chem 1987,
262:1907-1915.
6. Enríquez JA, Fernández-Silva P, Pérez-Martos A, López-Pérez MJ, Montoya J:
The synthesis of mRNA in isolated mitochondria can be maintained for
several hours and is inhibited by high levels of ATP. Eur J Biochem 1996,
237:601-610.
7. Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG,
Gustafsson CM: Mitochondrial transcription factors B1 and B2 activate
transcription of human mtDNA. Nat Genet 2002, 31:289-294.
8. Sologub M, Litonin D, Anikin M, Mustaev A, Temiakov D: TFB2 is a
transient component of the catalytic site of the human mitochondrial
RNA polymerase. Cell 2009, 139:934-944.
9. Fukuoh A, Ohgaki K, Hatae H, Kuraoka I, Aoki Y, Uchiumi T, Jacobs HT,
Kang D: DNA conformation-dependent activities of human mitochondrial
RNA polymerase. Genes Cells 2009, 14:1029-1042.
10. Kruse B, Narasimhan N, Attardi G: Termination of transcription in human
mitochondria: identification and purification of a DNA binding protein
factor that promotes termination. Cell 1989, 58:391-397.
11. Fernandez-Silva P, Martinez-Azorin F, Micol V, Attardi G: The human
mitochondrial transcription termination factor (mTERF) is a multizipper
protein but binds to DNA as a monomer, with evidence pointing to
intramolecular leucine zipper interactions. EMBO J 1997, 16:1066-1079.
12. Martin M, Cho J, Cesare AJ, Griffith JD, Attardi G: Termination factor-
mediated DNA loop between termination and initiation sites drives
mitochondrial rRNA synthesis. Cell 2005, 123:1227-1240.
13. Daga A, Micol V, Hess D, Aebersold R, Attardi G: Molecular characterization
of the transcription termination factor from human mitochondria. J Biol
Chem 1993, 268:8123-8130.
14. Christianson TW, Clayton DA: In vitro transcription of human
mitochondrial DNA: accurate termination requires a region of DNA
sequence that can function bidirectionally. Proc Natl Acad Sci USA 1986,
83:6277-6281.
15. Asin-Cayuela J, Schwend T, Farge G, Gustafsson CM: The human
mitochondrial transcription termination factor (mTERF) is fully active in
vitro in the non-phosphorylated form. J Biol Chem 2005, 280:25499-25505.
16. Hyvärinen AK, Pohjoismäki JL, Reyes A, Wanrooij S, Yasukawa T,
Karhunen PJ, Spelbrink JN, Holt IJ, Jacobs HT: The mitochondrial
transcription termination factor mTERF modulates replication pausing in
human mitochondrial DNA. Nucleic Acids Res 2007, 35:6458-6474.
17. Prieto-Martín A, Montoya J, Martínez-Azorín F: New DNA-binding activity
of rat mitochondrial transcription termination factor (mTERF). J Biochem
2004, 136:825-830.
18. Asin-Cayuela J, Helm M, Attardi G: A monomer-to-trimer transition of the
human mitochondrial transcription termination factor (mTERF) is
associated with a loss of in vitro activity. J Biol Chem 2004,
279:15670-15677.
19. Gelfand R, Attardi G: Synthesis and turnover of mitochondrial ribonucleic
acid in HeLa cells: the mature ribosomal and messenger ribonucleic acid
species are metabolically unstable. Mol Cell Biol 1981, 1:497-511.
20. Cantatore P, Flagella Z, Fracasso F, Lezza AM, Gadaleta MN, de Montalvo A:
Synthesis and turnover rates of four rat liver mitochondrial RNA species.
FEBS Lett 1987, 213:144-148.
21. Chomyn A, Martinuzzi A, Yoneda M, Daga A, Hurko O, Johns D, Lai ST,
Nonaka I, Angelini C, Attardi G: MELAS mutation in mtDNA binding site
for transcription termination factor causes defects in protein synthesis
and in respiration but no change in levels of upstream and downstream
mature transcripts. Proc Natl Acad Sci USA 1992, 89:4221-4225.
22. Shang J, Clayton DA: Human mitochondrial transcription termination
exhibits RNA polymerase independence and biased bipolarity in vitro. J
Biol Chem 1994, 269:9112-9120.
23. Viscomi C, Spinazzola A, Maggioni M, Fernandez-Vizarra E, Massa V,
Pagano C, Vettor R, Mora M, Zeviani M: Early-onset liver mtDNA depletion
and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum
Mol Genet 2009, 18:12-26.
24. Prieto-Martín A, Montoya J, Martínez-Azorín F: Phosphorylation of rat
mitochondrial transcription termination factor (mTERF) is required for
transcription termination but not for binding to DNA. Nucleic Acids Res
2004, 32:2059-2068.
25. Roberti M, Polosa PL, Bruni F, Manzari C, Deceglie S, Gadaleta MN,
Cantatore P: The MTERF family proteins: mitochondrial transcription
regulators and beyond. Biochim Biophys Acta 2009, 1787:303-11.
26. Park CB, Asin-Cayuela J, Cámara Y, Shi Y, Pellegrini M, Gaspari M, Wibom R,
Hultenby K, Erdjument-Bromage H, Tempst P, Falkenberg M, Gustafsson CM,
Larsson NG: MTERF3 is a negative regulator of mammalian mtDNA
transcription. Cell 2007, 130:273-285.
27. Wenz T, Luca C, Torraco A, Moraes CT: mTERF2 regulates oxidative
phosphorylation by modulating mtDNA transcription. Cell Metab 2009,
9:499-511.
28. Roberti M, Bruni F, Loguercio Polosa P, Manzari C, Gadaleta MN,
Cantatore P: MTERF3, the most conserved member of the mTERF-family,
is a modular factor involved in mitochondrial protein synthesis. Biochim
Biophys Acta 2006, 1757:1199-1206.
29. Pellegrini M, Asin-Cayuela J, Erdjument-Bromage H, Tempst P, Larsson NG,
Gustafsson CM: MTERF2 is a nucleoid component in mammalian
mitochondria. Biochim Biophys Acta 2009, 1787:296-302.
30. Loguercio Polosa P, Roberti M, Musicco C, Gadaleta MN, Quagliariello E,
Cantatore P: Cloning and characterisation of mtDBP, a DNA-binding
protein which binds two distinct regions of sea urchin mitochondrial
DNA. Nucleic Acids Res 1999, 27:1890-1899.
31. Fernandez-Silva P, Loguercio Polosa P, Roberti M, Di Ponzio B, Gadaleta MN,
Montoya J, Cantatore P: Sea urchin mtDBP is a two-faced transcription
termination factor with a biased polarity depending on the RNA
polymerase. Nucleic Acids Res 2001, 29:4736-4743.
32. Loguercio Polosa P, Deceglie S, Roberti M, Gadaleta MN, Cantatore P:
Contrahelicase activity of the mitochondrial transcription termination
factor mtDBP. Nucleic Acids Res 2005, 33:3812-3820.
33. Roberti M, Fernandez-Silva P, Loguercio Polosa P, Fernandez-Vizarra E,
Bruni F, Deceglie S, Montoya J, Gadaleta MN, Cantatore P: In vitro
transcription termination activity of the Drosophila mitochondrial DNA-
binding protein DmTTF. Biochem Biophys Res Commun 2005, 331:357-362.
34. Roberti M, Loguercio Polosa P, Bruni F, Musicco C, Gadaleta MN,
Cantatore P: DmTTF, a novel mitochondrial transcription termination
factor that recognizes two sequences of Drosophila melanogaster
mitochondrial DNA. Nucleic Acids Res 2003, 31:1597-1604.
35. Roberti M, Bruni F, Polosa PL, Gadaleta MN, Cantatore P: The Drosophila
termination factor DmTTF regulates in vivo mitochondrial transcription.
Nucleic Acids Res 2006, 34:2109-2116.
36. Enríquez JA, Fernández-Silva P, Garrido-Pérez N, López-Pérez MJ, Pérez-
Martos A, Montoya J: Direct regulation of mitochondrial RNA synthesis by
thyroid hormone. Mol Cell Biol 1999, 19:657-70.
37. Micol V, Fernández-Silva P, Attardi G: Functional analysis of in vivo and in
organello footprinting of HeLa cell mitochondrial DNA in relationship to
ATP and ethidium bromide effects on transcription. J Biol Chem 1997,
272:18896-188904.
Hyvärinen et al. BMC Molecular Biology 2010, 11:72
http://www.biomedcentral.com/1471-2199/11/72
Page 11 of 12
38. Maniura-Weber K, Goffart S, Garstka HL, Montoya J, Wiesner RJ: Transient
overexpression of mitochondrial transcription factor A (TFAM) is
sufficient to stimulate mitochondrial DNA transcription, but not
sufficient to increase mtDNA copy number in cultured cells. Nucleic Acids
Res 2004, 32:6015-6027.
39. Selwood SP, Chrzanowska-Lightowlers ZM, Lightowlers RN: Does the
mitochondrial transcription-termination complex play an essential role
in controlling differential transcription of the mitochondrial DNA?
Biochem Soc Trans 2000, 28:154-159.
40. Villegas J, Burzio V, Villota C, Landerer E, Martinez R, Santander M,
Martinez R, Pinto R, Vera MI, Boccardo E, Villa LL, Burzio LO: Expression of a
novel non-coding mitochondrial RNA in human proliferating cells.
Nucleic Acids Res 2007, 35:7336-7347.
41. Burzio VA, Villota C, Villegas J, Landerer E, Boccardo E, Villa LL, Martínez R,
Lopez C, Gaete F, Toro V, Rodriguez X, Burzio LO: Expression of a family of
noncoding mitochondrial RNAs distinguishes normal from cancer cells.
Proc Natl Acad Sci USA 2009, 106:9430-9434.
42. Mirkin EV, Mirkin SM: Replication fork stalling at natural impediments.
Microbiol Mol Biol Rev 2007, 71:13-35.
43. Rudolph CJ, Dhillon P, Moore T, Lloyd RG: Avoiding and resolving conflicts
between DNA replication and transcription. DNA Repair (Amst) 2007,
6:981-993.
44. Hyvärinen AK, Pohjoismäki JLO, Holt IJ, Jacobs HT: Overexpression of
MTERD1 or MTERFD3 impairs the completion of mitochondrial DNA
replication. Mol Biol Rep 2010.
45. Yasukawa T, Reyes A, Cluett TJ, Yang MY, Bowmaker M, Jacobs HT, Holt IJ:
Replication of vertebrate mitochondrial DNA entails transient
ribonucleotide incorporation throughout the lagging strand. EMBO J
2006, 25:5358-71.
46. Heller RC, Marians KJ: The disposition of nascent strands at stalled
replication forks dictates the pathway of replisome loading during
restart. Mol Cell 2005, 17:733-743.
47. Pomerantz RT, O’Donnell M: The replisome uses mRNA as a primer after
colliding with RNA polymerase. Nature 2008, 456:762-766.
48. Meskauskiene R, Würsch M, Laloi C, Vidi PA, Coll NS, Kessler F, Baruah A,
Kim C, Apel K: A mutation in the Arabidopsis mTERF-related plastid
protein SOLDAT10 activates retrograde signaling and suppresses (1)O
(2)-induced cell death. Plant J 2009, 60:399-410.
49. Schönfeld C, Wobbe L, Borgstädt R, Kienast A, Nixon PJ, Kruse O: The
nucleus-encoded protein MOC1 is essential for mitochondrial light
acclimation in Chlamydomonas reinhardtii. J Biol Chem 2004,
279:50366-50374.
50. Toompuu M, Tiranti V, Zeviani M, Jacobs HT: Molecular phenotype of the
np 7472 deafness-associated mitochondrial mutation in osteosarcoma
cell cybrids. Hum Mol Genet 1999, 8:2275-2283.
51. El Meziane A, Lehtinen SK, Hance N, Nijtmans LG, Dunbar D, Holt IJ,
Jacobs HT: A tRNA suppressor mutation in human mitochondria. Nat
Genet 1998, 18:350-353.
doi:10.1186/1471-2199-11-72
Cite this article as: Hyvärinen et al.: Effects on mitochondrial
transcription of manipulating mTERF protein levels in cultured human
HEK293 cells. BMC Molecular Biology 2010 11:72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hyvärinen et al. BMC Molecular Biology 2010, 11:72
http://www.biomedcentral.com/1471-2199/11/72
Page 12 of 12
1Effects on mitochondrial transcription
of manipulating mTERF protein levels in
cultured human HEK293 cells
Anne K. Hyvärinen, Mona K. Kumanto, Sanna K. Marjavaara, & Howard T. Jacobs
ADDITIONAL FILE 1
2SUPPLEMENTARY METHODS
Primer and probe sets for Q-RT-PCR using proximity-hybridization probes
See this file, Table S1.
Verification of mTERF transgene expression by RT-PCR
Ten mg of total RNA was used for cDNA synthesis using random hexamers (Pharmacia) and
M-MLV reverse transcriptase (Invitrogen) in a 20 ml reaction (manufacturer’s recommended
conditions). For PCR 2 ml of the RT reaction mix was used in a 25 ml reaction containing 0.4
mM dNTPs (Fermentas), 0.4 mM of both primers and 2 u of Dynazyme DNA polymerase
(Finnzymes). Transgene-specific primers were (all 5´ to 3 )´: (BGH –
TAGAAGGCACAGTCGAGGC  and mTERF465F – CGAGCAATAACACGTACTCC; 18S
specific primers were:  18S-F – TACCTGGTTGATCCTGCCAG and 18S-R –
TCGGGAGTGGGTAATTTGC.    To exclude possible contaminating DNA, PCR with 18S
primers was routinely carried out on each RNA sample, alongside a DNA positive control.
Verification of mTERF transgene expression by EMSA
EMSA was carried out as described previously [16], using probe ‘Leu-short’ for the mTERF
high-affinity binding site, 5 µg of protein in mitochondrial lysate and 5 µg of non-specific
competitor poly(dI-dC)–(dI-dC) (Amersham Pharmacia Biotech).
Western blotting to confirm induction of mTERF-MycHis
Western blotting to detect the mTERF-MycHis fusion protein in Flp-InTM T-RExTM-293 cells
transfected with the mTERF-MycHis construct was performed as previously [16].
3Image processing
Western blot and gel images are cropped to show relevant bands. In some cases brightness and
contrast were adjusted to make the images optimally visible, but no gamma correction was
performed and no other manipulations were done. Non-adjacent tracks of the same gel are
shown separately, alongside each other.
4SUPPLEMENTARY FIGURE LEGENDS
Figure S1
Manipulation of mTERF expression and effects on steady-state levels of mature
mitochondrial RNAs
(A) Verification of expression of mTERF transgene in transfected cell clones, by RT-PCR,
using primers specific for the transgene (mTERF 465F and BGH), and for 18S rRNA (18S-F
and 18S-R) as loading control, as described in Supplementary Materials and Methods. RNA
was extracted from clones, numbered as shown, of hygromycin-resistant cells transfected with
the natural mTERF expression construct described previously [16]. – denotes water control, H
untransfected HEK293T cells and M the marker ladder.  Clone 23 is included here as an
example of a clone negative for expression, which was not selected for use in the experiment
shown in Fig. 1B. Panels shown alongside each other are aligned, non-adjacent tracks from the
same gel.  (B) Overexpression of mTERF at the protein level was verified by EMSA using a
probe for the high-affinity mTERF binding site, together with mitochondrial protein extracts
from clones, numbered as shown, of hygromycin-resistant cells transfected with the mTERF
expression construct, plus v – empty vector-transfected cell clone and tr – cells transiently
transfected with the  mTERF expression construct. – denotes buffer-only control.  Clone 7 is
included here as an example of a clone negative for expression at the protein level, which was
not selected for use in the experiment shown in Fig. 1B. The unbound and bound probe
migrated as indicated. The specificity of binding was verified as previously, using cold
competitor. Panels shown alongside each other are aligned, non-adjacent tracks from the same
(two) gels.  (C) Northern blots of RNA samples as indicated, probed for mitochondrial
tRNAPhe, tRNALeu(UUR) and cytosolic 5S rRNA as shown. Data from the blots is compiled as
Fig. 1E, based on phosphorimaging. The three equivalent samples loaded alongside each are
independent RNA preparations from biological replicates.
5Figure S2
Effects of mTERF overexpression on mitochondrial transcript levels during EtBr-
induced depletion and recovery
Representative series of Northern blots probed successively for mitochondrial tRNAPhe and
tRNALeu(UUR) and for 5S rRNA as indicated. Similar sets of blots were used to compile
phosphorimager data for the graphs shown in (B) and (C) and in Fig. 2. RNA was from
mTERF overexpresor (OE) clone 3, as characterized in Fig. S1, and the same empty vector-
transfected clone as used in the experiment of Fig. S1B. Day -2 indicates sample taken
immediately before addition of EtBr to the culture to induce depletion of mitochondrial RNA.
Day 0 indicates sample taken 48 h later, immediately after EtBr was washed out from the
culture.  Days 1-5 indicate the period of subsequent recovery. (B), (C) Relative expression of
mitochondrial transcripts in cells overexpressing mTERF, based on phosphorimaging of
Northern blots probed successively for mitochondrial tRNAPhe, tRNALeu(UUR) and 5S rRNA.
Data (means + SD) are ratios of tRNAPhe to 5S rRNA (F/5S) normalized to the ratio at the start
of the experiment (time-point -2 d). (B) Cells stably transfected with empty-vector or mTERF
overexpression (OE) construct (clone 3, as shown in Fig. S1), sample blots shown in Fig. S2A.
(B) Cells treated with mTERF-specific siRNA (or mock-transfected) prior to the addition of
EtBr (day -2) and again 2 days after removal of EtBr (day 2).  Days 1-5 indicate the period of
subsequent recovery. For equivalent data on ratio of tRNAPhe to tRNALeu(UUR) from the same
experiment see Fig. 2. Note that this experiment only measures changes in the tRNA ratio
during the experiment, but does not allow to extrapolate an absolute ratio of the two tRNAs,
since the hybridization efficiency of the two probes may differ. Moreover, to control rigorously
for loading differences we used the same blot in each case for reprobing after stripping.
Impressionistically, we found nothing to contradict the findings of King and Attardi (J. Biol.
Chem. 268:10228;1993) that tRNAPhe is expressed normally at a higher level than
tRNALeu(UUR).
6Figure S3
Manipulation of mTERF expression affects the relative levels of antisense but not sense
transcripts of the 16S rRNA and ND1 genes
(A) Schematic diagram of the 16S rDNA and ND1 region of human mtDNA. For full details of
Q-RT-PCR primer sequences and location, see Table S1.  The same primer sets were used to
assay levels of sense and antisense transcripts, except that reverse transcription step was
carried out with the relevant strand-specific primer in each case.  (B) Relative steady-state
levels of anti-16S and anti-ND1 transcripts, as determined by Q-RT-PCR (primer sets R2 and
N2), using hybridization of proximity probes, under various manipulations of the level of
mTERF, i.e. the same mTERF overexpressor clone (OE) that exhibited a statistically
significant decrease in anti-16S:anti-ND1 ratio using primer sets R1 and N1 (Fig. 3B),
compared with cells transfected with empty vector, and HEK293T cells transfected with
mTERF-targeted shRNA versus mock-transfected cells.  In each case, data were normalized to
the corresponding control cells. * denotes statistically significant differences from control cells
(t test, p < 0.02). The alterations in the anti-16S:anti-ND1 ratio were qualitatively similar to
those obtained in similar experiments using primer sets R1 and N1 (Fig. 3B), although
quantitatively slightly lower.  (C) As an additional control we validated the earlier findings
regarding sense transcripts, using Q-RT-PCR with primer sets R2 and N2 combined with
hybridization of proximity probes, under the various manipulations of the level of TERF used
in the corresponding experiment on antisense transcripts (Fig. 3B). None of the comparisons
showed any significant difference (t test, p > 0.05). To validate the primer sets and RNA
preparations used in the Q-RT-PCR experiments of Fig. 3B and Fig. S3B, C, we conducted a
series of controls illustrated by the gels shown in (D).  Firstly, the 16S and ND1 primer sets
used for reverse transcription and PCR were tested alongside total cell DNA to verify that they
gave rise only to a single PCR product of the correct size when cDNA primed with either
primer of the set was amplified subsequently amplified with both  (panels i and ii). This was
7also checked by melting-curve analysis after PCR and proximity-probe hybridization.
Secondly, the purity of each RNA preparation was checked by standard PCR, using the primer
pairs employed, plus a primer pair for 18S rDNA, as shown here (panel iii), and thus shown to
be free of DNA contamination.  Thirdly, we excluded that the failure to detect such
contaminating DNA was due to inhibition by RNA in the sample, by repeating the analysis
after the RNA had been treated with boiled RNase A (panel iv). The shRNA construct used in
the experiments shown in Fig. 3B and Fig. S3B, C differs from the siRNA used in the earlier
experiments. Therefore, prior to use in this context, the effects of transfection of the shRNA
were validated using doxycyclin-induced Flp-InTM T-RexTM-293 cells transfected with the
tagged mTERF-MycHis expression construct [16] and Western blotting. As shown (E), shRNA
constructs mTERF.1 and 5 both effected knockdown, and shRNA mTERF.1 (the construct
described under Materials and Methods in the main paper) was selected for use in the
experiments shown in Fig. 3B and S3B, C. Note that the knockdown experiments in the main
paper, shown in Fig. 3, used normal HEK293T  cells, not mTERF-MycHis transfected cells.
The latter were used only for initial selection of the appropriate shRNA construct.
8SUPPLEMENTARY TABLES
Table S1
Primer/probe set Primer/probe ID, purpose Sequence (5´ to 3´) Annealing
Temp (°C)
Humit16S-fw, primer on antisense template GGTAGAGGCGACAAACCTACCG 55
Humit16S-as, primer on sense template TAGTGGGTGTTGAGCTTGAACG 55
Humit16S-FL, probe GGTTCTGTGGGCAAATTTAAAGTTGAACTAAGA-FL 60
R1
Humit16S-LC, probe LC640-TCTATCTTGGACAACCAGCTATCACCAGG-P 60
mtND1-se, primer on antisense template CCAACCTCCTACTCCTCATTGTAC 51
mtND1-rev, primer on sense template GATGGTAGATGTGGCGGGTT 51
mtND1-FL, probe GGGCCTTTGCGTAGTTGTATATAGCCT-FL 57
N1
mtND1-LC, probe LC640-GAATTTTTCGTTCGGTAAGCATTAGGAAT-P 57
916S F, primer on antisense template AGAGAGTAAAAAATTTAACACCCAT 47
16S A, primer on sense template TTCTATAGGGTGATAGATTGGTCC 47
16S FL, probe AAGCTCAACACCCACTACCTAAAAAA-FL 55
R2
16S LC, probe LC640-CCCAAACATATAACTGAACTCCTCACACC-P 55
ND1_F, primer on antisense template CCTCATTGTACCCATTCTAATC 45
ND1_R, primer on sense template CGTAGTTTGAGTTTGATGCT 45
ND1_FL, probe CGCCACATCTACCATCACCCTCTACA-FL 60
N2
ND1_LC, probe LC640-CACCGCCCCGACCTTAGCTCT-P 60
12SF101, primer on antisense template TAGAGGAGCCTGTTCTGTAATCGA 52
12SB211, primer on sense template TGCGCTTACTTTGTAGCCTTCAT 52
12S FL, probe CGATCAACCTCACCACCTCTTGCTC-FL 60
T1
12S LC640, probe LC640-CCTATATACCGCCATCTTCAGCAAACCC-P 60
10
MTERF S, primer for sense strand GCAGAGCCTTTCCTTAGGAC 50
MTERF A, primer for antisense strand GTCATCCAACATCTTGAACCAA 50
MTERF FL, probe AGGTTTCCTGGTGCCATAATGGT-FL 56
M1
MTERF LC, probe LC640-AGGTAGTTCAAACCTTTTGAAATGCTTGT-P 56
18S for, primer on antisense template ACGRACCAGAGCGAAAGCAT 52
18S rev, primer on sense template GGACATCTAAGGGCATCACAGAC 52
18S FL, probe TCGGAACTACGACGGTATCTGATCGTC-FL 59
C1
18S LC, probe LC640-CGAACCTCCGACTTTCGTTCTTGAT-P 59
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ABSTRACT
Mitochondrial transcription factor A (TFAM) is
an abundant mitochondrial protein of the HMG
superfamily, with various putative roles in mito-
chondrial DNA (mtDNA) metabolism. In this study
we have investigated the effects on mtDNA replica-
tion of manipulating TFAM expression in cultured
human cells. Mammalian mtDNA replication inter-
mediates (RIs) fall into two classes, whose mecha-
nistic relationship is not properly understood.
One class is characterized by extensive RNA incor-
poration on the lagging strand, whereas the other
has the structure of products of conventional,
strand-coupled replication. TFAM overexpression
increased the overall abundance of RIs and
shifted them substantially towards those of the
conventional, strand-coupled type. The shift was
most pronounced in the rDNA region and at various
replication pause sites and was accompanied by
a drop in the relative amount of replication-
termination intermediates, a substantial reduction
in mitochondrial transcripts, mtDNA decatenation
and progressive copy number depletion. TFAM
overexpression could be partially phenocopied by
treatment of cells with dideoxycytidine, suggesting
that its effects are partially attributable to a decrea-
sed rate of fork progression. TFAM knockdown
also resulted in mtDNA depletion, but RIs remained
mainly of the ribosubstituted type, although termi-
nation intermediates were enhanced. We propose
that TFAM influences the mode of mtDNA replica-
tion via its combined effects on different aspects of
mtDNA metabolism.
INTRODUCTION
In mammalian cells, mitochondrial DNA (mtDNA) was
long believed to replicate by an unusual, strand-asymmetric
mechanism (1). However, recent studies, using two-
dimensional neutral agarose gel electrophoresis (2DNAGE),
have revealed the presence, both in vertebrate tissues and
cultured cells, of two classes of mtDNA replication inter-
mediates (RIs) whose structures are not consistent with
the strand-asymmetric model. Both classes are essentially
duplex throughout their length, but differ in their ribo-
nucleotide content (2,3). One class shows extensive RNA
incorporation on the lagging strand [ERIOLS, Ref. (2)],
whereas the other has structures fully consistent with
conventional, strand-coupled DNA replication (3–5). ERI-
OLS intermediates are generally nicked or gapped on the
RNA strand (2) and are hence labile to partial degradation
during extraction.
The mechanistic relationship between RIs of the ERIOLS
and strand-coupled types, as well as how they relate to the
‘orthodox’, strand-asymmetric replication model, are not
properly understood. ERIOLS intermediates have been
suggested to be processed to resemble those of the strand-
coupled type via a maturation step (2). Different replication
modes may also operate simultaneously in the same cell. In
solid tissues, strand-coupled replication appears to initiate
bidirectionally in a broad origin zone, spanning at least
several kilobases downstream of the major non-coding region
(NCR) of the genome (5,6). In cultured cells recovering from
drug-induced mtDNA depletion, such initiation is confined to
a much narrower region of the NCR (3). The initiation
mechanism which gives rise to RIs of the ERIOLS type
remains unclear. Initiation within the NCR can also give
rise to the synthesis of 7S DNA (1), which establishes the
characteristic D-loop form of mtDNA, although its relation-
ship with productive replication of the genome remains
enigmatic.
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The mitochondrial transcription factor TFAM, an abundant
HMG-box protein of mitochondria, appears to have multiple
functions in mtDNA metabolism (7). It was originally
characterized by the absolute requirement for the protein
for transcriptional initiation in vitro at either the heavy- or
light-strand promoter of the genome (8). More recently,
these findings were confirmed using a fully reconstituted
system, containing mtDNA-derived templates, RNA poly-
merase and the additional transcription factor TFB1M or
TFB2M (9). Transcription from the light-strand promoter is
required to create the primer for heavy-strand mtDNA
synthesis according to the orthodox, strand-asymmetric
replication model. Therefore TFAM has been considered to
be an essential protein also for mtDNA replication. Consis-
tent with this view, abolition of TFAM expression using a
conditional knockout strategy in the mouse showed clearly
that TFAM is required for mtDNA maintenance as well as
cellular function and survival (10). However, this finding is
also consistent with TFAM protein having other essential
roles in mtDNA metabolism.
TFAM has been proposed to play a structural role in the
maintenance of the mitochondrial chromosome, independent
of its transcriptional activity. It is highly abundant, is mainly
(or entirely) complexed with mtDNA in nucleoid structures
(11,12), shows significant, non sequence-specific DNA-
binding (8) and promotes DNA compaction (13), leading to
the suggestion that it coats the entire DNA in a manner simi-
lar to histones in the eukaryotic nucleus or the HU protein
in bacteria (14). Its homologue in yeast, Abf2p, has been
shown to induce compaction by introducing sharp bends
into the DNA backbone (15) and is required for the stable
maintenance of wild-type mtDNA (16).
Mammalian TFAM has preference for binding to branched
DNA structures such as Holliday junctions (17) and to
cisplatin-damaged or oxidized DNA (18). In vitro, TFAM
promotes the resolution of D-loop forms (19). It also interacts
physically with p53 [Ref. (20)], suggesting a possible func-
tion in DNA repair or other recombinational processes.
Although it does not have a directly protective role, TFAM
overexpression in rat myoblasts has been reported to acceler-
ate the recovery of mtDNA levels after peroxide damage (21)
and transgenic expression of human TFAM in mice mitigates
mtDNA loss and other mitochondrial defects after cardiac
ischemia (22). In yeast, Abf2p is required for recombination
and segregation of mtDNA to daughter cells (23) and genetic
evidence also implicates it in non-recombinational mtDNA
repair pathways (24). All of these pieces of evidence point
to TFAM and its homologues being key regulators of DNA
transactions in mitochondria.
In organello, TFAM imported into rat liver mitochondria
stimulates the synthesis both of mitochondrial RNAs (25)
and 7S DNA (26). Transient overexpression of TFAM in
cultured HEK cells also results in increased transcription,
but with no change in mtDNA copy number (27). However,
high levels of TFAM added exogenously in vitro (9,28,29), as
well as prolonged over expression in HEKcultured cells (27),
bring about a paradoxical decrease in transcription. This
effect may be attributable to an over-condensed state in
the template DNA. The transient increase in mitochondrial
transcription brought about by TFAM over-expression in
HEK cells is accompanied by an increased level of RNase
H-sensitive mtDNA species (27), which may correspond
with RIs of the ERIOLS type.
Several lines of evidence suggest that TFAM regulates
mtDNA copy number independently of its role(s) in trans-
cription. Heterozygosity for TFAM knockout produces copy
number depletion of 40% in mice (10) and 50% in chicken
cells (30), but with minimal effects on RNA levels. Although
human TFAM has only a weak transcription-stimulatory
effect on mouse mtDNA promoters in vitro, transgenic
expression of human TFAM in mice produces a stoichio-
metric increase in mtDNA levels (31). Overexpression of a
transcriptionally inert variant of TFAM in human cells also
results in a proportionate copy number increase (14), whilst
TFAM knockdown by RNA interference (RNAi) causes
copy number depletion with only minor effects on trans-
cription per template molecule (14). In chicken cells in
which the endogenous c-TFAM gene has been disrupted,
transgenic c-TFAM lacking the C-terminal tail region
required for transcription-promoting activity is nevertheless
able to support maintenance of mtDNA at 50% of wild-
type levels (30).
The idea that TFAM regulates mtDNA copy number by a
simple titration model is, however, contradicted by the obser-
vation that, following transient, ethidium bromide (EtBr)-
induced mtDNA depletion in cultured cells, TFAM levels
were observed to recover more slowly than mtDNA. This
suggests that the packing ratio of TFAM on mtDNA can
vary and may influence the rate of mtDNA replication (32).
In order to investigate further the effects and mode of
action of TFAM on mtDNA replication and copy number
modulation, we analysed mitochondrial RIs from cells over-
expressing TFAM and from cells in which TFAM expression
was knocked down by RNAi. We report here that overexpres-
sion of TFAM brings about a dramatic change in the
relative abundance of strand-coupled versus ribosubstituted
(ERIOLS-type) RIs, accompanied by systematic alterations
in copy number, transcript levels and mtDNA topology.
In contrast, TFAM knockdown results in copy number
depletion, but with only minimal effects on mtDNA RIs.
The findings are consistent with the idea that the synthesis
of mtDNA is dependent on at least two different
TFAM-influenced processes, one of which is transcription-
associated, the other related to mtDNA organization.
MATERIALS AND METHODS
TFAM constructs
Full-length TFAM cDNA lacking its usual stop codon
was amplified from a cDNA clone (27, kind gift of
Dr R. Wiesner), using the following primers (restriction
sites as indicated, underlined, start codon in bold italics):
50-CCGGAATCCGCGATGGCGTTTCTCCGAAGC-30
(EcoRI) and 50-CGCGGATCCACACTCCTCAGCACCAT-
ATTTTCG-30 (BamHI)
The restriction-digested PCR product was ligated into
EcoRI + BamHI-cut pcDNA3.1()Myc-HisA (Invitrogen)
to create the construct mtTFA-myc, capable of directing
the expression of C-terminally Myc-His epitope-tagged
TFAM. The full-length TFAM cDNA, including the natural
stop codon, was amplified using the following primers
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(restriction sites as indicated, underlined, plus start and stop
codons in bold italics):
50-CCCAAGCTTGCGATGGCGTTTCTCCGAAGC-30
(HindIII) and 50-CGCGGATCCTTAACACTCCTCAGCAC-
CATATTTTC-30 (BamHI).
The restriction-digested PCR product was ligated into
HindIII + BamHI-cut pcDNA3.1(+) vector, to create the
construct mtTFApcDNA3.1 for transient expression.
In order to create cell lines inducibly expressing either
natural TFAM or C-terminally Myc epitope-tagged TFAM,
the two plasmids described above were digested with PmeI
and the liberated inserts recloned into the vector pcDNA5/
FRT/TO (Invitrogen), which was then transfected into the
Flp-InTM T-RexTM-293 host cell line (Invitrogen) according
the manufacturer’s recommendations. Full details of the
use of this system to create cell lines inducibly expressing
proteins involved in mtDNA metabolism will be published
elsewhere (S. Wanrooij et al., manuscript in preparation).
siRNAs for TFAM knockdown
TFAM siRNAs were synthesized using the SilencerTM siRNA
construction kit (Ambion). Six putative TFAM-specific
siRNA sequences were selected using the manufacturer’s
prediction programme (www.ambion.com/techlib/misc/
siRNA_finder.htlm). After testing by transfection and western
blotting (see below), two were found to be efficient. The
sequences of the relevant mRNA targets were as follows.
Si2: 50-AAGTTGTCCAAAGAAACCTGT-30 (np 273–293
of the TFAM mRNA sequence, Genbank NM_003201) and
Si4: 50-AAGATGCTTATAGGGCGGAGT-30 (np 431–451,
exon 4). See legend to Supplementary Figure 3 for details
of other siRNAs tested in trial experiments.
Cell-culture and transfection
HEK293T and Flp-InTM T-RexTM-293 cells (Invitrogen)
were cultured in DMEM containing 4.5 g/l glucose, 2 mM
L-glutamine, 1 mM sodium pyruvate, 50 mg/ml uridine and
10% fetal bovine serum, at 37C in a humidified atmosphere
with 5% CO2 in air. No antibiotics were added for HEK293T
cells, but transgenes in Flp-InTM T-RexTM-293 cells were
maintained under selection with hygromycin and blasticidin
according to the manufacturer’s recommendations. All cell
lines were routinely detached by pipetting alone and passaged
at 1:10 dilution every 3–4 days. TFAM transgene expression
was induced by adding 10 ng/ml doxycyclin (Sigma-Aldrich)
to the culture medium for the times indicated in the
Figures and legends. Transfections were carried out using
TransFectinTM-lipid reagent (Bio-Rad), following the manu-
facturer’s recommended procedure, with 12 mg of plasmid
DNA and 40 ml of reagent, both in 1.5 ml of serum-free
medium, per 10 ml plate.
For TFAM knockdown, HEK293T cells were transfected
using LipofectamineTM 2000 (Invitrogen) and a final concentra-
tion of 20 nM of siRNA. To arrest mtDNA synthesis by chain
termination, cells were treated for various times in medium
containing 100 mM dideoxycytidine (Sigma-Aldrich). To
suppress both mtDNA copy number and mitochondrial trans-
cription, cells were treated with medium containing EtBr
(50 ng/ml) for 72, after which cells were washed and replated
in fresh medium, then cultured for a further 48 h.
DNA and RNA extraction and quantitation
For mtDNA copy number analysis, total cellular DNA was
extracted using standard techniques (33). Copy number was
assessed independently by two different methods, to mini-
mize possible artefacts. For Southern blotting, total DNA
was cut by EcoRI and analyzed as described in Ref. (34),
with quantitation by phosphorimaging (Storm 840 scanner
and ImageQuant 5.1 software, all from Molecular Dynamics).
Copy number was also estimated by real-time quantitative
PCR (35) with Taqman probes for mitochondrial cytochrome
b and for amyloid precursor protein (APP), used as a single-
copy nuclear DNA standard. Primers and probes were as
follows (all 50–30): APP Forward: TTTTTGTGTGCTCTCC-
CAGGTCT, APP Reverse: TGGTCACTGGTTGGTTGGC,
APP Probe (FAM+BHQ): CCCTGAACTGCAGATCACCA-
ATGTGGTAG, Cyt-b Forward: GCCTGCCTGATCCTCC-
AAAT, Cyt-b Reverse: AAGGTAGCGGATGATTCAGCC,
Cyt-b Probe (TET+BHQ): CACCAGACGCCTCAACC-
GCCTT.
RNA extraction from cells, agarose or urea–PAGE and
Northern hybridization were as described previously
(34,36). Probes were 32P end-labelled oligonucleotide as
follows (50–30): for ND3 mRNA, GTCACTCATAGGCCAG-
ACTT, for 5S rRNA (loading control), GGGTGGTATGGC-
CGTAGAC, for tRNALeu(UUR) and tRNATyr as described
previously (37). Quantitation was by phosphorimaging as
for mtDNA copy number.
For the preparation of mtDNA (mitochondrial nucleic
acids) for analysis of RIs, mitochondria were isolated from
cells essentially as described by Spelbrink et al. (38). Briefly,
cells from 10 to 20, 14 cm plates were collected by pipetting
in PBS, centrifugation at 400 gmax for 3 min at room tempera-
ture and transfer to ice. The cell pellet was resuspended by
gentle pipetting in two volumes of ice-cold 0.1· homogeniza-
tion buffer (4 mM Tris–HCl, pH 7.8, 2.5 mM NaCl, 0.5 mM
MgCl2), kept on ice for 5 min and homogenized in a glass
homogenizer with 20 strokes of a tight-fitting pestle. Disrup-
tion of the cells was monitored by microscopy. One-ninth
volume of 10· homogenization buffer was added and nuclei
and cell debris were pelleted by sequential centrifugations at
1200 gmax for 3 min at 4
C until no pellet was visible.
Mitochondria from the post-nuclear supernatants were recov-
ered by centrifugation at 16 000 gmax for 10 min at 4
C.
The mitochondrial pellet was washed once in resuspension
buffer (10 mM Tris–HCl pH 7.4, 0.32 M sucrose, 1 mM
EDTA, 5 mM MgCl2) and re-centrifuged at 16 000 gmax for
10 min at 4C. The pellet was placed immediately on ice
and resuspended thoroughly in 500 ml of DNA extraction
buffer (25 mM EDTA pH 8.0, 75 mM NaCl) followed by
the addition of 50 ml 10% SDS with gentle mixing and
incubation on ice for a further 10 min. An equal volume
of phenol:chloroform:isoamyl alcohol (25:24:1, pH 8,0) was
added and the tube was shaken gently overnight at 4C on a
rotatory shaker, then centrifuged at 5000 gmax for 15 min at
4C. The aqueous phase was transferred to a fresh tube and
phenol extraction repeated several times until the interface
was clear, after which 0.2 vol. 10 M ammonium acetate
and 2 vol. 80% EtOH were added to the final aqueous
phase. The solution was gently mixed, incubated on ice for
15 min and centrifuged at 5000 gmax for 15 min at 4
C.
The precipitated nucleic acids were washed once with 80%
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EtOH and centrifuged at 5000 gmax for 5 min at 4
C min. The
pellet was air- dried, dissolved in 80 ml of TE buffer and
stored at 4C.
Enzymatic treatment of DNA
MtDNA samples were treated with the following DNA-
modifying enzymes under conditions recommended by the
manufacturers: T7 gp3 endonuclease (New England Biolabs),
topoisomerase I (New England Biolabs) and topoisomerase
IV (John Innes Enterprises).
Two-dimensional neutral agarose gel electrophoresis
One microgram of total mitochondrial nucleic acids was used
per analysis. Restriction digestions were performed following
manufacturers’ recommendations, except for BclI which
was carried out at 37C for double the usual reaction time.
If subsequent nuclease treatments were used, DNA was first
recovered by ethanol precipitation and resuspended in the
appropriate reaction buffer, before treatment with 50 U of
RNaseI (New England Biolabs), 2 U of RNaseH (Promega),
each for 1 h at 37C or 50 U S1 Nuclease (Promega) for 30 s.
Reactions were stopped by the addition of an equal volume of
phenol–chloroform–isoamyl alcohol (25:24:1, pH 8.0) and
immediately extracted. 2DNAGE was performed essentially
as described in Kajander et al. (39). The first-dimension
was run without EtBr in a 0.4% agarose gel in TBE buffer,
1.2 V/cm for 24 h at 4C. The gel was stained with EtBr
(300 ng/ml) in TBE. Individual lanes were cut out, rotated
90 and 1.0% agarose containing 300 ng/ml EtBr, precooled
to 55C, was cast around them. The second dimension was
run at 6 V/cm for 5 h at 4C with constant buffer recircu-
lation. For analysis of high molecular weight fragments
(e.g. 16.6 kb mtDNA linears), the first-dimension gels were
0.28% agarose, run at 1.4 V/cm for 24 h at room temperature,
with the second dimension in 0.58% agarose, 300 ng/ml EtBr,
run at 2.6 V/cm for 67 h at room temperature with constant
buffer recirculation. Gels were processed for Southern
blotting using standard procedures.
Radiolabelled probes and blot hybridization
For Southern hybridization, the following probes were
created by Pfu-PCR, using cloned segments of human
mtDNA as template and subsequently sequenced to
confirm their identity: OH (np 35–611, Anderson et al.,
1981), ND2 (np 4480–4988), A8-6 (np 8460–9107), ND4
(np 11 161–11 640) and ND5 (np 12 992–13 670).
Probes were labelled using RediprimeTM II random prime
labelling kit (Amersham) and [a-32P]dCTP (Amersham;
3000 Ci/mmol).
Sub-fractionation of mitochondria
For assaying the localization of recombinant TFAM the
mitochondrial pellet, prepared as above, was resuspended in
2 vol. of lysis buffer (0.25 M sucrose, 20 mM Tris–HCl,
pH 7.6, 2 mM EDTA, 7 mM b-mercaptoethanol). Mitochon-
dria were lysed by adding 20% NP40 to a final concentration
of 0.5% (v/v) with incubation on ice for 1 h. After centri-
fugation at 16 000 gmax for 10 min at 4
C the pellet and
supernatant fractions were processed for SDS–PAGE.
SDS–PAGE and western blotting
SDS–PAGE used 7.5–12% polyacrylamide (Laemmli) gels
under standard conditions. Sample preparation, western
blotting and immunodetection were carried out as described
previously (38). Primary antibodies used were: mouse anti-
Myc monoclonal 9E10 (Roche Molecular Biochemicals),
1:15 000 dilution of a 5 mg/ml stock, rabbit anti-human
TFAM (kind gift of Dr R. J. Wiesner), 1:10 000 dilution
and mouse anti-a-actinin monoclonal AT6/172 (Upstate)
1:5000 of a 1 mg/ml stock. Signals were quantified using a
ChemiDoc XRS chemiluminescence detection instrument
and associated QuantityOne software.
RESULTS
Effects on mitochondrial nucleic acids of modulating
TFAM expression levels in vivo
We manipulated TFAM expression levels in cultured human
cells using transient or inducible expression of epitope-tagged
or untagged TFAM, as well as TFAM knockdown by RNAi
(Figure 1, see also Supplementary Figures 1–3). Transient
expression (data not shown) produced essentially the same
effects on all parameters studied as inducible over-expression
using the Flp-In T-Rex system, although with less quanti-
tative reproducibility. Inducible over-expression of TFAM
carrying a C-terminal MycHis tag produced qualitatively
similar but quantitatively more dramatic effects, namely
a small but transient increase in mtDNA copy number,
followed by progressive mtDNA depletion. After 10 days
of full induction (10 ng/ml doxycyclin, full details on the
use of the induction system to be published elsewhere,
Wanrooij et al., manuscript in preparation), TFAM-MycHis
expression resulted in the reduction of mtDNA levels to
20% of control levels. Over-expression of TFAM with its
normal stop codon (TFAM-stop) caused a decrease in
mtDNA copy number of 40–60%. Copy number depletion
was verified by two independent methods, real-time PCR
and phosphorimaging of Southern blots (Supplementary
Figures 1 and 2).
Although the absolute amount of TFAM protein did not
increase markedly during induction, measured relative to a
loading control (Supplementary Figures 1 and 2), the progres-
sive drop in mtDNA copy number means that the amount of
TFAM protein per mtDNA molecule did increase substan-
tially and consistently during induction: in the case of
TFAM-stop to over twice the endogenous level, in the case
of TFAM-MycHis by an order of magnitude. Crude fractiona-
tion of mitochondrial protein lysates by sucrose density-
gradient centrifugation (Supplementary Figure 2) showed
that over-expressed TFAM-MycHis partitioned, like endo-
genous TFAM, mainly into the pellet fraction, forming
high-molecular weight complexes in the same proportion as
endogenous TFAM, indicating that it is likely complexed
with mtDNA.
Previous experiments in vitro and in organello have
suggested that a large excess of TFAM can suppress rather
than activate transcription. We measured the steady-state
levels of various mitochondrial transcripts using northern
blot analysis (Supplementary Figures 1 and 2 and other
5818 Nucleic Acids Research, 2006, Vol. 34, No. 20
data not shown), under conditions where over-expression
of TFAM-stop or TFAM-MycHis was induced in vivo.
The level of short-lived mRNAs such as ND3 showed a
marked decline even relative to the decreased amount
of mtDNA. Although modulation of post-transcriptional
processing and RNA stability contribute to changes in the
steady-state level even of short-lived transcripts, the drop in
ND3 mRNA levels is consistent with a substantial drop in
transcription per template molecule, under conditions of
TFAM over-expression, which was especially marked for
TFAM carrying the C-terminal MycHis tag. As a more
rigorous and direct test of its effects on transcriptional activ-
ity, we also analysed the consequences of TFAM-MycHis
expression on the rate of recovery in mitochondrial tRNA
levels in cells treated for 72 h with EtBr, following removal
of the drug (Supplementary Figure 4).
In conformity with the published literature, RNAi knock-
down of TFAM produced a progressive reduction of TFAM
protein levels and mtDNA copy number. A combination of
two siRNAs was selected, based on preliminary trials,
which decreased TFAM protein to low levels (<10%) during
7 or 14 days continuous culture (Supplementary Figure 3).
Over shorter-time periods, both TFAM protein and mtDNA
depletion by RNAi were rather modest and the levels of
TFAM protein or ND3 mRNA per template mtDNA molecule
were almost unchanged from control cells (Figure 1).
Altered TFAM expression leads to systematic effects on
mtDNA replication intermediates
The copy number depletion of mtDNA produced either
by RNAi knockdown or by over-expression prompted us
to investigate further the effects of these treatments on
mtDNA replication, using 2DNAGE. Transient expression
of TFAM-stop or inducible overexpression of either TFAM-
stop or TFAM-MycHis, produced dramatic and systematic
effects on the patterns of mtDNA RIs, which were essentially
the same in all three cases (Supplementary Figure 5b). The
most consistent effects on RIs were seen after 48 h of induced
over-expression (or 48 h after transient transfection), when
effects on mitochondrial transcripts were clearly evident
and quite similar in all cases.
TFAM overexpression resulted in a substantially increased
abundance of RIs relative to the unit-length restriction
fragment (Figure 2; see Supplementary Figure 5 for further
explanations and interpretations of the gel data). For example,
Figure 1. Effects of induced expression of TFAM-stop and TFAM-MycHis and of RNAi knockdown of TFAM expression. Mitochondrial proteins, DNA and
RNA were analysed from Flp-InTM T-RexTM -293 cells stably transfected with the TFAM-stop (a–c) or TFAM-MycHis construct (d–f), induced over the times
indicated or from HEK293T cells (g–i) following transfection with siRNAs Si2 and Si4 over the times indicated. In each case, error bars indicate means ± SEs
from at least three independent experiments. a.u., arbitrary units. Measurements of mtDNA levels (a, d and g) are arbitrarily normalized to the mean values for
uninduced or untreated cells. For cells under TFAM induction, the measurements were made by two independent methods, Southern blotting and Q-PCR and the
values plotted for each time point are the means of measurements by the two methods, shown in Supplementary Figures 1 and 2. (b, e and h) show TFAM protein
levels normalized to the mtDNA levels shown in (a, d and g), then normalized against the level in uninduced or untreated cells. (c, f and i) show ND3 mRNA
levels normalized first against the 5S rRNA loading control, then against the mtDNA levels shown in (a, d and g), then finally against the level in uninduced or
untreated cells. Samples of the raw data and compiled data for TFAM protein, mtDNA and RNA levels on which this figure is based, are shown in Supplementary
Figures 1–3.
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using a restriction enzyme which cuts only once in the gen-
ome (PvuII, np 2560, Figure 2b), TFAM over-expression
gave a clear enhancement of the clubheaded bubble arc
indicative of initiation far upstream of the restriction site,
as well as revealing a prominent simple Y-arc. In uninduced
cells these RIs were either much fainter or absent. The main
features were the clubheaded bubble arc and corresponding
double-Y arc, as well as a number of species that were
sensitive to or modified by, RNaseI treatment. The RNaseI-
sensitive species included circular molecules, a short arc
which corresponds with dimeric circles and/or broken theta
forms (T. Yasukawa, personal communication), plus a diffuse
cloud of material migrating in the region between circular
molecules and the bubble arc. A putative termination arc
was also visible only in uninduced cells, although this was
revealed more clearly when other species were modified by
RNaseI (Supplementary Figure 5).
In other digests, the exact transformations of RIs resulting
from TFAM overexpression varied according to which region
of the genome was being analysed (Figure 2c–e). In general,
ERIOLS-type RIs, i.e. slow-moving arcs and ‘clouds’ of hete-
rogeneous, nuclease-sensitive material were diminished and
migrated as more discrete entities. There was general
enhancement of nuclease-resistant arcs, in particular those
resistant to S1 nuclease. In addition, rather specific sub-
types of RIs were seen to accumulate along the arcs, which
differed from those seen in uninduced or untransfected cells.
Changes were most dramatic in the rDNA region, extend-
ing to OL (Figure 2d). In uninduced cells, in contrast to the
patterns of RIs from this region of the genome seen in solid
tissues or in cultured cells recovering from drug-induced
mtDNA depletion (2–4), complete Y-arcs of the strand-
coupled type were not detectable, even on long exposure.
Instead, a heterogeneous ‘cloud’ of complex, high-molecular
weight material was seen, plus the ascending portion of a
Y-like arc, ending in a faintly detected replication pause
site within the ND1 gene. These forms were partially sensi-
tive to or modified by nucleases. In TFAM overexpressing
cells, a complete Y-arc was easily detected, even at relatively
low exposure. The descending portion of this arc was now the
most prominent, although this segment was relatively sensi-
tive to nucleases. The cloud of heterogeneous material was
replaced by at least two discrete, slow-moving Y-like arcs,
which were also nuclease-sensitive. The replication pause
Figure 2. 2DNAGE analysis of mtDNA replication intermediates (RIs) in cells induced to overexpress TFAM-stop. (a) Diagrammatic map of human mtDNA,
showing the origins of heavy- (OH) and light-strand (OL) replication according to the orthodox model, relevant restriction sites and probes for the three regions of
the genome analysed (approximate location of probes indicated by asterisks). NCR shown as dark grey bar, rDNA as pale grey bar. (b–e) 2DNAGE of mtDNA
from uninduced cells and from cells induced to express TFAM-stop for 48 h, analysed using the restriction digests and probes indicated, with or without
additional enzymatic treatments as shown. In each panel, the various arcs and other salient features are denoted as follows: Y, standard Y arcs, dY, standard
doubleY arcs, c, ‘cloud’ of RNase-sensitive material, o, circular molecules, b, standard bubble arcs, s, slow-moving Y-like arcs, sensitive to various nucleases, t,
termination intermediates lying on a portion of a standard X arc, p, prominent pause sites. See Supplementary Figure 5 for diagrammatic interpretations of the
various arcs. Panels i and iv of part (b) and panels iii and iv of part (c) are equivalent exposures, for comparison. Other panels of uninduced cell mtDNA are 5- to
10-fold more exposed than induced cell material, in order to reveal the main features of the arcs. Note the general enhancement of RIs, relative loss of nuclease-
sensitive species, of termination intermediates and of bubble arcs, following TFAM induction. The appearance of a complete or almost complete, Y arc in
Figure 2b, panels iv–vi, is consistent with frequent strand breakage at OH or with recombinational strand-switching (also generating a free end at OH) or with
frequent initiation far distant from the NCR.
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in ND1 was prominently detected after S1 nuclease
treatment.
The major NCR (Figure 2c), containing the principal sites
of replication initiation and termination, showed more subtle
changes, affecting most obviously the termination region. In
uninduced cells, the most prominent species were termination
intermediates lying on or close to the apex of the X-arc, plus
a heterogeneous cloud of material migrating at high mole-
cular weight which, after nuclease treatment, was either
modified (RNaseI or H) or abolished (S1). The ascending
portion was the most prominent portion of the partial Y arc
and this was also sensitive to ribonucleases, as was the bubble
arc. In TFAM overexpressing cells the bubble arc was barely
visible even on long exposure and the descending portion of
the partial Y arc, leading to the termination site, was strongly
enhanced. However, termination intermediates lying on the
X-arc were less prominent, especially after S1 nuclease treat-
ment. Heterogeneous, high molecular weight, S1-sensitive
material was less dispersed and its migration less affected
by ribonucleases.
We next analysed the nature of fully double-stranded
(i.e. S1 nuclease-resistant) RIs around the genome in further
detail, under conditions of TFAM overexpression (Figure 3).
Different restriction digests (Figure 3b) confirmed that TFAM
overexpression led to an accumulation of material on the
standard Y arc in the region approaching the terminus at
OH, with a corresponding loss of termination intermediates
in which the fork had entered the fragment from the other
end and stalled at the terminus prior to resolution.
A number of pause sites or regions were strongly
enhanced, in addition to the strong pause in ND1
(Figure 3d). These included the pause at OL (Figure 3d),
several discrete sites in the regions of ND4, ND3, COXIII,
A6 and A8, most of the COXII gene (Figure 3c) and a
broad region of the ND5 gene (Figure 2c). Conversely,
the abundance of 7S DNA was diminished by TFAM
overexpression (Figure 6).
RNAi knockdown of TFAM expression produced more
subtle effects on RIs (Figure 4). RIs resistant to S1 nuclease
were little altered (Figure 4c), but ribonuclease-sensitive
‘clouds’ of heterogeneous, nuclease-sensitive material were
somewhat enhanced, especially in the rDNA region
(Figure 4c) or showed altered mobility. The clearest
transformation was seen in the origin/termination region
encompassing OH, where there was an increase in the
abundance of double-Y termination intermediates lying on
the X-arc, relative to the bubble and partial Y arcs
(Figure 4b), an opposite result to that produced from
TFAM overexpression, which diminished the abundance of
termination intermediates (Figures 2 and 3).
Figure 3. 2DNAGE analysis of S1 nuclease-resistant mtDNA RIs in cells induced to overexpress TFAM-stop. (a) Diagrammatic map of human mtDNA,
nomenclature as for Figure 2a. (b–d) 2DNAGE of mtDNA from uninduced cells and from cells induced to express TFAM-stop for 48 h, analysed using the
restriction digests and probes indicated. All samples were treated with S1 nuclease before electrophoresis. Nomenclature as for Figure 2, plus pr, pause region
(replication slow-zone). See Supplementary Figure 5 for diagrammatic interpretations. Comparable exposures are shown, to illustrate the general enhancement of
S1-resistant RIs, the strengthening of pause sites and regions and the decrease in termination intermediates. Note that bubble arcs are not visible at these
exposures following S1 nuclease treatment.
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TFAM over-expression shows similarities with
ddC treatment
Arcs of fully double-stranded, ribonuclease-insensitive RIs
should be generated by true strand-coupled replication. How-
ever, they could also arise from maturation of ERIOLS type
intermediates and, if so, should be enhanced where leading-
strand synthesis has stalled randomly or has been drastically
slowed (i.e. if the rate of lagging-strand maturation is now
comparable with that of fork progression). The effects of
TFAM overexpression could thus be interpreted either as a
switch to strand-coupled-type replication or as a general
slowing in progression of the replication fork, such that
maturation of the lagging strand now occurred as fast as the
fork progressed.
To address this issue we compared the effects on mtDNA
RIs of TFAM over-expression with treatment of cells with the
replication inhibitor dideoxycytidine, ddC (Figure 5). After
conversion to ddCTP this drug produces repeated chain
termination events during mtDNA replication, requiring
removal of the incorporated dideoxynucleotide by exonucle-
ase action or recombination, thus greatly slowing down the
overall rate of fork progression and leading to mtDNA deple-
tion. As shown in Figure 5, ddC treatment induced rather
similar transformations in the pattern of mtDNA RIs as
those brought about by TFAM overexpression: progressive
and dramatic reduction in ERIOLS-type RIs, a corresponding
increase in fully double-stranded RIs of the strand-coupled
type (Figure 5d) and the disappearance of termination inter-
mediates (Figure 5b, panels i–iii). Removal of the drug
rapidly induced a burst of mtDNA replication but with inter-
mediates remaining initially of the strand-coupled type and
with a delayed re-appearance of termination intermediates
(Figure 5b, panel vii). However, both during and following
ddCTP treatment, the enhancement of RIs of the strand-
coupled type was more general than that resulting from
enhanced TFAM expression, rather than being concen-
trated in the rDNA region and at replication pause sites
(e.g. compare Figure 5e, panels ii and iii).
Alterations to TFAM expression modify
mtDNA topology
The effects of TFAM overexpression on mtDNA replication
might reflect TFAM-induced changes in transcription or
in the overall organization of mtDNA. To test whether
modulation of TFAM expression affects mtDNA topology
or organization, we analysed uncut mtDNA from TFAM-
induced and uninduced cells, both before and after treatment
with various DNA-modifying enzymes (Figure 6). In unin-
duced cells, most of the mtDNA migrated either as relaxed
circles or in high molecular weight catenated forms that
were sensitive to topoisomerase IV but not topoisomerase I.
A pronounced smear of material was also visible in the
high molecular weight region of the gel. Induced TFAM
over-expression resulted in a pronounced shift towards mono-
meric supercoils, with much less catenated mtDNA, includ-
ing the high molecular weight smear, as well as creating
novel junctional forms that were resolved by phage T7 gp3
endonuclease. Despite these differences, the residual products
from combined treatment with topoisomerase IV and T7 gp3
were strikingly similar, when comparing TFAM-induced and
uninduced cells. ddC treatment also resulted in a shift away
from catenated forms in favour of monomeric circles, both
relaxed and supercoiled (Supplementary Figure 6). TFAM
knockdown by RNAi produced more subtle changes in
mtDNA topology (Figure 6), with an increased level of
one particular high molecular weight species (arrowed in
Figure 6) and of linear molecules. The arrowed species
corresponded in mobility with a catenated form which
could be enhanced in control cell mtDNA by treatment
with T7 gp3 endonuclease and thus might represent an
abortive termination product.
Finally, we analysed the effects of various treatments on
the steady-state level of 7S DNA. Both ddC treatment
[(40); Supplementary Figure 6] and TFAM overexpression
(Figure 6b) resulted in a substantial drop in the amount of
7S DNA relative to other forms of mtDNA, whereas TFAM
knockdown resulted in a small increase in 7S DNA
(Figure 6b).
DISCUSSION
In this study we investigated the effects on mtDNA replica-
tion of modulating TFAM expression in cultured human
cells. Sustained over-expression, resulting in a >2-fold
increase in the ratio of TFAM to mtDNA, greatly enhanced
the steady-state levels of RIs of the strand-coupled
type, with corresponding depletion of ribonucleotide-rich,
ERIOLS-type RIs. This was accompanied by decreased
mitochondrial transcription, depletion of 7S DNA and of
replication-termination intermediates, reduced copy number
and decatenation of mtDNA. TFAM knockdown in the
same cell background also produced copy number depletion,
Figure 4. 2DNAGE analysis mtDNA RIs in cells treated with TFAM-specific
siRNAs. (a) Diagrammatic map of human mtDNA, nomenclature as for
Figure 2a. (b) and (c) 2DNAGE of mtDNA from control (or mock-
transfected) cells and from cells treated with TFAM siRNAs for 24 h, using
the restriction digests and probes indicated, with or without additional S1
nuclease treatment as shown. Nomenclature as for Figure 2. See
Supplementary Figure 5 for diagrammatic interpretations. Comparable
exposures are shown, to illustrate the general enhancement of termination
intermediates and of the cloud of nuclease-sensitive material migrating at
high molecular weight.
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but with different alterations to mtDNA topology, no
systematic effects on transcription and, apart from a strong
enhancement of termination intermediates, virtually no
change in the pattern of RIs. The findings suggest that
TFAM can influence mtDNA replication and copy number
in several different ways.
TFAM as a structural protein of the
mitochondrial chromosome
Previous views of TFAM as a copy number regulator have
assumed that the ratio of TFAM:mtDNA is invariant, so
that changes in the rate of TFAM synthesis determine
the amount of mtDNA present in the cell (10,14,30,31).
Figure 5. 2DNAGE analysis of RIs in cells induced to overexpress TFAM-stop or treated with ddC. (a) Diagrammatic map of human mtDNA, nomenclature as
for Figure 2a. (b–e) 2DNAGE of mtDNA from uninduced cells, cells induced to express TFAM-stop for 48 h or HEK293T cells treated with ddC for the
indicated times (72 + 2 h meaning 72 h of treatment followed by 2 h of recovery in fresh medium). Restriction digests and probes as indicated. All samples were
treated with S1 nuclease before electrophoresis. Nomenclature as for Figure 2. See Supplementary Figure 5 for diagrammatic interpretations. Exposure times
vary, as needed to reveal the main features of arcs of RIs. Note the similar effects of TFAM overexpression and ddC treatment: general enhancement of S1
nuclease-resistant RIs, suppression of termination intermediates. Panel vi of part (c) is a longer exposure of panel v.
Figure 6. Effects of TFAM overexpression and knockdown on mtDNA topology. One-dimensional agarose gel blots, hybridized with OH probe. (a) mtDNA
from uninduced cells and from cells induced to overexpress TFAM-stop for 48 h, fractionated on a 0.4% agarose gel run in TBE. Only the high molecular weight
portion of the gel is shown. Samples were either untreated (U) or treated with T7 gp3 endonuclease (gp3), topoisomerase I (tI), topoisomerase IV (tIV) or
topoisomerase IV plus T7 gp3 endonuclease. Identity of the main topoisomers was inferred from enzymatic sensitivity and confirmed by other treatments (data
not shown). DNA from cells treated with TFAM-specific siRNAs (RNAi) for 24 h was run on a separate gel. (b) MtDNA from TFAM-induced, uninduced and
siRNA-treated cells, fractionated on 0.4% agarose gels run in TBE. Only the low molecular weight portion of each gel is shown. First 4 lanes of upper panel are
equally exposed, whereas the right-most two lanes are 3-fold overloaded, to reveal the presence of 7S DNA in induced cells. Samples were either heated for
2 min at 95C (+) or left unheated, as indicated.
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However, the observation of a reduced ratio of TFAM protein
to mtDNA during mtDNA reamplification following EtBr
treatment (32) suggests that the TFAM:mtDNA ratio is not
invariant and may indeed be subject to regulation, affecting
mtDNA copy number in ways distinct from a simple titration
model.
The present study offers support to the latter view, by
confirming that an increased ratio of TFAM protein to
mtDNA can be sustained in human cells and has systematic,
but opposite effects on mtDNA copy number than would
be predicted by the simple titration model. Moreover,
whereas most experiments hitherto conducted on TFAM
have employed highly non-physiological tools, such as cells
treated with EtBr, heterologous expression of a human pro-
tein in mice or of a truncated TFAM variant never seen in
nature, we observed alterations in mtDNA replication and
copy number resulting from increased expression of a protein
identical to endogenous TFAM. The fact that we were able to
achieve and sustain an increased ratio of TFAM to mtDNA
contradicts the titration model, but is consistent with the
results of studies using in organello footprinting (41–44),
which indicate that protein binding to mtDNA is not uniform
and thus that there are sites ordinarily unoccupied by protein
where over-expressed TFAM can potentially bind.
The effects of TFAM over-expression on RIs were
qualitatively very similar to those brought about by treatment
with the drug ddC which, following conversion to ddCTP, is
assumed to be a potent inducer of repeated replication stalling
via premature DNA chain termination. ddC treatment
also resulted in a large increase in the steady-state levels of
nuclease-resistant RIs of the strand-coupled type from all
around the mitochondrial genome, with concomitant loss of
termination intermediates. Although the effects of these
treatments were not absolutely identical, with TFAM over-
expression generating a subtly different pattern of such RIs,
especially in the rDNA region and in the vicinity of pause
sites, their overall similarity strongly suggests that the
main effect of TFAM is, like ddC, to provoke a substantial
decrease in the net rate of DNA synthesis. This may
reflect an increased compaction of mtDNA when the ratio
of TFAM protein to mtDNA is increased, such that deconden-
sation of the nucleoid becomes rate-limiting for fork progres-
sion. The TFAM-specific transformations of RIs may reflect
different degrees of compaction and inhibition of fork
progression in different regions of the mitochondrial genome,
depending on their affinity for TFAM and other proteins.
The increased abundance of strand-coupled RIs may thus
be due to maturation of ERIOLS-type intermediates, which
we assume normally to be a slow step compared with the
rate of fork progression. If the latter is slowed by increased
compaction, the rate of maturation may become comparable
with it. Alternatively, if the two classes of RI represent
entirely different modes of DNA replication, ERIOLS type
replication might be unable to use a highly compacted
mtDNA template, leaving only strand-coupled replication
(with a less discrete origin, as implied by Figure 2b).
Initiation of bidirectional, strand-coupled replication in
many bacterial plasmids is stimulated by or dependent
on, DNA-bending proteins functionally related to the
HMG superfamily (45). Excess TFAM may thus lead to
copy number depletion by enforcing a switch to an inherently
slower replication mode or simply by suppressing the
alternative mode.
Exactly the same transformations of RIs were produced by
transient expression of TFAM as were produced by inducible
expression of either natural or C-terminally MycHis-tagged
TFAM. However, the two inducible variants brought about
copy number depletion with markedly different kinetics
(Figure 1). Copy number depletion may thus not be due
entirely to a change in the rate of fork progression, but
involve also another TFAM-related process with which the
C-terminal tag may interfere. Such an effect could, however,
be indirect. The amount of TFAM-MycHis protein rose much
more steeply than TFAM-stop during induction (Figure 1,
Supplementary Figures 1 and 2), suggesting that it may
escape physiological turnover mechanisms. This is supported
by the observation (Supplementary Figure 2) that TFAM-
MycHis almost completely replaced endogenous TFAM
during induction. The fact that sustained overexpression of
natural TFAM is comparatively difficult to achieve may
reflect a natural homeostatic mechanism, whereby TFAM
levels can modulate copy number only within certain limits.
Another possibility is that, as for other HMG proteins (46),
the C-terminal tail of TFAM recruits or interacts with other
nucleoid proteins. It is already implicated in interactions
with specific components of the transcriptional apparatus
(47). The epitope tag may therefore disturb interactions
with other nucleoid proteins involved in copy number home-
ostasis. Copy number derangement produced in cells or mice
by C-terminally truncated or heterologous TFAM variants
(14,30,31) may prove to be due to loss of such regulation,
rather than by the titration model inferred previously.
The fact that RNAi knockdown of TFAM results in copy
number depletion without substantial changes in the patterns
of RIs is further evidence that at least one other TFAM-
dependent process is critical for mtDNA maintenance. One
obvious possibility already mentioned is the compaction of
nascent mtDNA into TFAM-containing nucleoid structures,
in the absence of which the newly replicated mtDNA may
simply be unstable. Other possibilities are discussed below.
TFAM as a regulator of mitochondrial transcription
Although TFAM was originally identified and named on the
basis of its being essential for mtDNA transcription, previous
studies have shown that excess TFAM, supplied either to a
reconstituted in vitro system (9) or produced by sustained
overexpression in HEKcultured cells (27), results in a para-
doxical suppression of transcription. Our own observations
are consistent with this (Figure 1, Supplementary Figures 1
and 2).
A drop in transcriptional activity could, conceivably,
underlie the switch in DNA replication mode that favours
the generation of strand-coupled RIs. Although the decrease
in transcriptional activity which accompanies TFAM overex-
pression appears modest, according to the data of Figure 1
(Supplementary Figures 1 and 2), the steady-state level of
ND3 mRNA is a relatively insensitive measure of the actual
transcription rate. The mechanism by which ERIOLS-type
RIs are generated remains unknown. However, since on
2DNAGE they include heterogeneous ‘clouds’ of material
sensitive to both RNaseI and RNaseH which are suppressed
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by TFAM overexpression (Figure 2), it is possible that
they could arise by a mechanism involving either
preformed RNA or nascent transcripts. Transcriptional
suppression by excess TFAM, rather than over-compaction
of the nucleoid, may therefore be the mechanism driving
replication towards the slower, strand-coupled mode. In
support of this, the segment of the genome most affected
by TFAM overexpression is also the most heavily transcribed
region (rDNA), in which discrete RIs are ordinarily hard
to detect (Figure 2d), but became prominent when TFAM
was overexpressed.
Whereas copy number depletion brought about by TFAM
overexpression was accompanied by a clear drop in transcrip-
tion, transcription per template molecule appeared unchanged
when copy number was depleted by TFAM knockdown.
Copy number regulation may therefore be independent of
transcription. However, transcription was more severely
affected by overexpression of epitope-tagged TFAM than
natural TFAM and also provoked a more rapid drop in
mtDNA copy number. The issue of a relationship between
the transcriptional activity of TFAM and copy number con-
trol thus remains open.
TFAM overexpression leads to reduced levels of
7S DNA, which might reflect decreased transcriptional
activity at the light-strand promoter and/or enhanced resolu-
tion of D-loop forms in vivo, another known property of
TFAM [(19), see also following section]. If D-loops represent
a precursor step in DNA replication, as proposed by the
orthodox model, their depletion by TFAM overexpression
may be crucial in bringing about copy number reduction
or in inducing a switch to strand-coupled replication. On
the other hand, the increased level of 7S DNA resulting
from TFAM knockdown shows clearly that the D-loop form
is not sufficient to maintain a high copy number.
TFAM as an enhancer of replication pausing
Replication pauses are well documented in both bacteria
and eukaryotes, as well as in plasmids and mtDNA (4,48).
However, their roles in DNA homeostasis are unclear,
except where they function as definitive terminators. In
human mtDNA, prominent pauses occur at the so-called
termination-associated site delimiting 7S DNA, at OL and
in the region immediately downstream of rDNA, within the
ND1 gene (Figures 2 and 3). One possibility is that, as in
yeast rDNA, these pauses are the signatures of proteins
which bind at specific sites to facilitate the passage of
oppositely moving replication and transcription complexes
(49) or simply markers of collision sites, as in bacteria
(50), at which replication finally resumes after dissociation
of the transcriptional machinery (51). Although TFAM has
only a low sequence-specificity for DNA-binding, it may
enhance such pauses by promoting DNA-bending, as
proposed for the protein Sap1p at one of the replication
pause sites in Schizosaccharomyces pombe rDNA (52).
Such bending may also facilitate the binding of other, more
sequence-specific DNA-binding proteins, which directly
function in fork arrest. Both copy number depletion and
transcriptional inhibition following TFAM overexpression
may therefore be due, at least in part, to its effect as a strong
enhancer of replication pausing.
TFAM as a cofactor in junctional resolution
TFAM overexpression and TFAM knockdown produced
opposite effects on the abundance of termination interme-
diates. Whereas these were depleted by TFAM overexpres-
sion (or ddC treatment), they were strongly enhanced by
TFAM knockdown (Figures 3–5). A simple interpretation is
that resolution of these forms is a late and slow step in
mtDNA replication, which is in some way dependent on
the supply of TFAM. Under conditions of TFAM overexpres-
sion, either that step is facilitated by increased loading of
TFAM onto the nascent DNA or the rate of fork progression
is slowed down so much that resolution of termination
intermediates is no longer rate-limiting. Under conditions of
TFAM ‘starvation’ this resolution step would conversely be
inhibited and this may be the primary reason for copy number
depletion following TFAM knockdown.
TFAM is already known to have binding preference for
junctional structures (17), to facilitate the resolution of
D-loops (19) and to bend DNA in a manner analogous with
bacterial proteins such as HU and IHF. The exact molecular
structure of mtDNA replication-termination intermediates is
unclear, although it cannot simply comprise two oppositely
moving forks that have almost met, since such a structure
would be thermally unstable unless the unreplicated region
between them were at least 50 bp, in which case they
would not lie precisely on the X-arc on 2DNAGE gels. One
possibility is that they are held together by hemicatenation
after ligation of at least one strand, although such forms
should be S1 nuclease-sensitive (53). Another is that they
are converted to true Holliday junctions. A third option is
that they contain a single or even double chicken-foot
structure.
Whatever their precise nature, a complex enzymatic
machinery should be required both to form and to resolve
them, in which TFAM is a plausible player, both because
of its DNA-binding preferences and bending properties and
by its putative ability to recruit other proteins to the DNA.
DNA-bending is required for the protein-based partition
systems of low copy-number bacterial plasmids such as P1
(54) and binding sites for the DNA-bending proteins H-NS
and FIS appear to be clustered around the replication
terminus in Escherichia coli (55). HMG and related proteins
are widely implicated as cofactors in recombination. For
example, mammalian HMGB1 facilitates V(D)J recombi-
nation by the RAG proteins (56). In bacteria, HU is essential
for efficient homologous recombination (57) and IHF is
required for the action of lambda integrase (58). HMG
proteins are able to facilitate recombination even in hetero-
logous systems [see Ref. (59)]. In yeast mitochondria,
overexpression of Abf2p promotes the formation of recombi-
nation intermediates (60). DNA-bending by TFAM may
facilitate analogous processes in human mtDNA.
A rather different interpretation would also be consistent
with the 2DNAGE data, namely that TFAM overexpression
leads to a high frequency of strand breakage at OH. This
would account both for the relative paucity of bubble arcs
in OH-containing fragments, (Figure 2b and c), for the
corresponding increase in simple Y arcs and for the loss of
termination intermediates (Figures 2c, and 3b). Such strand-
breakage is very unlikely to be an extraction artefact, since
these differences from control cells were seen in all of the
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many DNA preparations analysed. If this interpretation is
correct, it may imply a need for true recombination reaction
to resolve daughter molecules, which could be much slower
than the usual termination/resolution step. Copy number
depletion might therefore be due to interference with termina-
tion when TFAM is either overexpressed or downregulated.
In addition, TFAM overexpression resulted in apparent
decatenation of mtDNA, whereas TFAM knockdown increa-
sed the level of linear molecules and of one decatenated
species that could also be generated in control cell mtDNA
by treatment with T7 gp3 endonuclease, a promiscuous
junctional resolvase. It is tempting to suggest that these
species may be aberrant breakdown products resulting from
failure of the normal termination step under conditions of
TFAM deficiency. The loss of catenated species in favour
of monomeric supercoils under conditions of TFAM over-
expression may again reflect the altered kinetics of mtDNA
replication, since it too was brought about by ddC treatment.
Alternatively an overcompacted state of mtDNA resulting
from excess TFAM may directly prevent catenation or
stimulate decatenation, as is known for the E.coli HU protein
acting on circular plasmid molecules (61). Decatenation
might also result from frequent strand-breakage at OH.
Under conditions of decreased copy number, decatenation
should be important for dispersal of newly replicated
mtDNAs into nucleoids, to restrain mitotic segregation of
possibly deleterious mtDNA sequence variants. In yeast, the
TFAM homologue Abf2p is required for efficient parsing of
mtDNA into nucleoids (62), although this process appears to
involve recombination rather than decatenation.
Physiological role of TFAM as a mtDNA
copy number regulator
Our findings indicate that, at least in this particular proli-
ferating cell background, TFAM expression is finely poised.
Any marked deviations from what appears to be an optimal
expression level provoke alterations to mtDNA replication
that result in decreased mtDNA levels.
Previous studies of the transcriptional regulation of
the TFAM gene indicate that it is sensitive to signals
connected with metabolite supply (63) and redox stress, via
the phosphorylation of NRF-1 (64) and to proliferative,
differentiation-linked and environmental signals via the
co-activators PGC1 and PRC (65–67) and the transcription
factor Myc (68). This raises the issue of whether there is an
additional homeostatic, mechanism to fine-tune TFAM
expression to the physical state of mtDNA, which can be
circumvented by the manipulations we carried out. A retro-
grade signalling pathway of this type might serve to ensure
that disturbances in mtDNA replication or segregation
do not lead to a copy number catastrophe. Alternatively,
the level of TFAM expression and possibly also its post-
translational modification (69), may function in vivo to accel-
erate or decelerate mtDNA replication, thus constituting a
key determinant of copy number.
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SUPPLEMENTARY DATA
Legends to Supplementary Figures
Supplementary Figure 1
Effects of induced expression of TFAM-stop.  Mitochondrial proteins, DNA and RNA were analysed from
Flp-In™ T-Rex™ -293 cells stably transfected with the TFAM-stop construct, induced over the times
indicated. In each case, error bars indicate means + SEs from at least three independent experiments. (a)
Western blot probed for TFAM protein, stripped and reprobed for ?-actinin as loading control. Bar chart
shows TFAM chemiluminescence signals normalized first against those of ?-actinin, then against that the
value for uninduced cells (t=0).  (b) Southern blot probed for nuclear and mitochondrial DNA, using ND4
and 18S rDNA probes, respectively.  Bar chart shows the ratio of hybridization signals, normalized against
the mean value for uninduced cells. (c) Q-PCR analysis of mtDNA copy number on the same samples, again
normalized to the mean value for uninduced cells.  Note that this assay measures all mtDNA, not just the
full-length mtDNA detected in Southern blots, i.e. it includes also replication intermediates.  Conversely,
mtDNA which is amplified poorly, e.g. due to ribosubstitution, may be under-quantified by this method.
Southern blotting, on the other hand, measures only mature mtDNA, but is potentially subject to artefacts
arising from minor variations in sample quality.  The two methods in fact gave slightly different results.  The
transient increase in copy number in the first hours of TFAM over-expression seen by Q-PCR. may, indeed,
be due to an increased level of replication intermediates. To minimize any artefacts introduced by one or
other method, the mean of the two values was used to calculate the data plotted in Fig. 1. (d) Northern blot
probed for mitochondrial ND3 mRNA, stripped and reprobed for 5S rRNA.  Bar chart shows the ratio of
hybridization signals, normalized against the mean value for uninduced cells.
Supplementary Figure 2
Effects of induced expression of TFAM-MycHis.  Mitochondrial proteins, DNA and RNA were analysed
from Flp-In™ T-Rex™ -293 cells stably transfected with the TFAM-MycHis construct, induced over the
times indicated. In each case, error bars indicate means + SEs from at least three independent experiments.
(a) Western blot probed for TFAM protein, stripped and reprobed for ?-actinin as loading control.  The
identity of the band denoted as the TFAM-MycHis protein (TFAM-mh) was confirmed by probing with anti-
Myc monoclonal antibody.  Bar chart shows total TFAM chemiluminescence signals (i.e. endogenous
TFAM plus transgenic TFAM-MycHis) normalized first against those of ?-actinin, then against the value for
uninduced cells (t=0).  Note that endogenous TFAM declines as overexpressed TFAM-MycHis increases,
indicating that TFAM levels are also regulated translationally or post-translationally, most likely at the level
of incorporation into protein-DNA complexes. (b) Southern blot probed for nuclear and mitochondrial DNA,
using ND4 and 18S rDNA probes, respectively.  Bar chart shows the ratio of hybridization signals,
normalized to the mean value for uninduced cells. (c) Q-PCR analysis of mtDNA copy number on the same
samples, again normalized to the mean value for uninduced cells.  See legend to Supplementary Fig. 1 for
discussion of the issues relating to the two methods used to estimate mtDNA copy number changes. (d)
Northern blot probed for mitochondrial ND3 mRNA, stripped and reprobed for 5S rRNA.  Bar chart shows
the ratio of hybridization signals, normalized against the mean value for uninduced cells. (e) Western blot of
mitochondrial protein extracts from TFAM-MycHis after 24 h of induction, sub-fractionated into pellet (Pel)
and supernatant (Sup) fractions, and probed for TFAM.  The adjacent tracks are equally loaded in regard to
the starting material. Based on chemluminescence, approximately 90% of both the endogenous and the
transgenic  TFAM fractionate in the pellet, along with mtDNA.
Supplementary Figure 3
Effects of RNAi knockdown of TFAM expression.  Mitochondrial proteins, DNA and RNA were analysed
from HEK293T cells, following transfection with siRNAs Si2 and Si5, at the times indicated. In each case,
error bars indicate means + SEs from at least three independent experiments. (a) Western blot probed for
TFAM protein, stripped and reprobed for ?-actinin as loading control.  Bar chart shows TFAM
chemiluminescence signals normalized first against those of ?-actinin, then against the value for untreated
cells (t=0).  (b) Q-PCR analysis of mtDNA copy number, normalized to the mean value for untreated cells.
(c) Northern blot probed for mitochondrial ND3 mRNA, stripped and reprobed for 5S rRNA.  Bar chart
shows the ratio of hybridization signals, normalized against the mean value for untreated cells. (d) Western
blot of mitochondrial protein extracts from cells treated for 5 d in trial experiments with various
combinations of putative TFAM-specific siRNA oligonucleotides.  The sequences of the relevant mRNA
targets were as follows.  Si1:  5´-AAAGAAACCTGTAAGTTCTTA -3´ (np 282-302 of the TFAM mRNA
sequence),   Si3:  5 -´AAAGAAAAAAATATATCAAGA-3´ (np 414-434), Si5
5 -´AAAGAAGAGATAAGCAGATTT-3´ (np 463-483),  Si6: 5 -´AAGCAGATTTAAAGAACAGCT-3´ (np
474-494).  The final lane shows protein from cells treated with an siRNA directed against mTERF mRNA, as
a negative control.
Supplementary Figure 4
Suppression of de novo mtDNA transcription in cells induced to express TFAM-MycHis.  Cells were
cultured in EtBr-containing medium for 72 h, with or without concomitant induction of TFAM-MycHis
expression by doxycyclin, followed by replating in fresh medium containing no EtBr. Mitochondrial tRNA
levels at different time-points were measured by Northern hybridization and phosphorimaging, with
normalization first to 5S rRNA as a loading control, and then to the starting level of the relevant tRNA in
uninduced cells on the first day of measurement (24 h after the start of the experiment).  Over 5 days of
induction, TFAM-MycHis expression reduces mtDNA copy number only by 30-50% (Supplementary fig. 2),
therefore the almost complete suppression of de novo transcription revealed by this experiment is not due to
the absence of template.
Supplementary Figure 5
Explanations and supplementary data for 2DNAGE analyses.  (a) Various panels from Figs. 2, 3 and 4 are
reproduced, alongside interpretative illustrations of the various classes of replication intermediate assumed to
be represented by the arcs indicated.  Restriction sites remaining uncut due to ribosubstitution on the lagging
strand are indicated by red bars.  The clouds of RNAse-sensitive material associated with slow-moving arcs
are suggested to have attached tails of nascent RNA, as shown in red. Replication pause regions are shown as
filled circles: the one at OL in yellow, a second one within the ND1 gene in blue.  The short ‘eyebrow’ arc,
migrating in the region of the termination intermediates from Fig. 2b, panel ii, is proposed to derive from
broken theta molecules forms as shown, although it may, alternatively, comprise dimeric circles.  A
comprehensive explanation of 2DNAGE methodology and gel interpretation is given in Refs. 70 and 71. (b)
Comparison of 2DNAGE analyses of the ND2 region (AccI digest, ND2 probe, see Fig. 2a) in cells
overexpressing TFAM-stop or TFAM-MycHis (TFAM-mh) by induction in stably transfected Flp-In™ T-
Rex™ -293 cells, or TFAM-stop by transient transfection of HEK2923T cells, with or without additional
enzymatic treatments as shown.  Panels v and vi are scaled versions of panels i and ii of Fig. 3d. The patterns
of  mtDNA RIs are virtually indistinguishable in the three cases of TFAM overexpression, but quite different
from those seen in uninduced cells.
Supplementary Figure 6
Effects of ddC treatment on mtDNA topology. DNA samples were analysed as in Fig. 6.  ddC treatment was
for the times indicated (h), 72 + 2 meaning 72 h of treatment followed by 2 h of recovery in fresh medium
etc. The panel showing 7S DNA is a longer exposure of the bottom of the same gel blot.
Additional References for Supplementary Figures
70.   Brewer,B.J. and Fangman,W.L. (1987) The localization of replication origins on ARS plasmids in S.
cerevisiae. Cell, 51, 463-471.
71.   Brewer,B.J. and Fangman,W.L. (1988) A replication fork barrier at the 3' end of yeast ribosomal RNA
genes. Cell, 55, 637-643.
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